Nanostructured vectors for the transport of active molecules through biological membranes for pharmaceutical and nutraceutical applications by Bochicchio, Sabrina
Nanostructured vectors for the transport of 
active molecules through biological 







   
 Unione Europea UNIVERSITÀ DEGLI  
 STUDI DI SALERNO 
 
FONDO SOCIALE EUROPEO 
Programma Operativo Nazionale 2007/2013 
“Ricerca Scientifica, Sviluppo Tecnologico, Alta Formazione”  
Regioni dell’Obiettivo  1 – Misura III.4 
“Formazione superiore ed universitaria” 
 
Department of Industrial Engineering 
Corso di dottorato in Ingegneria Industriale-
curriculum Ingegneria Chimica 
(XV ciclo) 
 
Nanostructured vectors for the transport of 
active molecules through biological membranes 
for pharmaceutical and nutraceutical 
applications 
 
Supervisor Ph.D. student 
Prof. Anna Angela Barba Sabrina Bochicchio 
  
Scientific Referees 
Prof. Gaetano Lamberti 
Prof. Sotiris Missailidis  
Prof. Gabriele Grassi  
 












(Inherent the Ph.D. project) 
International Journals 
 Bochicchio S.; Dapas B.; Russo I.; Ciacci C.; Piazza O.; De Smedt S.; Pottie 
E.; Barba A.A.; Grassi G.; “In vitro and ex vivo delivery of tailored siRNA-
nanoliposomes for E2F1 silencing as a potential therapy for colorectal 
cancer”; IJP - International Journal of Pharmaceutics, 2017, in press 
 
 Bochicchio S.; Dalmoro A.; Recupido F.; Lamberti G.; Barba A.A.; 
“Nanoliposomes production by a protocol based on a simil-microfluidic 
approach”; accepted as publication in “Lecture Notes in Bioengineering 
(LNBE)”, Springer Ed., 2017 
 
 Bochicchio S.; Dalmoro A.; Barba A.A.; D’Amore M.; Lamberti G.; “New 
preparative approaches of micro and nano drug delivery carriers”; Current 
Drug Delivery, 2017, 14(2), 203-215 
 
 Dalmoro A.; Abrami M.; Galzerano B.; Bochicchio S.; Barba A.A.; Grassi 
M.; Larobina D.; “Injectable chitosan/b-glycerophosphate system for 
sustained release: gelation study, structural investigation, and erosion tests”; 
Current Drug Delivery, 2017, 14(2), 216-223 
 
 Piazza O.; Russo I.; Bochicchio S.; Barba A. A.; Lamberti G.; Zeppa P.; Di 
Crescenzo V.; Carrizzo A.; Vecchione C.; Ciacci C.; “Cyclin D1 Gene 
Silencing by siRNA in ex vivo human tissues cultures”; Current Drug 
Delivery, 2017, 14(2), 246-252 
 
 D’Apolito R.; Bochicchio S.; Dalmoro A.; Barba A. A.; Guido S.; 
Tomaiuolo G.; “Microfluidic investigation of the effect of liposome surface 
charge on drug delivery in microcirculation”; Current Drug Delivery, 2017, 
14(2), 231-238 
 
 Bochicchio S.; Barba A.A.; Grassi G.; Lamberti G.; “Vitamin delivery: 
carriers based on nanoliposomes produced via ultrasonic irradiation”; LWT - 
Food Science and Technologies, 2016, 69, 9 -16 
 
 Bochicchio S.; Dalmoro A.; Barba A.A.; Grassi G.; Lamberti G.; 




 Barba A.A.; Bochicchio S.; Lamberti G.; Dalmoro A.; "Ultrasonic energy in 
liposome production: process modelling and size calculation”; Soft Matter, 
2014, 10 (15), 2574 – 2581 
 
Technical Journals 
 Bochicchio S.; Barba A.A.; Lamberti G.; “Nanovettori per il rilascio di 
farmaci antitumorali a base di acidi nucleici”; ICF- Chemical and 
Pharmaceutical Industry italian journal, n. 2, 2015 
 Dalmoro A., Bochicchio S., Lamberti G., d’Amore M., Barba A.A.; 
“Intensificazione di processo per nuove formulazioni”; AIDIC news, n. 3, 
2016 
Work submitted: 
 Bochicchio S.; Sala M.; Spensiero A.; Scala M.C.; Gomez-Monterrey I.M.; 
Lamberti G.; Barba A.A.; “On the design of tailored liposomes for peptide 
delivery” 
Book Chapters 
 Bochicchio S.; Lamberti; Barba A.A.; “Phenomenological and formulation 
aspects in tailored nanoliposomes production” chapter in book Liposomes, 
InTech Ed., 2016, in press 
 Barba A.A.; Bochicchio S.; Dalmoro A.; Caccavo D.; Cascone S.; Lamberti 
G.; “Polymeric and lipid-based systems for controlled drug release: an 
engineering point of view; submitted as chapter in book to Pharmaceutical 
Nanotechnology, Volume IX: Sustained and controlled delivery systems, 
2017 
Work in preparation: 
 Russo I.; Bochicchio S.; Piazza O.; Lamberti G.; Barba A.A.; Carrizzo A.; 
Vecchione C.; Zeppa P.; Iovino P.; Bucci, C.; Ciacci C.; “Control of 
inflammation progression in inflammatory bowel disease by suitable 





 Russo I.; Bochicchio S.; Piazza O.; Barba A.A.; Lamberti G.; Carrizzo A.; 
Zeppa P.; Vecchione C.; Iovino P.; Bucci, C.; Ciacci C.; “Evaluation of 
efficacy of new vectors for siRNA CYCLIN D1 and E2F1 delivery in 
control of cancer progression in inflammatory bowel disease” presented to 
12th Congress of European Crohn’s and Colitis organization 15-
18/02/2017, Barcelona (Spain) 
 
 Bochicchio S.; Dalmoro A.; Recupido F.; Lamberti G.; Barba A.A.; 
“Nanoliposomes production by a protocol based on a simil-microfluidic 
approach”, presented to WIVACE 2016/BIONAM 2016 workshop, 4-
7/10/2016, University of Salerno, Fisciano (SA) (Italy) and in proceedings 
on “Lecture Notes in Bioengineering (LNBE)”, Springer Ed. 
 
 Sala M.; Bochicchio S.; Spensiero A.; Scala M. C.; Gomez-Monterrey I. 
M.; Dalmoro A.; Lamberti G.; Campiglia P.; Barba A. A.; “Drug delivery 
system of peptide KRX 29 for treatment of chronic heart failure”, 15th 
Naples Workshop on Bioactive Peptides, 23-25 June 2016 Naples (Italy) 
 
  D'Apolito R.; Bochicchio S., Tomaiuolo G.; Guido S.; Dalmoro A; Barba 
A.A.; “Liposomes as drug delivery system: effect of superficial charge on 
margination in blood flow”, 14th European Symposium on Controlled Drug 
Delivery, 13-15/04/2016 Egmond aan Zee (Holland) 
 
 Bochicchio S.; Sala M.; Spensiero A.; Scala M.C.; Gomez-Monterrey I.M.; 
Campiglia P.; Dalmoro A.; Lamberti G.; Barba A.A.; “Liposomal 
structures design for peptide delivery in heart failure therapy”, 14th 
European Symposium on Controlled Drug Delivery, 13-15/04/2016, 
Egmond aan Zee (Holland) 
 
 Bochicchio S.; Dalmoro A.; Cavallaro G.; Craparo F.; Sardo C.; 
Giammona G.; Lamberti G.; Barba A.A.; “Nanoparticle based PHEA-
DETA-PLA copolymer for NABDs delivery”, 14th European Symposium 




 Barba A.A.; Bochicchio S.; Lamberti G; Sala M.; Campiglia P.; 
“Ultrasonic assisted production of nanoliposomes as peptide delivery 
vectors”, 42nd Annual Meeting & Exposition of the Controlled Release 
Society CRS  2015, 26-29/07/2015, Edinburgh (Scotland) 
 
 Cascone S.; Bochicchio S.; Lamberti G.; Titomanlio G.; Barba A.A.; “In 
vitro and in silico models in pharmacokinetic studies”, 42nd Annual 
Meeting & Exposition of the Controlled Release Society CRS 2015, 26-
29/07/2015, Edinburgh (Scotland) 
 
 Caccavo D.; Cascone S.; Bochicchio S.; Lamberti G.; Dalmoro A.; Barba 
A.A.; “Hydrogels-based matrices behavior: experimental and modeling 
description”, 42nd Annual Meeting & Exposition of the Controlled Release 
Society CRS 2015, 26-29/07/2015, Edinburgh (Scotland) 
 
 Bochicchio S.; Dalmoro A.; Cascone S.; Lamberti G.; Barba A.A.; 
“dsDNA encapsulating in nanoliposomal structures towards gene 
therapies”, 1st International Congress of the Controlled Release Society- 
Greek local chapter 2015, 27-28/05/2015, Athens (Greece) 
 
 Dalmoro A.; Bochicchio S.; Apicella P.; d’Amore M.; Barba A.A.; “Micro 
and nano structured vectors for the drug delivery”, 21st International 
Congress of Chemical and Process Engineering CHISA 2014, 23-
27/08/2014, Praga (Czech Republic) 
 
 Bochicchio S.; Dalmoro A.; Grassi G.; Lamberti G.; Barba A.A. “Vectors 
for vitamins delivery: nano liposomes production via ultrasonic 
irradiation”, 13th European Symposium on Controlled Drug Delivery, 16-
18/04/2014, Egmond aan Zee (Holland) 
 
 Dalmoro A.; Bochicchio S.; Lamberti G.; d’Amore M.; Barba A.A. 
“Vectors for vitamins delivery: shell-core microparticles production via 
ultrasonic atomization and microwave stabilization”, 13th European 
Symposium on Controlled Drug Delivery, 16-18/04/2014, Egmond aan Zee 
(Holland) 
 
 Barba A.A.; Bochicchio S.; Dalmoro A.; Lamberti G. “Liposomal SUVs 
preparation by ultrasonic energy: a new approach based on a conventional 
technique”, 8th World Meeting on Pharmaceutics, Biopharmaceutics and 
Pharmaceutical Technology, 31/03-03/04/2014, Lisbona (Portugal) 
  
National  
 Bochicchio S.; Dalmoro A.; Lamberti G.; d’Amore M.; Barba A.A. 
“Chemical Engineering approaches in the production of dedicated systems 
for the dosage of active molecules” Microwaves and ultrasound as process 
intensification tools for drug carriers production, national convention 
GRICU 2016, 12-14/09/2016, Anacapri (NA), Italy 
 
 Barba A.A.; Lamberti G.; Dalmoro A.; Bochicchio S.; d’Amore M. “Nuovi 
sviluppi della terapia genica: approcci multidisciplinari al dosaggio 
controllato di siRNA”, National Workshop, 14-15/09/2015, University of 
Salerno, Fisciano (SA), Italy 
 
 d’Amore M.; Dalmoro A.; Bochicchio S.; Lamberti G.; Barba A.A. 
“Produzione di sistemi di rilascio ottimali per i Nucleic Acid Based Drugs 
in terapie antitumorali”, Le Giornate del Farmaco, I edizione , 12/04/2013 











Publications ........................................................................ iii 
Proceedings .......................................................................... v 
Contents ................................................................................ I 
Figures index .................................................................... VII 
Tables index ...................................................................... XI 
Abstract ............................................................................ XV 
1. Topic and aims ................................................................. 1 
1.1 Nanostructured vectors ................................................ 2 
1.2 Aims of this thesis .......................................................... 2 
1.3 Planned activities ........................................................... 3 
Gantt _____________________________________________ 3 
1.4 Outline of the thesis ....................................................... 4 
2. Introduction ..................................................................... 7 
2.1 Importance of microencapsulation processes ............. 8 
2.1.1 Critical issues in microencapsulation ________________ 8 
2.1.2 Materials of vectors ______________________________ 9 
   
 II 
2.2 Lipid carrier systems for therapeutic and 
nutraceutical agents delivery: liposomes ........................ 10 
2.2.1 Critical issues in therapeutic and nutraceutical agents 
delivery _______________________________________ 13 
3. Liposomes production:     State of the art .................. 17 
3.1 Lipid carrier production ............................................ 18 
3.1.1 Methods for lipid nanoparticles production __________ 18 
3.1.1.1 High Pressure Homogenization 18 
3.1.1.2 Microemulsion 19 
3.1.1.3 Emulsification-Solvent Evaporation 20 
3.1.1.4 Phase Inversion Technique 20 
3.1.2 Methods for liposomes production _________________ 21 
3.1.2.1 Lipid hydration techniques 21 
3.1.2.2 Liposome size reduction 25 
3.1.2.3 Removal of non-encapsulated drugs 25 
3.1.2.4 Liposomes stabilization 26 
3.1.2.5 Recent development in liposomes production techniques 26 
4. Novel developed techniques for liposomes production31 
4.1 Ultrasound assisted Thin Film Hydration: layout, 
principles and phenomenological aspects ....................... 32 
4.1.1 Generalities ___________________________________ 32 
4.1.1.1 Principles of the ultrasound process and benefits 32 
4.1.2 Experimental section ____________________________ 34 
4.1.2.1 Materials 34 
4.1.2.2 Layout 34 
4.1.2.3 Liposomes preparation 35 
4.1.2.4 Modelling 36 
4.1.3 Results and discussion ___________________________ 41 
4.1.3.1 Part 1: Model testing 41 
   
 III 
4.1.3.2 Part 2: Experimental results description and interpretation 43 
4.1.4 Remarks ______________________________________ 48 
4.2 Simil-microfluidic liposome preparation method: 
layout, principles and phenomenological aspects .......... 49 
4.2.1 Generalities ___________________________________ 49 
4.2.2 Experimental section ____________________________ 50 
4.2.2.1 Materials 50 
4.2.2.2 Layout 50 
4.2.2.3 Liposomes preparation 54 
4.2.2.4 Process productivity evaluation 55 
4.2.2.5 Scale up of the ultrasound assisted homogenization process 55 
4.2.3 Results and Discussion __________________________ 56 
4.2.3.1 Simil-microfluidic apparatus 56 
4.2.3.2 Unloaded nanoliposomes production: process parameters effect on 
dimensional features 59 
4.2.3.3 Productivity of the process 61 
4.2.3.4 Scale up of the ultrasound assisted homogenization process 62 
4.2.4 Remarks ______________________________________ 64 
5. Applications ................................................................... 65 
5.1 Liposomal vectors for vitamins delivery ................... 66 
5.1.1 Generalities ___________________________________ 66 
5.1.2 Materials _____________________________________ 67 
5.1.3 Methodology and sperimental set-up _______________ 67 
5.1.3.1 Preparation of MLVs and SUVs loaded with vitamin B12 67 
5.1.3.2 Preparation of MLVs and SUVs loaded with vitamin α-tocopherol69 
5.1.3.3 Preparation of MLVs and SUVs loaded with vitamin ergocalciferol70 
5.1.3.4 Physicochemical characterization of vesicles 70 
5.1.3.5 Evaluation of vitamins encapsulation and stability test 70 
5.1.4 Results _______________________________________ 72 
   
 IV 
5.1.4.1 MLVs production from lipidic film via ultrasonic irradiation: loading 
and characteristics 72 
5.1.4.2 SUVs production from lipidic film via ultrasonic irradiation: loading 
and characteristics 73 
5.1.5 Discussion ____________________________________ 74 
5.1.5.1 Thin film hydration technique assisted by ultrasonic irradiation 74 
5.1.5.2 Vitamins solubility and SUVs load analysis 76 
5.1.6 Remarks ______________________________________ 79 
5.2 Nanoliposomes vectors for ferrous sulfate delivery 81 
5.2.1 Generalities ___________________________________ 81 
5.2.2 Materials _____________________________________ 82 
5.2.3 Methodology and sperimental set-up _______________ 82 
5.2.3.1 Preparation of iron loaded nanoliposomes 82 
5.2.3.2 Physicochemical characterization of vesicles 84 
5.2.3.3 Evaluation of iron encapsulation and stability test 84 
5.2.4 Results and Discussion _______________________ 86 
5.2.4.1 Iron loaded nanoliposomes production 86 
5.2.4.2 Iron loaded nanoliposomes characterization 87 
5.2.4.3 A comparison between the simil-microfluidic apparatus and the 
classical bench scale techniques 92 
5.2.5 Remarks ______________________________________ 94 
5.3 Nanoliposomes vectors for peptide delivery ............. 95 
5.3.1 Generalities ___________________________________ 95 
5.3.2 Materials _____________________________________ 96 
5.3.3 Methodology and sperimental set-up _______________ 96 
5.3.3.1 Peptide KRX29 synthesis 96 
5.3.3.2 MLVs and SUVs preparation at different charge ratio 97 
5.3.3.3 MLVs and SUVs physicochemical characterization 98 
5.3.3.4 Determination of encapsulation efficiency, peptide KRX29 recovery 
and achieved loading 99 
   
 V 
5.3.3.5 MLVs at constant charge ratio but with different peptide concentration: 
preparation and characterization 100 
5.3.3.6 Stability test 101 
5.3.4 Results ______________________________________ 102 
5.3.4.1 MLVs and SUVs at different charge ratio 102 
5.3.4.2 MLVs at constant charge ratio and different peptide concentration105 
5.3.4.3 Stability test 106 
5.3.5 Discussion ___________________________________ 107 
5.3.5.1 Effect of formulation 108 
5.3.5.2 Efficacy of ultrasound assisted technique in KRX29-liposomes 
production 113 
5.3.6 Remarks _____________________________________ 114 
5.4 Nanoliposomes vectors for dsDNA delivery ........... 115 
5.4.1 Generalities __________________________________ 115 
5.4.2 Materials ____________________________________ 115 
5.4.3 Methodology and sperimental set-up ______________ 116 
5.4.3.1 Phosphate buffer solution preparation 116 
5.4.3.2 Tris-buffered saline solution (TBS) preparation 116 
5.4.3.3 Duplex-DNA generation 116 
5.4.3.4 dsDNA PolyAcrylamide Gel Electrophoresis (PAGE) analysis 117 
5.4.3.5 Preparation of cationic SUVs containing dsDNA 117 
5.4.3.6 Physicochemical characterization of vesicles 118 
5.4.3.7 Evaluation of dsDNA load and stability test 119 
5.4.4 Results ______________________________________ 119 
5.4.4.1 dsDNA purity and integrity 119 
5.4.4.2 Cationic liposomes: loading and characteristics of the tree formulations
 120 
5.4.5 Discussion ___________________________________ 124 
5.4.5.1 Ultrasound assited technique in dsDNA-liposomes production 124 
5.4.5.2 Including DOTAP in liposomes formulation 124 
5.4.5.3 Effect in changing DOTAP/DNA charge ratio on liposomes final 
features 125 
   
 VI 
5.4.6 Remarks _____________________________________ 127 
5.5 Nanoliposomes vectors for siRNAs delivery .......... 129 
5.5.1 Generalities __________________________________ 129 
5.5.2 Materials and methods _________________________ 131 
5.5.2.1 Unloaded and siRNA loaded vesicles preparation 131 
5.5.2.2 Unloaded and siRNA loaded vesicles characterization 133 
5.5.2.3 Cell culture condition 134 
5.5.2.4 Colon tissue culture condition 134 
5.5.2.5 Uptake study in tissue biopsies 135 
5.5.2.6 siRNA-SUVs transfection in cells 135 
5.5.2.7 siRNA-SUVs transfection in colon tissue 136 
5.5.2.8 Evaluation of E2F1 protein expression after transfection in tissue: 
Western blot 137 
5.5.3 Results and discussion __________________________ 138 
5.5.3.1 Unloaded and siRNA loaded vesicles 138 
5.5.3.2 Effects of siRNA-nanoliposomes on the vitality of human colon 
carcinoma cell lines 143 
5.5.3.3 Uptake study in colon tissue cultures 146 
5.5.3.4 Evaluation of E2F1 protein expression after transfection in tissue: 
Western blot 147 
5.5.4 Remarks _____________________________________ 153 
6. Concluding Remarks .................................................. 155 
Appendix .......................................................................... 159 
Pubblications ................................................................... 160 
 National Journals _______________________________ 166 
 Book chapter __________________________________ 167 




Figure 1. Cellular mimetic behaviour of liposomes as delivery systems (van der 
Meel et al., 2014) ...................................................................................................... 10 
Figure 2 Liposomes representation (Deshpande et al., 2013) .................................. 11 
Figure 3. Process schematization of nanoliposomes production through the 
ultrasound assisited Thin Film Hydration method; the main steps are reported: 
lipids/organic solvent solution (1) is introduced in a rotary evaporator (D-1) 
where solvents are evaporated (2) leading to the formation of a dryied lipid film 
(3) which is then hydrated (4) and stirred (D-2) After this step a suspension 
containing MLVs is produced and submitted to a duty cycle sonication process 
(Z-1) thus producing SUVs (5), finally recovered .................................................... 34 
Figure 4. The phenomena which take place during liposome formation .................. 38 
Figure 5. The model calculation flow-sheet .............................................................. 40 
Figure 6. Output of the calculation model for the simulated test .............................. 41 
Figure 7. Output of the calculation model for real test Run 1 .................................. 44 
Figure 8. Experimental and calculated liposome diameters for Run 1 ..................... 46 
Figure 9. Output of the calculation model for the real test Run 2.a ......................... 46 
Figure 10. Experimental and calculated liposome diameters for Run 2.a ................ 47 
Figure 11. Process schematization of nanoliposomes production through the 
semicontinuous simil-microfluidic apparatus; the main sections are reported: 
feeding, pumping, production, homogenization and recovery. From the tanks 
(D-1, D-2) lipids/ethanol and water solutions are pushed through peristaltic 
pumps (G-1, G-2) to the production section (I-1) were nanometric vesicles are 
formed. The hydroalcoholic solution (7) is recovered in a tank (D-3) and 
subjected to a duty cycle sonication process (Z-1). Finally the suspension (8) is 
recovered and characterized .................................................................................... 52 
Figure 12. Representation of the liposome formation process by a microfluidic 
approach ................................................................................................................... 58 
Figure 13. Fluorescence microscopy images of lipid vesicles labelled with 
Rhodamine B dye and visualized with a 100 X objective ......................................... 59 
   
 VIII 
Figure 14 A) Sonicated and not sonicated liposomes diameter size at different 
volumetric flow rates ratio. B) Polydispersity Index (PDI) of sonicated and not 
sonicated liposomes at different volumetric flow rates ratio. Results are 
expressed as average of three determinations and reported along with the 
standard deviation .................................................................................................... 60 
Figure 15 A) Sonicated and not sonicated liposomes diameter size at different 
PC concentrations in the hydroalcoholic solution. B) Polydispersity Index (PDI) 
of sonicated and not sonicated liposomes at different PC concentrations in the 
hydroalcoholic solution. Results are expressed as average of three 
determinations and reported along with the standard deviation .............................. 61 
Figure 16 A) Sonicated and not sonicated liposomes number (Nlip) for unit 
volume of solution obtained at different volumetric flow rates ratio. B) 
Sonicated and not sonicated liposomes number (Nlip) for unit volume of 
solution obtained at different PC concentrations in the hydroalcoholic solution .... 61 
Figure 17. Linearity between the number of duty cycle sonication rounds 
applied and the power supplied to 110 ml nanoliposomes suspension ..................... 62 
Figure 18 A) Liposomes diameter size after different number of duty cycle 
sonication rounds. B) Polydispersity Index (PDI) of liposomes after different 
number of duty cycle sonication rounds. Results are expressed as average of 
three determinations and reported along with the standard deviation ..................... 63 
Figure 19. Three main units of the simil-microfluidic set-up: a production unit 
according to the simil-microfluidic approach, an ultrasound assisted 
homogenization and recovery unit, a storage unit .................................................... 63 
Figure 20. Ultrasonic irradiation protocol (duty cycle, A) and its effect on 
liposomal structures size (from Multilamellar Vesicles –MLVs- to Small 
Unilamellar Vesicles –SUVs-, B). In Figure A, starting with MLVs, following 
two irradiation rounds (all irradiation rounds are of 10 seconds and are all 
followed by a 20-second pause) Large Unilamellar Vesicles-LUVs with 
micrometric diameter size are obtained as showed by LUVs size distribution in 
Figure B. In Figure A, starting with LUVs, after three and four more irradiation 
rounds (50 and 60 seconds), SUVs of nanometric size are obtained as showed 
by SUVs size distribution in Figure B. ...................................................................... 68 
Figure 21. Optical microscope pictures (in bright field, Obj. 63X) of loaded 
MLVs......................................................................................................................... 72 
Figure 22. Vitamins retention in nanoliposomes (SUVs) and released in PBS. 
Full symbols: squares, triangles and circles are referred to B12, tocopherol and 
ergocalciferol, respectively, and represent vitamin retained in the pellet. Open 
symbols: squares, triangles and circles are referred to B12, tocopherol and 
ergocalciferol, respectively, and represent the vitamin losses in phosphate 
buffer solution ........................................................................................................... 74 
Figure 23. Fluorescence microscopy images of ferrous sulfate lipid vesicles 
labelled with Rhodamine B dye and visualized with a 100 X objective .................... 87 
   
 IX 
Figure 24. Iron retained in nanoliposomes and released in deionized water. The 
open symbols are referred to the ferrous sulfate mass retained in the pellet, the 
full symbols represent the iron losses in deionized water ........................................ 92 
Figure 25. Optical microscope pictures (in bright field, Obj. 63 X) of KRX29 
loaded liposomes at the different tested charge ratios ........................................... 102 
Figure 26. Peptide release profile in Tris-HCl solution at 37°C ............................ 107 
Figure 27. Effect of PG/KRX29 (-/+) charge ratio on recovery efficiency ............. 111 
Figure 28. Effect of PG/KRX29 (-/+) charge ratio on encapsulation efficiency .... 111 
Figure 29. Native PAGE of dsDNA. In the first lane a 100 bp ladder molecular 
weight, in the second lane 2 µg of 21 bp dsDNA molecule (simulating "Homo 
sapiens siRNA probe Luciferase", 12833.4 g/mol). The relative band is well 
visible ..................................................................................................................... 120 
Figure 30 Optical microscope pictures (in bright field, Obj. 63 X and 100 X) of 
dsDNA loaded Multilamellar Vesicles (MLVs), achieved respectively from the 
first, second and third formulation ......................................................................... 121 
Figure 31. Fluorescence microscope picture of dsDNA liposome vesicles (Obj 
100X). DAPI-labeled dsDNA at left; Rhodamine B-labeled liposomes at right ..... 121 
Figure 32. dsDNA retention in Small Unilamellar Vesicles (SUVs) and release 
in PBS: circles symbols are referred to dsDNA retained in the pellet; squares 
symbols are referred to dsDNA lost in phosphate buffer solution .......................... 123 
Figure 33. RNA interference mechanism. Double-stranded RNAs (dsRNAs) are 
processed by a complex consisting of Dicer and other protein activators and 
kinase into small interfering RNAs (siRNAs), which are loaded into Argonaute 2 
(AGO2) and RNA-induced Silencing Complex (RISC). siRNAs are denatured 
and become single-strand molecules. The RISC is then active and, using the 
incorporated single-strand siRNA as template, recognizes the target mRNA to 
degrade (mRNA cleavage). RISC analyzes mRNAs and identifies as targets only 
the one with sequences perfect complementary to the 21-22 nucleotides of the 
siRNA, thus silencing their expression ................................................................... 129 
Figure 34. Fluorescence microscopy images of merged lipid vesicles labelled 
with Rhodamine B dye and visualized with a 100 X objective. A) Multilamellar 
Vesicles (MLVs) not subjected to the size reduction process; B) Large Vesicles 
(LVs) after two rounds of duty cycle sonication; C) Small Vesicles (SUVs) after 
six rounds of duty cycle sonication ......................................................................... 139 
Figure 35. Fluorescence images of siRNA loaded nanometric vesicles labelled 
with Rhodamine B (on the left) and siRNA DAPI labelled (on the right) 
visualized with a 100 X objective ........................................................................... 140 
Figure 36. UV-image of the agar gel after the electrophoretic assay. Following 
the order: M.M., DNA 123 bp; Lane 1, Naked siE2F1-1117; Lane 2, 
Nanoliposomes-siE2F1-1117; Lane 3, Naked siE2F1-1324; Lane 4, 
Nanoliposomes-siE2F1-1324 ................................................................................. 142 
   
 X 
Figure 37. A) siE2F1-nanoliposome complexes and siE2F1-Lipofectamine® 
2000 effects on HT29 cell vitality (*P=0.0001 siE2F1 vs siGL2 nanolipo, 
Unpaired t test; **P=0.01 siE2F1 vs siGL2 lipo2000, Unpaired t test with 
Welch correction); B) Un-specific effects on cell of nanoliposomes and 
Lipofectamine®2000 alone or loaded by the control siGL2; C) Cell counting 
after siE2F1-nanoliposomes transfection in HT29 cell line; D) E2F1 mRNA 
levels after siE2F1 –nanoliposomes transfection in HT29 cells (*P=0.0068 
siE2F1 vs siGL2 nanolipo, Unpaired t test); E) siE2F1-nanoliposome 
complexes effects on LoVo109 cell vitality. All data are reported as mean ± 
SEM ........................................................................................................................ 145 
Figure 38. Fluorescence microscope images of colon tissue section after 24 h of 
incubation with liposomes; 20 X objective. A) cell nuclei were visualized with 
DAPI, B) unloaded liposomes were Rhodamine B-labelled, C) cell nuclei and 
labelled liposomes images merge ........................................................................... 146 
Figure 39. E2F1 and GAPDH expressions in donor 1 after siRNA-nanoliposome 
transfection at 100 nM. The proteins band quantification is normalized to Actin. 
The order of the analyzed samples is: Tissue incubated in 1. Only medium; 2. 
Medium with EC-LPS; Tissue transfected with: 3. siE2F1-1117 nanoliposomes; 
4. siE2F1-1117 nanoliposomes in medium with EC-LPS; 5. siE2F1-1324 
nanoliposomes; 6. siE2F1-1324 in medium with EC-LPS; 7. Positive control 
nanoliposomes and 8. Negative control nanoliposomes. Figures A are referred 
to E2F1 expression levels normalized respect to the not treated (NT) or basal 
sample. Figures B are referred to E2F1 expression levels normalized respect to 
the siRNA negative control (CTRL – siRNA) treated sample ................................. 148 
Figure 40. E2F1 and GAPDH expressions in donors 2 (A) and 3 (B) after 
siRNA-nanoliposome transfection at 200 nM. The proteins band quantification 
is normalized to Actin. The order of the analyzed samples is: 1. Tissue fragment 
incubated in medium; Tissue fragments transfected with: 2. siE2F1-1324 
nanoliposomes; 3. Positive control nanoliposomes; and 4. Negative control 
nanoliposomes. E2F1 expression levels are normalized respect to the basal (not 
treated) sample and respect to the siRNA negative control (CTRL – siRNA) 
treated sample......................................................................................................... 150 
Figure 41. E2F1 and GAPDH expressions in donors 4 (A) and 5 (B) after 
siRNA-nanoliposome transfection at 200 nM and 50 nM. The proteins band 
quantification is normalized to Actin. The order of the analyzed samples is: 1. 
Tissue fragment incubated in medium; Tissue fragments transfected with: 2. 
siE2F1-1324 nanoliposomes; 3. Positive control nanoliposomes; and 4. 
Negative control nanoliposomes. E2F1 expression levels are normalized respect 
to the basal (not treated) sample and respect to the siRNA negative control 




Table 1. Thesis map .................................................................................................... 5 
Table 2 Liposomes classification by size / structure (Coelho et al., 2010, Samad 
et al., 2007) ............................................................................................................... 12 
Table 3. Problems of naked siRNA for clinical uses (David et al., 2012) ................ 14 
Table 4. Summary of experimental results ............................................................... 45 
Table 5. Reynolds number relative to the polar phase, the organic phase and the 
hydroalcholic solution at the different volumetric flow rates ratio tested ................ 57 
Table 6. Process parameters adopted in Multiamellar Vesicles (MLVs) and 
Small Unilmellar Vesicles (SUVs) preparation, achieved loading and 
encapsulation efficiency. Results are expressed as average of three 
determinations; SD is the standard deviation .......................................................... 69 
Table 7. Structures size of loaded Multilamellar Vesicles (MLVs) and Small 
Unilamellar Vesicles (SUVs). Results are expressed as average of three 
determinations; SD is the standard deviation .......................................................... 72 
Table 8. Large Unilamellar Vesicles (LUVs) and Small Unilamellar Vesicles 
(SUVs) mean diameter size and Standard Deviation (SD) after sequential 
sonication rounds. Triplicate measurements were performed .................................. 75 
Table 9. Main vitamins properties and Small Unilamellar Vesicles 
characterization........................................................................................................ 77 
Table 10. Sonicated and not sonicated liposomes diameter size, polydispersity 
index (PDI) and zeta potential produced at different weight ratio of ferrous 
sulfate to the total formulation components. Results are expressed as average of 
three determinations and reported along with the standard deviation (SD) ............ 88 
Table 11. Theoretical load, effective load and encapsulation efficiency (e.e.) of 
sonicated liposomes produced at different weight ratio of ferrous sulfate to the 
total formulation components. Results are expressed as average of three 
determinations and reported along with the standard deviation (SD) ..................... 91 
Table 12. Size, PDI, zeta potential and encapsulation efficiency (e.e.) of ferrous 
sulfate loaded nanoliposomes produced adopting the 0.01 w/w Fe/total 
components formulation ........................................................................................... 93 
   
 XII 
Table 13. A comparison in terms of process yield between the use of the simil-
microfluidic set-up and the classical bench scale methods in nanoliposomes 
production. A volumes of 110 ml (one batch volume), 3000 ml (maximum round 
bottom flask volume) and 50 ml (maximum sysringe volume) were considered 
for Simil microfluidic set-up, ultrasound assisted TFI and the EI techniques, 
respectively with a production time of 2.5 min, 10 min and 24 h ............................. 94 
Table 14. Peptide KRX29 chemico-physical properties ........................................... 97 
Table 15. Liposomal formulations for KRX29 encapsulation with different 
charge ratio (-/+)...................................................................................................... 98 
Table 16. Process parameters adopted in Small Unilmellar Vesicles (SUVs) 
preparation, starting from Multilamellar Vesicles (MLVs) ...................................... 98 
Table 17. Composition of two 1:1 charge ratio formulations with different 
amount of peptide KRX29 ....................................................................................... 100 
Table 18. Size of unloaded and loaded Multilamellar Vesicles (MLVs) and Small 
Unilamellar Vesicles (SUVs) at the different PG/KRX29 studied charge ratios. 
PDI is the polydispersity index. Results are expressed as average of three 
determinations with SD as standard deviation ....................................................... 103 
Table 19. Zeta potential of unloaded and loaded Multilamellar Vesicles (MLVs) 
and Small Unilamellar Vesicles (SUVs) achieved using different PG/KRX29 
charge ratios. Results are expressed as average of three determinations; SD is 
the standard deviation ............................................................................................ 103 
Table 20. Encapsulation efficiency and amount of peptide KRX29 accounted for 
in MLVs and SUVs loaded with KRX29 at the studied different charge ratios. 
Results are expressed as average of three determinations; SD is the standard 
deviation ................................................................................................................. 104 
Table 21. Theoretical load and effective load of MLVs and SUVs loaded with 
KRX29 at the studied different PG/KRX29 charge ratios. Results are expressed 
as average of three determinations; SD is the standard deviation ......................... 104 
Table 22. Mass balance of KRX29 loaded in MLVs and SUVs at the studied 
different charge ratios. Results are expressed as average of three 
determinations; SD is the standard deviation ......................................................... 105 
Table 23. Encapsulation efficiency and amount of peptide KRX29 accounted for 
in MLVs loaded with different amounts of KRX29 at the same PG/KRX29 
charge ratio (1:1 -/+). Results are expressed as average of three 
determinations; SD is the standard deviation ......................................................... 105 
Table 24. Theoretical load and effective load of MLVs loaded with different 
amounts of KRX29 at the same PG/KRX29 charge ratio (1:1 -/+). Results are 
expressed as average of three determinations; SD is the standard deviation ......... 106 
Table 25. Mass balance of KRX29 loaded in MLVs at the two studied different 
KRX29 concentrations. Results are expressed as average of three 
determinations; SD is the standard deviation ......................................................... 106 
   
 XIII 
Table 26. Loaded Multilamellar Vesicles (MLVs) and Small Unilamellar 
Vesicles (SUVs) dimensional characterization at different DOTAP/dsDNA 
charge ratio; Results are expressed as average of three determinations; SD is 
the standard deviation ............................................................................................ 122 
Table 27. Zeta potential and encapsulation efficiency of dsDNA-liposomes 
complexes formulated starting from different DOTAP/dsDNA charge ratio; 
Results are expressed as average of three determinations; SD is the standard 
deviation ................................................................................................................. 122 
Table 28 Theoretical and effective loads (%) in Small Unilamellar Vesicles 
(SUVs) at different DOTAP/dsDNA charge ratio; for the third formulation also 
Multilamellar Vesicles (MLVs) loads are reported. Results are expressed as 
average of three determinations; SD is the standard deviation ............................. 123 
Table 29. Size of produced unloaded Multilamellar Vesicles (MLVs), Large 
Unilamellar Vesicles (LUVs) and Small Unilamellar Vesicles (SUVs). Results 
are expressed as average of three determinations with SD as standard deviation 140 
Table 30. Size, PDI and zeta potential of siE2F1-1117 and siE2F1-1324 
produced loaded Small Unilamellar Vesicles (SUVs). Results are expressed as 
average of three determinations with SD as standard deviation ............................ 141 
 
  







Purpose of the PhD thesis was to develop dedicated lipid nanostructured 
vectors with tailored features (in terms of size, surface charge, load 
capability, stimuli responsive ability and stability) through the design of 
novel production processes expressly developed for nutraceutical and 
therapeutic agents encapsulation. 
The preliminary performed review of the main processes used for liposomes 
production have underlined that the majority of the conventional and more 
innovative methods adopted show a number of drawbacks such as few 
product volumes in output (directly linked to the impossibility in scaling up 
the process), high energy consumption, long times of production together 
with the use of toxic solvents and other process drastic conditions. To the 
light of these literature findings and with the aim to produce nanostructured 
vectors through more sustainable processes, two novel techniques, sharing 
the ultrasound technology as process intensification tool used in particles 
size reduction and homogenization operations, were designed and developed 
to respond to the needs of a better process performance, improving its 
efficiency and cutting down energy consumption. 
At first, based on the use of ultrasound as alternative energy resource, a solid 
particles size reduction process was developed and coupled with the bench 
scale conventional Thin Film Hydration (TFH) method. This technique 
provides the generation of a lipid film which is formed after solvents 
evaporation through the use of a rotary evaporator. The dried film is then 
hydrated, spontaneously producing micrometric vesicles characterized by the 
presence of several bilayers. Then the method was revisited by adding the 
ultrasound assisted step developed in order to produce, in a versatile manner, 
structures with the desired dimension (on micro/nano scale), starting from 
the micrometric ones. 
Four are the main sections composing the set-up to apply this innovative 
protocol: a feeding section, a solvent evaporation section, a liposomes 
production/homogenization section and a recovery section. In particular, the 
homogenization section is composed of a 3 mm sonication tip (operative 
frequency 20 kHz) which acts on micrometric vesicles sample aliquots. 
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Subsequently to the realization of the production bench scale apparatus, the 
phenomenology connected to the vectors constitution was investigated and a 
dynamic model able to describe the curvature of a lipid bilayer under the 
effect of ultrasonic energy was then proposed and tested.  
In that regard, starting from micrometric vesicles, the ultrasound energy is 
used to break the lipid bilayer into smaller pieces, then these pieces close 
themselves in spherical structures producing small vesicles. Moreover the 
role of several process parameters were also elucidated. 
Once established its reliability and due its great potential in reducing time 
spent, without compromising the integrity of the liposomal systems 
produced (in terms of structure and load), the ultrasound intensification tool 
was also used for liposomes homogenization operation during vesicles 
production through a simil-microfluidic approach. 
As a matter of fact, in order to produce higher volumes of lipid vectors, 
potentially on production scale, directly with nanometric size, a simil-
microfluidic apparatus was expressly designed and fabricated, overcoming 
the limitations of the small output volumes typical of the conventional bench 
scale techniques.  
There are five main sections composing the realized apparatus: a feeding 
section, a pumping section, a production section, an homogenization section 
and a recovery section. In particular the homogenization section is composed 
of a 6 mm sonication tip (operative frequency 20 kHz) directly immersed in 
the entire hydroalcholic solution containing nanoliposomes. 
As previously done, the phenomenological aspects involved in vectors 
constitution were investigated for this new adopted set-up. In particular, the 
reproduction of the phenomenology connected to the vesicles formation 
through a microfluidic approach was achieved by the use of constructive 
expedients (millimetric diameter of tubes, peristaltic pumps, injection 
needle). Particularly, nanostructured vectors formation happens at the 
interfaces between the alcoholic and water phases, when they start to 
interdiffuse in a direction normal to the liquid flow stream; changes in flow 
conditions result in size variations of the insertion section of the organic 
phase reflecting on the vesicles dimensional features. 
In that regards, taking into account that size and size distribution are key 
parameters determining liposomes performance as carrier systems in both 
pharmaceutical and nutraceutical applications, a control on the produced 
nanoliposomes dimensional features was demonstrated by tuning the 
volumetric flow rates and the lipids concentration process parameters. In 
particular, it was understood that increasing the ratio between the water 
volumetric flow rate to the lipids-ethanol volumetric flow rate the liposomes 
dimensional distibution increases; on contrary, ultrasonic energy enhances 
the homogenization of the hydroalcoholic bulk and, as expected on the bases 
of previous studies conducted on smaller volumes, its duty cycle application 
efficaciously promoted a better vesicles dimensional distribution. This result 
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was also confirmed by working at equal flow rates but at different lipid 
concentrations. Finally, the developed simil-microfluidic apparatus, working 
at room conditions and in absence of toxic solvents, makes nanoliposomes 
production a safe and low cost process, highly productive due to the use of 
ultrasound which was demonstrated to be a scalable means for process 
intensification. By using the two developed experimental set-up, several 
classes of liposomal structures were formulated and produced to respond to 
specific requests of nutraceutical and pharmaceutical applications. Through 
the ultrasound assisted tool at first coupled with the conventional THF 
method and subsequently used as integrant part of the homogenization 
section of the simil-microfluidic apparatus, different active molecules were 
successfully encapsulated in lipid nanostructured vectors solving the critical 
issues linked to their naked administration and transport through biological 
membranes. In particular, nanoliposomes containing vitamins with different 
hydrophobicity (α-tocopherol, ergocalciferol, vitamin B12) and ferrous 
sulfate, with highly interesting features for nutraceutical market, were 
produced achieving stable loaded nanoliposomes with high encapsulation 
efficiencies and good dimensional features. 
In details, for vitamins-nanoliposomes productions, neuter vesicles with 
micrometric size, ranging from 2.9 μm to 5.7 μm, were produced, obtaining, 
after sonication in duty cycle, small vesicles in the average range of 40 nm to 
51 nm in size. High encapsulation efficiency (e.e.) was obtained in both 
micrometric vesicles, with a e.e. % of 72.0 ± 00 % for vitamin B12, 95.0 ± 
7.07 % for α-tocopherol and 81.5 ± 2.12 % for ergocalciferol, and small 
vesicles, with an e.e. % of 56.2 ± 8.51 % for vitamin B12, 76.3 ± 14.02 % 
for α-tocopherol and 57.5 ± 13.9 % for ergocalciferol (the higher the vitamin 
hydrophobicity, the higher the encapsulation efficiency). Finally, a 
comparison between vitamin B12 load achievable with the developed 
technique and the vitamin load achievable by breaking unloaded preformed 
liposomes (conventional approach) showed an increase of encapsulation 
efficiency in small vesicles from 40% to 56.2 %, confirming the 
effectiveness of the pointed out technique. 
Regarding the ferrous sulfate-nanoliposomes, their massive production was 
possible due to the simil-microfluidic approach with a precise control on 
particles size and size distribution. In particular, the effect of different 
weight ratios of iron to the total formulation components (0.06, 0.035, 0.02 
and 0.01 iron/total components weight ratio) on the final vesicles 
encapsulation efficiency was investigated obtaining with the last formulation 
an high encapsulation efficiency (up to 97%). 
In general, ferrous sulfate loaded nanoliposomes, negative charged, with 
good dimensional features (127-135 nm for not sonicated and 48-76 nm for 
sonicated liposomes) were successfully produced through the use of the 
simil-microfluidic method developed, obtaining an elevated process yield if 
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compared to the classical bench scale techniques (THF and Ethanol 
Injection). 
For pharmaceutical purposes, anionic nanoliposomes containing a new 
synthetized peptide (KRX29) for a not conventional heart failures therapy 
and new, cutting edge, nucleic acids based therapeutics agents (NABDs), 
used in gene therapy, were successfully produced. 
Regarding KRX29-nanoliposomes production, micrometric particles of 7.2-
11.7 μm were obtained and sized with the use of the developed ultrasound 
assisted process thus achieving 22 – 35 nm vesicles. The effect of liposomes 
charge on both peptide encapsulation and recovery efficiencies was at first 
studied, showing an higher encapsulation efficiency (about 100%) achieved 
(both in small and large vesicles) by using the higher charge ratio 
formulation (13:1 (-/+)). Viceversa, the ability to recover the entrapped 
peptide was obtained for loaded systems (both in small and large vesicles) at 
the lower charge ratio formulation (1:1 (-/+)). As the charge ratio, also the 
peptide concentration showed influence on the liposomes encapsulation 
efficiency. 
For NABDs complexes production, at first preliminary experiments in which 
dsDNA was used to simulate the structure of siRNA molecule were done by 
testing different dsDNA/DOTAP lipid charge ratio (3:1, 5:1 and 7:1 (+/-)) in 
order to achieve the higher dsDNA encapsulation efficiency in the smaller 
carrier possible. DOTAP phospholipid was used due to its positive charge. 
The performed activities have confirmed the versatility of the ultrasound 
assisted technique for producing micro (2.2 – 2.9 μm) and nano lipid vectors 
(28 - 56 nm) encapsulating NABDs. In particular, the charge ratio (+/-) 
variation from 3:1 to 7:1 (+/-) by changing the amount of positive lipid 
(DOTAP) used in liposome preparation have allowed to an improved e.e. 
wich was 64 % and 100 % respectively for small and large vesicles by using 
the 7:1 (+/-) charge ratio. 
Starting from these preliminary tests, siRNAs-nanoliposomes complexes 
were produced for the inhibition of E2F1 protein expression, studied as a 
potential way to treat colorectal cancer associated to Inflammatory Bowel 
Diseases. By the TFH/sonication technique nanoliposomes with 33-38 nm 
range size and 100% siRNA encapsulation efficiency were obtained. The 
produced loaded nanoliposomes demonstrated a very low cytotoxicity in 
cells when compared with the commercial transfection agent 
Lipofectamine 2000 and an excellent uptake in the cultured human colon 
mucosa tissues. A remarkable anti-E2F1 expression effect after siE2F1-
1324-nanoliposome samples transfection has been demonstrated also in a 
dynamic human model such the colon tissue microenvironment (i.e. an 
80.5% reduction of E2F1 expression respect to the basal tissue was achieved 
in patient 4), a clear tendency to respond in a patient-dependent way was 
observed. 
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All the achieved results highlight the potentiality of the purposely designed 
nanoliposomes in deliver, in a controlled manner, different active molecules 
for both pharmaceutical and nutraceutical purposes. The formulative and the 
chemical engineering approaches adopted in this thesis for nanostructured 
vectors production respectively enhance the product quality (nanoparticles 
with tailored features) and make the process more attractive in terms of 






1. Topic and aims 
This chapter underlines the reason why the 
necessity of nanostructured vectors for the 
transport of active molecules through 
biological membranes is of critical 
importance. Moreover the aims of the thesis 
and the research organization plan to reach 
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1.1 Nanostructured vectors 
Advanced Drug Delivery Systems (DDSs) production is one of the main 
challenges in the development of effective pharmacological therapies as well 
as in the growth of new nutraceutical products. Main purposes of an ideal 
DDSs are: to protect loaded active molecules from degradation in 
physiological environments; to deliver them in a controlled manner (time 
period and releasing rate) and towards a specific organ or tissue (targeted 
drug delivery); to allow the maintenance of the drug level in the body within 
therapeutic window. Smart features, such as to respond to physiological 
stimuli and to trigger active molecules release, are also desirable. To achieve 
all these properties, delivery systems material, size, charge, affinity with 
entrapped active molecules – biological membranes, play a crucial role. 
Being characterized by a promising pharmacokinetic and a favorable safety 
profile, liposomes are ideal carriers of relevant active molecules classes: 
important micronutrients, such as vitamins and minerals, and powerful and 
cutting-edge therapeutic agents, such as Nucleic Acid Based Drugs 
(NABDs) and novel synthetized active ingredients. 
1.2 Aims of this thesis 
Aims of this research project are: to develop dedicated nanostructured 
vectors with tailored features (in terms of size, surface charge, load 
capability, stimuli responsive ability) and the relative suitable 
characterization procedures; to investigate the mechanisms that regulate 
vectors constitution and release of the loaded active molecules to propose 
mathematical descriptions of the main physical phenomena; to study the role 
of the main process parameters optimizing both production stages and 
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During the first year, the research activity was focused on the literature 
review concerning the nanostructured vector for the transport of active 
molecules through biological membrane and the techniques relatives to their 
production. At first, based on the use of ultrasound as alternative energy 
resource, a particles size reduction process was developed and coupled with 
the bench scale conventional Thin Film Hydration (TFH) method for 
nanoliposomes production. In particular, the phenomena which take place 
during liposome formation after sonication were analyzed and a 
mathematical model for the prediction of the final liposomes size was 
proposed. Then the activity was focused on the production of nanostructured 
liposomal vectors, loaded with vitamins, peptides and dsDNA (simulating 
siRNA structure), through the ultrasound assisted technique developed. In 
the second year the literature review has been continued and nanostructured 
vectors able to encapsulate siRNA, for their transfection in cells and ex vivo 
human tissue, have been produced. The relevant transport phenomena have 
been analyzed along with the relevant formulative and process parameters 
tuning. Furthermore, the design of a semi-continuous experimental set-up for 
a larger scale lipid vectors production, including the component selection 
and plant layout design, has been started and continued during the third year. 
In this year the research activity concerns the realization and testing of a 
simil-microfluidic experimental apparatus for the production of 
nanostructured vectors with tailored features, in terms of size, charge and 
load capability was done and the relevant phenomena have been analyzed 
again along with the formulative and process parameters tuning. Finally, the 
developed semi-continuous experimental set-up was applied to ferrous 
sulfate nanostructures vectors production for nutraceutical applications. 
1.4 Outline of the thesis 
An introduction on the importance of microencapsulation and liposomes as 
drug delivery systems (Chapter two) is followed by the review of the 
literature concerning conventional and emerging technologies to produce 
micro- and nano- structured lipid carrier systems (Chapter three). Then, two 
developed techniques for liposomes production, the ultrasound-assisted Thin 
Film Hydration technique and the simil-microfluidic method developed, are 
shown and their layout, principles and phenomenological aspects are 
described (Chapter four). Afterwards, all the applications concerning the 
encapsulation of active molecules for nutraceutical (vitamins and ferrous 
sulfate) and pharmaceutical (NABDs and peptides) purposes through the 
ultrasound-assisted Thin Film Hydration technique and the simil-
microfluidic apparatus developed are presented (Chapter five). The 
conclusive part endorses the usefulness of the novel techniques for lipid 
nanostructured vectors production, based on an ultrasound assisted size 
reduction/homogenization process used as powerful intensification tool 
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(Chapter six). Finally, the abstracts relative the main pubblications inherent 
the Ph.D. project are reported (Appendix). 
Table 1. Thesis map 
Chapter 2 Liposomes generalities 
Chapter 3 State of art of liposomes production 
Chapter 4 Experimental set-up: design and realization 
Phenomenological aspects 
Chapter 5 Applications – each of them is self-standing 
Chapter 6 Conclusive remarks about the main findings of this 
PhD research project  
















This chapter outlines the importance of 
microencapsulation processes with their 
related critical issues. Moreover the features 
and the advantages of liposomes as carrier 
systems for therapeutic and nutraceutical 
agents delivery are presented along with the 
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2.1 Importance of microencapsulation processes 
Microencapsulation is a process by which solid, liquid or gaseous active 
ingredients are packaged within a second material for the purpose of 
shielding the active ingredient from the surrounding environment (Dubey, 
2009). Nanoencapsulation is similar to microencapsulation but at sizes on 
the nano scale. Microparticles are particles with a diameter of 1-1000 μm, 
while nanopaticles are <1 μm in size. Micro/nanoencapsulation process has a 
lot of applications such as in medical, pharmaceutical, cosmetic, food and 
beverages and agriculture fields. Encapsulation in micro or nanoparticles can 
be used to protect molecules from the environment, to convert liquid active 
components into a dry solid system, to mask undesired properties of the 
active components, to control release of the active components for timed 
release and/or sustained release (Bansode et al., 2010). In the food sector 
particles as liposomes have great potential as packaging material and 
represent an efficient way for controlling nutraceutical delivery and 
improving and promoting the growth of the nanofood industry (Teixeira et 
al., 2008). In medical field the delivery of drug at the right time, in the target 
where it is needed, is essential to realize the full potential of therapeutic 
molecules (Orive et al., 2005); this can be achieved encapsulating drugs in 
suitable carriers. Micro and nanoparticles as controlled drug delivery 
systems can minimize active molecules degradation and loss and, at the 
same time, reduce side effects and prevent collateral and toxic effects; can 
increase drug absorbance and bioavailability improving drug biodistribution 
and penetration in cellular compartment, overcoming the biological 
membrane barrier. 
2.1.1 Critical issues in microencapsulation 
There are a large number of microencapsulation processes and the selection 
of the preferred once is not always a simple task and depends on the active 
molecules dimension and solubility, the solvents employed, the delivery 
systems desired size, the process and product economics (Nack, 1970). What 
is common to the most of the methods certainly is the difficult concerning 
technical problems such as to control the final properties of the produced 
carriers in terms of size, stability, drug encapsulation efficiency, all issues 
becoming more pronounced as particle size is reduced. In particular, 
bioactive molecules, especially those of new biotechnological production to 
be used as therapeutic agents, are usually high degradable and sensitive to 
heat and organic solvents, available only in small quantities and very 
expensive. Therefore, the stability and the biological activity of the drugs 
should be not affected during the microencapsulation process, moreover the 
drug yield and its encapsulation efficiency as well as its stability should be 
high. Vectors final features and quality should be good and reproducible and 
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the process should be easy and cheap, useful at an industrial scale. Moreover 
the process should ensure a residual level of organic solvent lower than the 
limit value imposed by the European Pharmacopeia (Benita, 2006). 
Unfortunately, most of the conventionally used methods to produce active 
molecules delivery systems are too expensive, not energy-efficient and with 
any consideration for the source of materials used and manufacturing waste. 
A process intensification is required in order to achieve a process 
miniaturization, reduce the capital cost, improve safety and energy efficiency 
and improve product quality. 
To the light of these difficulties affecting the conventionally used 
techniques, novel microencapsulation processes including simpler scale-up 
procedures should be developed, which may also increase the scope of 
commercial products reducing its costs and improving their quality. In that 
regard the ultrasonication is the key process intensification tool adopted in 
this thesis for nanostructured vectors production, its principles and benefits 
will be in dept discussed in 4.1.1.1 paragraph. 
2.1.2 Materials of vectors 
Micro and nanoparticles, included several reservoirs, such as micro/ 
nanocapsules, micro/nano-spheres and lipid micro/ nanoparticles, have 
attracted wide attention of researchers in various areas as they can be 
structured starting from a variety of materials whose nature can be organic or 
inorganic. Inorganic structures include magnetic particles, quantum dots, 
carbon nanotubs and gold particles whereas organic complexes include lipid 
and polymer conjugated particles (Yildirimer et al., 2011). 
Among them, lipidic and polymeric micro and nanoparticles are the most 
important ones reflecting not only the functions but also the main features of 
an ideal drug delivery system (Bochicchio et al., 2016b). 
In particular, polymeric particles can be prepared from both natural polymers 
(e.i., chitosan) and synthetic biodegradable and biocompatible polymers (e.i., 
poly-lactic-co-glycolic acid (PLGA)) (Hadinoto et al., 2013), due to their 
high structural integrity, stability during storage, and controlled release 
capability have been widely used as therapeutic delivery vehicles (Peer et 
al., 2007). Compared to polymeric carriers, the lipid once, which can be 
prepared from both natural and synthetic phospholipids, have been 
considered as the more ideal drug delivery vehicles because of their superior 
biocompatibility and similarity to biological membranes (Figure 1). 
However, the choice between them is highly dependent on the chemico-
physical properties of the active molecules to be encapsulated and on the 
usage. 
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Figure 1. Cellular mimetic behaviour of liposomes as delivery systems (van der 
Meel et al., 2014) 
Taking into account that each application requires a particular carrier 
features in term of size, surface charge, and other specific characteristics 
such as stimuli responsive ability (i.e. mucoadhesion), the evaluation of the 
starting material which will constitute the carrier is of fundamental 
importance. 
2.2 Lipid carrier systems for therapeutic and 
nutraceutical agents delivery: liposomes 
Among the several vectors used or the use of which has been explored/is 
under investigation, the main role is played by lipid carriers for their 
advantages of higher degree of biocompatibility and versatility. Lipid-based 
Drug Delivery Systems (DDSs) are safety and efficacy carriers which can be 
eaisily tailored to meet different disease conditions, route of administrations, 
costs, product stability, toxicity and efficacy (Attama et al., 2012). Lipid 
DDSs can assume disparate structures. Solid Lipid Nanoparticles (SLNs) are 
lipid-based DDS and represent an evolution of emulsions, the oil of the fat 
emulsion is replaced by solid lipids giving a solid at room temperature. SLN 
are stable and can give protection of the incorporated drug from degradation 
assuring drug controlled release and low cytotoxicity (Weber et al., 2014). 
These particles can be prepared without the use of organic solvents and a 
large scale production through high pressure homogenization can be 
obtained, however the drug loading capacity of conventional SLN is limited 
by the solubility of drug in the lipid melt and its rapid loss due to the 
structure of the lipid matrix. To overcome these limits Nanostructured Lipid 
Carriers (NCLs) have been proposed. These particles are similar to the SLN 
but are composed of different fatty acids mix, this composition increases the 
drug loading and prevents drug expulsion (Mukherjee et al., 2009). Lipid 
Nanocapsules (LNCs) are also lipid particles characterized by a core-shell 
structure, with a liquid oil core and an external solid lipid layer. These 
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particles can be produced through the phase inversion temperature (PIT) 
method (all the production techniques are described in chapter 3).  
Finally, there are liposomes, the lipid vesicles object of study of this thesis, 
whose main features are below discussed. 
Liposomes 
Liposomes are closed vesicular structures, constituted by one or more 
phospholipid bilayers, which are formed when membrane lipids are 
dispersed in an excess of water. Differently from micelle, in the liposomes 
both the internal and the external regions are aqueous. 
According to their lipophilicity, active molecules can be encapsulated in 
liposomes by different ways: inside the lipid bilayer, in the aqueous volume, 
or at the interface between the lipid bilayer and the aqueous volume (Figure 
2). 
 
Figure 2 Liposomes representation (Deshpande et al., 2013) 
In addition liposomes are highly biocompatible and biodegradable carriers 
known to possess low intrinsic toxicity and immunogenicity (Sawant and 
Torchilin, 2012). Liposomes are also versatile systems in terms of size and 
chemical modifications. They can be easily reduced in size and coated with 
different polymers and their surface can be chemically modified with 
specific ligands to give active targeting. These characteristics together with 
their similarity to biological membranes make them vectors of great interest 
when compared with the more common polymer-based vectors, even if the 
polymeric vectors can be intelligent carriers due to the stimuli-responsive 
behaviours (Cascone et al., 2012, Dalmoro et al., 2010, Dalmoro et al., 2012, 
Barba et al., 2013). 
Liposomes can be classified on the basis of their size and their composition 
(Coelho et al., 2010), as detailed in Table 2. 
  
Chapter 2   
12 
Table 2 Liposomes classification by size / structure (Coelho et al., 2010, 
Samad et al., 2007) 
Liposome Essential description 
Liposome classification by size 
SUV 
(Small Unilamellar Vesicle) 
Size: from about 20 to 200 nm. 
They have only one lipid bilayer. They are 
thermodynamically instable with tendency to 
fusion; are not rapidly degraded by the RES 
(Reticuloendothelial System), thus have a long 
half-life in the blood stream. 
LUV 
(Large Unilamellar Vesicle) 
Size: from about 200 nm to 1 μm. 
They have only one lipid bilayer. They can 
carry hydrophilic drugs and macromolecules 
and have a short half-life in the blood stream. 
GUV 
(Giant Unilamellar Vesicle) 
Size: bigger than 1 μm. 
They are constituted by one phospholipid 
bilayer. 
OLV 
(Oligo Lamellar Vesicle) 
Size: from 100 nm to 1 μm. 
They are constituted by several concentric 
phospholipid bilayers (approximately 5 lipid 
bilayers). 
MLV 
(Multi Lamellar Vesicle) 
Size: bigger than 0.5 µm. 
They are constituted by several concentric 
phospholipids bilayer membranes (5-25 lipid 
bilayers). Both lipophilic and hydrophilic drugs 
can be encapsulated. They are stable structures 
and are easily eliminated by the 
Reticuloendothelial System (RES). 
MVV 
(Multi Vesicular Vesicle) 
Size: bigger than 1 µm. 
They are similar in size to MLVs but are multi 
compartmental structures constituted by vesicles 
surrounded by other vesicles. 
Liposome classification by composition 
Conventional liposome Composed by neutral or anionic phospholipids 
and cholesterol; quickly adsorbed by the RES. 
pH-sensitive liposome Characterized by the carboxyl group of 
cholesteryl hemisuccinate or oleic acid; they 
release their content in acidulous environment. 
Cationic liposome Characterized by cationic phospholipids; able to 
carry big molecules with negative charges such 
as DNA or RNA. 
Long-circulating liposome Composed by neutral phospholipids and 
cholesterol; they have a long circulation time in 
blood (half-life 40 h). 
Immunoliposome Characterized by the presence of antibodies on 
their surface which increase their specificity. 
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Due to their unic features, liposomes can be used as delivery systems in 
many fields of application such as pharmaceutical, medical, nutraceutical 
and cosmoceutical. In particular, in nutraceutical field liposomes are used as 
packaging material to deliver many bioactive ingredients such as vitamins, 
proteins and other micronutrients (i.e. iron) (LIU et al., 2013). On the other 
hand, in pharmaceutical field, the flexibility of liposomes to couple with site-
specific ligands to achieve active targeting makes them increasingly 
important to deliver NABDs for gene therapy and different kind of peptides 
for new treatments (Smith et al., 1997, Immordino et al., 2006). In that 
regards, liposomes protect molecules by the action of degrading agents 
present in the blood stream and prevent their elimination by the immune 
system, solving the problem of therapeutic molecules short half-life. 
2.2.1 Critical issues in therapeutic and nutraceutical agents 
delivery 
During recent years, new therapeutic strategies, such as gene therapy, have 
been introduced into clinical practice. The discovery of NABDs, for 
instance, such as siRNA molecules, has definitely opened new therapeutic 
perspectives, however their use is still very limited due to their low stability, 
their limited membrane-permeability and their short half-life in the 
circulatory system. Indeed, the delivery of genetic material in vivo is the 
major obstacle in siRNA therapies and a number of intracellular and 
extracellular barriers must be overcome. SiRNAs, as well as all nucleic acid 
structures, are hydrophilic and negatively charged molecules. In normal 
conditions, the double phospholipid layer, which forms the cell plasma 
membrane, represents an impermeable barrier to polar and big 
macromolecules (Bochicchio et al., 2014). At physiological pH, the 
phosphate groups of the RNA backbone are deprotonated, therefore 
negatively charged, and the diffusion of these poly-anions is particularly 
difficult in the cells. Moreover, nucleic acids have a short half-life in the 
circulatory system indeed they are easily degraded by endo- or exo-
nucleases and, subsequently, they are eliminated by the kidneys. Another 
problem regards siRNA immune response activation and, because immune 
reactions can vary among different cell types, it is difficult to anticipate all in 
vivo response based on in vitro work. In Table 3 the main problems related 
to “naked” siRNA administration are shortly summarized. 
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Table 3. Problems of naked siRNA for clinical uses (David et al., 2012) 
Naked siRNA 
Problems Causes 
Short half life 
- Serum nuclease susceptibility 
- Rapid renal clearance 
- Phagocyte uptake 
Reduced uptake by cells 
- Anionic nature 
- Too large to pass membrane 
To solve these issues, the current strategy is the encapsulation of these 
macromolecules not only to reduce their toxicity, to improve their 
pharmacokinetics properties and to improve the stability of the drugs, but 
also to increase their efficiency (Miele et al., 2012). 
The increasingly knowledge about the mechanisms involved in cell signaling 
pathways and their communication systems has allowed to identify new 
therapeutic targets which can involve such the use of molecules already 
know, but never used before for treatment of that disease, as the use of new 
chemically manufactured active-molecules. In addition to the NABDs, there 
are many different molecules which can have therapeutic properties such as 
protein, peptides, vitamins and antibody. 
Peptides are molecules of great interest in therapeutic field as, along with 
proteins, are key regulators of biological functions and, as therapeutic 
agents, offer high biological activity associated with high specificity and low 
toxicity (Funke and Willbold, 2012). Protein engineering has revolutionized 
the therapeutic field by providing new tools to customize existing proteins or 
to create novel ones for specific clinical applications (Carter, 2011). New 
synthetized molecules can be for example copies or optimized versions of 
endogenous human proteins which can be used for receptors inibition or can 
be themselves overexpressed in order to treat the deseases. In medical field 
these molecules suffer from the same problems seen for NABDs, concerning 
their delivery in naked form through biological membranes, this step is 
particularly difficult for high molecular weight and hydrophilic peptides. 
Furthermore, their susceptibility to enzymatic degradation makes peptidic 
structures high degradable, characterized by in vitro and in vivo instability, 
immunogenicity and short half-life (Pisal et al., 2010). Encapsulation is an 
effective approach which can be used to prolong the shelf life and improve 
the bioavailability of peptides such as a wide variety of other molecules 
(Ulrich, 2002). 
The situation is not different for micronutrients, such as vitamins and iron, 
which have great beneficial effects both when used in strictly medical field 
that if used in nutraceutical once but, due to their low stability, it is essential 
to encapsulate these molecules in suitable nanostructured vectors (LIU et al., 
2013). Indeed, antioxidant nutraceutical products have received considerable 
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interest due to their safety profile and their potential therapeutic effects 
against cardiovascular diseases (CVD), cancer, diabetes and obesity 
(Rajasekaran et al., 2008) but it is essential to wrap this micronutrients in 
protective materials in order to prevent their deterioration. 
Moreover, during food processes such as pasteurization and sterilization, 
vitamins and micronutrients such as iron are exposed to adverse thermal 
degradation, in this case packaging material represent an efficient way for 
controlling nutraceutical delivery and improving and promoting the growth 
of the nanofood industry. 
It is important to underline that a market insight report on liposomes, divided 
into Therapeutic, Cosmetic and Other fields of applications, covering more 
then 330 companies that are engaged in liposomes research/supply, 
worldwide Patents, partnership, collaborations, mergers and acquisitions, 
shows a tremendous growth of this carriers in all the application fields and 
all over the world. The report gives a global market estimation and 
prediction of liposomes trend for the 2005-2020 time period (RITMIR028: 
Liposomes – A Market Insight Report, July 2013 © RI Technologies - 
www.researchimpact.com). 
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3.1 Lipid carrier production 
Nowadays there is a vast array of possibilities to produce lipid-based drug 
delivery systems. The choice of the preparation method is influenced by 
several factors, the main of which to be considered are: 
1. the physicochemical characteristics of both the molecule to be 
encapsulated and the lipid material used in carrier formulation; 
2. the application and its involved processes; 
3. the nature of the medium in which the lipid vesicles are dispersed. 
Different are the methods that have been described in the literature for the 
production of lipid nanoparticles and are discussed along, with their 
advantages and disadvantages. 
3.1.1 Methods for lipid nanoparticles production 
Different are the methods used for the production of lipid nanoparticles, the 
main used are: High Pressure Homogenization, Microemulsion, 
Emulsification-Solvent Evaporation and Phase Inversion Technique, along 
described. 
3.1.1.1 High Pressure Homogenization 
High Pressure Homogenization technique was introduced by Siekmann and 
Westesen in 1992 for lipid nanoparticles dispersion production (Siekmann 
and Westesen, 1992) and then the technique was developed by Mϋller and 
Lucks, in 1996, for solid lipid nanoparticles (SLNs) production. This method 
is widely used for SLN, nanostructured lipid carriers (NLC) and lipid-drug 
conjugates (LDC) preparation (How et al., 2013, Mukherjee et al., 2009, 
Üner, 2006) as well as for downsizing large lipid vesicles in order to achieve 
nanometric liposomes (Pupo et al., 2005, Barnadas-Rodrı́guez and Sabés, 
2001). 
In High Pressure Homogenization method lipids are pushed with high 
pressure (100–2000 bar) through a narrow gap of few micron ranges 
(Singhal et al., 2011). The fluid accelerates on a very short distance to very 
high velocity (over 1000 Km/h) and the high shear stress and cavitation 
forces generated in the homogenizer cause the distruption of lipid particles to 
submicron range (Chaturvedi and Kumar, 2012). There are Hot and Cold 
High Pressure Homogenization. In the first technique the lipid nanoparticle 
dispersion is achieved using tempertures above the melting point of the lipid 
used. The drug to be loaded and lipids are dispersed, under stirring by a 
high-shear mixing device, in a hot surfactant solution. The pre-emulsion 
formed is then homogenized by using a piston-gap homogenizer or a jet-
stream homogenizer in order to produce a hot colloidal emulsion. This o/w 
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nanoemulsion is cooled down to room temperature to recrystallize the lipids 
leading to nanoparticles formation. The process produces nanoparticles on 
large scale but the technique presents some disadvantages: increasing the 
homogenization leads to an increases of the particle size due to the 
coalescence which occurs because of the high kinetic energy of the particles 
(Mukherjee et al., 2009). Furthermore, high temperature lead to degradation 
of active compounds and hence loss of drug into the aqueous phase during 
homogenization. Finally, the tecnique is not appropriated for hydrophilic 
drugs, infact during the homogenization of the melted lipid phase the drug 
will partition to the water phase resulting in a too low encapsulation rate 
(Chaturvedi and Kumar, 2012). Cold High Pressure Homogenization has 
been developed to overcome some of problems of the hot homogenization. 
The first preparatory step is the same as in the hot homogenization, the lipid 
formulation is melted above its melting point and drug is dissolved in it. 
Then the system is rapidly cooled down using dry ice or liquid nitrogen to 
minimize the thermal exposure of the sample. After solidification, the lipid 
mass is grounded using mortar milling to yield lipid microparticles in a 
range between 50 and 100 µm. Then the lipid microparticles are dispersed in 
a cold surfacatant solution obtaining a cold pre-suspension of micronized 
lipid particles. This suspension is passed through an high pressure 
homogenizer at/or below room temperature and the microparticles are 
broken down to nanoparticles (Bleve et al., 2011). Large particles can be 
achieved but drug can be expulsed during storage (Shah et al., 2015). 
High pressure homogenization is a process that can be used for large scale 
production of lipid nanoparticles and to downsize lipid vesicles, however, 
this technique require extremely high energy inputs, such as pressure, heat 
and shear forces. 
3.1.1.2 Microemulsion  
In 1943 Hoar and Shulman introduced the concept of microemulsion, they 
prepared the first oil in aqueous surfactant solution, adding an alcohol as a 
cosurfactant (Hoar and Schulman, 1943). Microemulsion technique can be 
used for lipid nanoparticle production. In particular, this method is used for 
solid lipid nanoparticles production using microemulsion dilution technique 
(Gasco, 1993). In this method water, co-surfactant and surfactant are mixed 
and heated to the same temperature as the lipids, the mixture is then added, 
uder stirring, to the lipids, obtaining a microemulsion. The hot 
microemulsion is then diluted into an excess of cold water and this reduction 
in temperature causes breaking of the microemulsion, converting it into 
nanoemulsion, which upon recrystallization of lipid phase produces lipid 
particles (Chaturvedi and Kumar, 2012). In order to incapsulate hydrophilic 
molecule, a multiple w/o/w microemulsion can be prepared and lipophilic 
drug can be added in it. Microemulsion technique offers different advantages 
which include no need for specialized equipment, low energy inputs and it 
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can be used for scale-up the production of lipid nanoparticles. The major 
limitation in using this method is that additional efforts are needed to remove 
the surfactant, which can be toxic, using additional steps such as 
ultrafiltration, ultracentrifugation or dialysis (Battaglia et al., 2014). 
3.1.1.3 Emulsification-Solvent Evaporation 
In 1992 Sjöström and Bergenståhl described solid lipid nanoparticles 
production using Emulsification-Solvent Evaporation technique (Sjöström 
and Bergenståhl, 1992). In this method lipids are dissolved in a water-
immiscible organic solvent and emulsified in an aqueous phase. Then the 
organic solvent is evaporated under mechanical stirring at room temperature 
and reduced pressure, living lipid precipitates nanoparticles (Mehnert and 
Mäder, 2001, Bouchemal et al., 2004). Hydrophilic drugs can be 
incorporated by this techniques preparing a w/o/w emulsion and dissolving 
the drug in the internal water phase (Yassin et al., 2010). The solvent 
evaporation must be fast in order to avoid particles aggregation. Particles of 
100 nm can be produced with no sophisticated equipment however different 
are the limits of this technique. First of all the solubility of some lipids in 
organic materials lead to dilute dispersions with low lipid particles content. 
The diluited dispersion need to be concentrate by different processes such as 
ultra-filtration, evaporation and lyophilization. On the other hand increasing 
lipid content the efficiency of homogenization decreases due to the high 
viscosity of the dispersed phase (Mehnert and Mäder, 2001). 
3.1.1.4 Phase Inversion Technique 
Phase Inversion is a common technique used for nanoemulsion preparation. 
In 2002 Heurtault and his research group adapted this method for lipid 
nanoparticles preparation (Heurtault et al., 2002) and in 2009 Huynh and 
coworkers used this method for the preparation of LNCs (Lipid 
Nanocapsules) (Huynh et al., 2009). 
This tecnique takes advantage of polyethoxylated surfactants ability to 
modify their affinities for water and oil as a function of the temperature. The 
inversion take place at the temprature know as Phase Inversion Temperature 
(PIT) which concept was introduced in 1964 by Shinoda and Arai (Shinoda 
and Arai, 1964). Above the PIT an oil/water emulsion will change to a 
water/oil emulsion (Das and Kinsella, 1990). At first lipid, surfactant and 
water are mixed in the right ratio, the sample is then exposed to thermal 
treatment after which the inversion of emulsion is generated. The last step is 
the dilution with cold water which induced a thermal irreversible shock 
leading to the formation of nanometric lipid particles. 
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3.1.2 Methods for liposomes production 
Since their discovery in 1965, many techniques and methodologies have 
been envolved for the manufacture of liposomes on small and large scales, 
for different applications (Mozafari, 2005). There are three main classes of 
liposomes conventional production methods, classified on the bases of the 
three principal liposome production steps: 1) lipid hydration; 2) regulation of 
liposome size; 3) removal of non-encapsulated drug (Samad et al., 2007). 
Lipid hydration step includes mechanical methods, methods based on 
organic solvents and methods based on detergent removal. After the lipid 
hydration step liposome size have to be regulated and the non-encapsulated 
drug have to be removed. 
In recent years new techniques have been introduced for liposomes 
formulation such as Membrane Contactor Technique, Supercritical Fluid 
methods, Heating method, Spray Drying, Freeze Drying, Microfluidic 
channel method, Dense Gas technique and Cross Flow Injection technique, 
these methods along with the conventional once are discussed below. 
3.1.2.1 Lipid hydration techniques 
The first step in liposome production is the lipid hydration which can be 
achieved through mechanical methods, methods based on organic solvents 
and methods based on detergent removal. 
Mechanical methods 
Thin film hydration 
The thin film hydration was the first mechanical method, introduced by 
Bangham and coworkers, for liposome preparation and nowadays is one of 
the most widely used technique for liposome production (Meure et al., 2008, 
Bangham and Horne, 1964). A rotating evaporator is used in these methods. 
Lipids are firstly dissolved in an organic solvent such as chloroform or 
methanol. The organic solution is then evaporated and the wall of a rotating 
vessel covered by a thin lipid layer. The layer is then hydrated, under 
adequate stirring, by an aqueous buffer solution containing the hydrophilic 
drug to be loaded. The temperature of the hydrating medium should be 
above the gel-liquid crystal transition temperature (Tc or Tm) (Dua et al., 
2012). If the drug have hydrophobic nature it can be mixed with the organic 
solvent and lipid formulation. The process allows the formation of 
Multilamellar Vesicles (MLVs), which can be reduced in size to produce 
Small Unilamellar Vesicles (SUVs). The process can be optimized by using 
glass beads which allow the generation of thinner lipid layers by increasing 
their surface, thinner layers increase the efficiency of hydration and drug 
entrapment. One of the main advantages in using this methods lies in its 
easiness to perform and low cost, in addition all different kinds of lipid 
mixtures can be used and high encapsulation rates of hydrophobic and 
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hydrophilic molecules can be achieved (Wagner and Vorauer-Uhl, 2010). On 
the other hand the method is not scalable and toxic solvent traces could be 
remain in the final formulation. To overcome this limitation Ran and 
Yalkowsky have used halothane, a commonly inhalation anesthetic,
 
in place 
of either chloroform or ether, to prepare liposomal formulations (Ran and 
Yalkowsky, 2003). 
Methods based on organic solvents 
Double emulsion 
Double emulsion involves lipids dissolution in a water/organic solvent 
mixture, the aqueous phase will form droplets in the organic solvent. Then 
the organic solution, containing water droplets, is introduced into an excess 
of aqueous medium followed by mechanical dispersion. By this way water-
in-oil-in-water (W/O/W) double emulsion is achieved. After mechanical 
vigorous shaking, part of the water droplets collapse giving Large 
Unilamellar Liposomes (LUVs) (Dwivedi and Verma). In 1994 Zengh and 
coworkers have utilized the double emulsion technique for the 
microencapsulation of hemoglobin in liposomes using a film 
dehydration/rehydration approach (Zheng et al., 1994). In 2006 Wang and 
coworkers have described a double emulsion based method for the 
preparation of unilamellar liposomes containing disaccharides as 
lyoprotectants in both the inner and outer aqueous phase. In 2008 a novel 
method for fabricating phospholipid vesicles with high encapsulation 
efficiency using controlled double emulsions was described by Shum and his 
research group. With this approach a W/O/W double emulsion is generated 
in a glass microcapillary device where the size of the capillaries used and the 
flow rates of the different phases are controlled. The solvent is removed 
through evaporation at low rate giving 20 μm to 150 μm liposome vesicles 
with high encapsulation efficiency (Shum et al., 2008). 
Solvent injection 
In solvent injection methods there are two miscible phases, one of which 
contains dissolved lipids, which are mixed together leading to lipids 
aggregation to form liposomes. The most studied solvent injection methods 
includes Ether Infusion and Ethanol Injection methods. In the first step of 
Ether diffusion method lipids are dissolved in diethyl ether or ether/methanol 
mixture and slowly injected to an aqueous solution mantained at 55-65 °C or 
under reduced pressure. If the drug to be encapsulated is hydrophilic it can 
be dissolved in this aqueous solution. The second step consists in the 
removal of ether under vacuum which leads to the formation of liposomes 
70-190 nm in size (Riaz, 1996). The Ethanol Injection method was described 
in 1973 by Batzry and Korn (Batzri and Korn, 1973) and then by Kremer 
and coworkers in 1977 (Kremer et al., 1977). In this method lipids are 
dissolved in ethanol then the rapid injection of the lipid solution into the 
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aqueous media allows to the formation of liposomes 30-110 nm in size. 
Many variants of this technique have been made by several reaserch groups 
(Phapal and Sunthar, 2013). In 2001 Maitani and coworkers modified this 
method to produce liver targeting liposomes. At first, phosphatidylcholine, 
cholesterol, β-sitosterol β-D glucoside and oleic acid were mixed in warm 
absolute ethanol in a round bottom flask at about 60 °C and then 70 °C water 
was added rapidly to the lipid-ethanol solution. After liposomes formation 
the ethanol was removed by evaporation uder reduced pressure. They have 
obtained 150-160 nm liposomes (Maitani et al., 2001). By the same method 
in 2007 they have produced cationic liposomes rich in DOPE, containing 
DNA, in order to improve the efficacy of liposomes as vector systems for 
gene delivery (Maitani et al., 2007). Hauschild and collaborators have 
developed a modern variation of ethanol injection method: the inkjet 
method. They used an inkjet printer to inject a phospholipid solution into 
water, achieving 50-200 nm SUVs with efficient encapsulation of drugs 
(Hauschild et al., 2005, Meure et al., 2008). In general, the ethanol injection, 
being a bulk technique, does not allow to have a strict control on liposomes 
final size and the product volumes in output are small. Although, considering 
its simplicity, low cost and rapid execution, some aspects of this technique 
have been resumed in this thesis and coupled with the microfluidic principles 
(Chapter 4; 4.2 section), overcoming the limitations of ethanol injection 
method linked to low volumes in output and the impossibility in having 
particles dimensional features control. 
Cross-flow Injection 
Wagner and coworkers in 2002 have developed the cross-flow injection 
system. Based on the ethanol injection method, they developed a scalable 
production technique of liposomes to overcame some of limitation of the 
precedent technique (Wagner et al., 2002a). They invented the crossflow 
injection apparatus consisting of the crossflow injection module, vessels for 
the polar phase (PBS-buffer solution) and ethanol/lipid solution and a 
nitrogen pressure device. At first lipids are dissolved in 95% ethanol at 55 
°C. The aqueous solution is pumped with a peristaltic pump; while pumping 
the polar phase through the crossflow injection module the ethanol/lipid 
solution is injected into the polar phase with varying pressures applied by a 
nitrogen pressure device. By varying different parameters such as the 
injection pressure, buffer flow rates and lipid concentration they 
demonstrated that parameters such as the injection hole diameter do not 
influence the vesicle forming process in contrast with lipid concentration and 
the injection pressures which instead strongly influence vesicles size 
distribution (Wagner et al., 2002b). 
Reverse Phase Evaporation (REV)  
In 1978 Szoka and Papahadjopoulos described the reverse phase evaporation 
(REV) method for unilamellar liposome production (Szoka and 
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Papahadjopoulos, 1978). In this technique phospholipids are dissolved in 
organic solvent, usually diethylether, isopropylether or a mixture of 
isopropyl ether and chloroform and aqueous buffer. The resulting two-phase 
system is sonicated briefly until the mixture becomes a clear one-phase 
dispersion. The organic solvent is then evaporated under reduced pressure 
leading to liposome formation. This technique has been used to encapsulate 
different large and small hydrophilic molecules (Pidgeon et al., 1987, 
Canova-Davis et al., 1986). In 2014 Oliveira and coworkers utilized this 
method to produce diminazene aceturate loaded liposomes for the treatment 
of trypanosomosis (Oliveira et al., 2014). As for the other techniques also for 
this method some variations have been developed by different research 
groups. Otake and coworkers in 2003 have described the Supercritical 
Reverse Phase Evaporation Method (scRPE) (Otake et al., 2003). They used 
a mixture of L-a-dipalmitoylphosphatidylcholine (DPPC), supercritical 
carbon dioxide (scCO2) and ethanol for the preparation of liposomes with 
high trapping efficiency for water-soluble substances, examining the effects 
of phospholipid structure, preparation pressure, and amount of ethanol used 
on liposomes physicochemical properties. 
Methods based on detergent removal 
In this technique detergents, such as bile salts or alkylglycosides, are 
utililized to solubilize lipids (Wagner and Vorauer-Uhl, 2010). Detergents 
are amphiphilic molecules which are soluble in its monomeric form until 
they reach their critical micellar concentration (CMC). Above CMC, they 
aggregate to form micelles. Lipids are mixed with detergents at their critical 
micellar concentrations leading to the formation of mixed lipid-detergent 
micelles. When the detergent is removed micelles become increasingly 
richer in lipids and finally spontaneous form LUVs. The size and properties 
of the produced liposomes depend on several factors such as the chemical 
nature of the detergent, its elimination rate, the temperature and the ionic 
strength. By this method the production of liposomes, homogeneous in sizes, 
can be carried out but detergents may denature macromolecules and may 
form aggregates with smaller compounds (Schubert, 2002). The removal of 
detergents may be difficult, many different techniques are used for its 
elimination such as dialysis, gel-permeation chromatography, contact with 
non-ionic polystrene beads. The choice of the method to be employed 
depends on the detergent nature. One of the main application of detergent 
removal method is the model membrane reconstitution, in 1995 Rigaud and 
coworkers described a strategy for proteoliposome preparation that involves 
the use of detergents. In such preparation proteins are solubilized with 
phospholipids and detergent which is then removed, resulting in the 
formation of bilayer vesicles with incorporated proteins (Rigaud et al., 
1995). 
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3.1.2.2 Liposome size reduction 
Sonication, extrusion through polycarbonate membranes and High-pressure 
homogenization are the main methods used for liposomes size reduction. 
Sonication technique is a simple and efficient method to reduce liposomes 
size (Huang et al., 2010, Woodbury et al., 2006). The cavitation phenomena 
induced by sonication can break up MLVs turning them into SUVs with 
diameters in the range of 20-100 nm. Being the ultrasounds used in this work 
as tool for liposomes size reduction and homogenization, this technique, 
along with the phenomenological aspects, will in detail described in Chapter 
four (4.1 section). In general, it is possible to adopt two different sonication 
technique on the basis of the sonicator type: probe sonication and bath 
sonication (Dwivedi et al., 2014). With the first method the tip of a sonicator 
is directly immersed into the liposomes dispersion while in the second 
method the liposomes sample is immersed in a bath and ultrasound are 
applied. 
The extrusion technique is the process whereby multilamellar liposomes are 
forced through filters with defined pore sizes to obtain a liposome population 
with a mean diameter reflecting that of the filter pore (Hope et al., 1993). 
Due to the pressure forces generated when liposomes are passed through the 
membrane, SUVs are produced from MLVs (Cho et al., 2013). The great 
number of passages of liposomes through polycarbonate filters in order to 
obtain monodispersal sample makes this technique laborious. Furthermore, a 
freezing and thawing process prior to extrusion have to be made in order to 
increases the unilamellarity and the entrapment efficiency of the liposomes. 
With high-pressure homogenization technique is also possible to reduce in 
size liposomes in order to obtain SUVs as already described in paragraph 
3.1.1.1. 
3.1.2.3 Removal of non-encapsulated drugs 
To remove non-encapsulated drugs different techniques can be adopted and 
the choice depends on the properties of both liposomes and molecules which 
have to be separate. Ultracentrifugation, for example, is a convenient and 
rapid technique but the high forces generated can be traumatic for the 
physical properties of liposomes. If the liposomes and the encapsulated 
molecules are characterized by an opposite charge a ionic-exchange resins 
can be used (Lasic and Papahadjopoulos, 1998). The size exclusion 
chromatography (SEC) is also a well know technique to separate small 
solutes from liposomes but is very laborious when an high quality separation 
is wanted due to the column pre-treatments which are required (Ruysschaert 
et al., 2005). Finally, a dialysis membrane, with the right characteristic 
depending on the molecules to be separate, can be easily used (Wallace et 
al., 2012). 
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3.1.2.4 Liposomes stabilization 
The Freeze-Drying (FD) is a well know method used to ensure the long-term 
stability of liposomes and is the most used method to store liposomes in the 
dried state. To overcame the stresses associated with freeze-drying, 
carbohydrates can be added to lipid solution as lyoprotectants before the 
lyophilization. Three main steps characterize the FD process: the freezing of 
liposomes, the primary drying, which is a sublimation process, and the 
secondary drying, which is a desorption process (Chen et al., 2010). The 
freezing step can be obtained by different way such as freezing liposomes in 
liquid nitrogen or freezing down the liposomes to −45 °C at 0.6–1 °C/min or 
at 1 °C/min, in all cases the primary freezing temperature and the freezing 
rate have a key role in determining the liposomes morphology and stability. 
Other factors influencing the formulation stability are the properties of 
drugs, the composition of lipid bilayers, the particle size, the composition in 
lyoprotectants, the dry mass ratio of lyoprotectant/lipid. These and other 
factors have to be optimized in order to improve liposome lyophilization. 
Many new techniques for liposomes production have included lyophilization 
as a foundamental step in their processes. In 2014, Yin and collaborators 
have described the ultrasonic Spray Freeze-Drying (SFD) technique for 
protein-loaded liposomal production in order to obtain transdermal delivery 
of human epithelial growth factor (Yin et al., 2014). Li and Deng have 
utilized the freeze drying of monophase solutions to achieve sterile and 
pyrogen-free submicron liposomes (Li and Deng, 2004) while Wang and 
coworkers have prepared submicron unilamellar liposomes by freeze-drying 
double emulsions (Wang et al., 2006). 
3.1.2.5 Recent development in liposomes production techniques 
Dual asymmetric centrifugation 
In 2008 Massing and collaborators proposed the Dual Asymmetric 
Centrifugation (DAC) method for the production of liposomes (Massing et 
al., 2008). This technique differs from the usual centrifugation because the 
sample is undergone, during the normal centrifugation process, to an 
additional rotation around its own vertical axis. By this way an efficient 
homogenization is achieved due to the two overlaying movements of the 
sample generated: the sample is pushed outwards, as in a normal centrifuge, 
and it is pushed to the center of the vial due to the additional rotation. At 
first, mixing hydrogenated phosphatidylcholine, cholesterol (55:45 mol%) 
and 0.9% NaCl-solution, they achieved a viscous vesicular phospholipid gel 
(VPC) which is then diluted to obtain liposomal dispersion. Liposome size 
can be regulated by optimizing DAC speed, lipid concentration and 
homogenization time. Glass beads can be also used to mix lipids. In 
optimized conditions, Massing and his research group have achieved 60 ± 5 
nm liposomes with a trapping efficacy of 56 ± 3.3% for calcein. The year 
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later they prepared also small amounts of sterile siRNA-liposomes, about 
109 nm in size, with high entrapping efficiency, ranging from 43 to 81%, 
depending on batch size (Hirsch et al., 2009). In 2011, also Adrian and 
collaborators have used the DAC method to produce liposomes containing 
siRNA, targeting the particles surface with an antibody for selective 
interaction with neuroblastoma cells, achieving 190 to 240 nm particles with 
a siRNA encapsulation efficiency up to 50% (Adrian et al., 2011). By this 
technique, in only one step, SUVs in a highly reproducible manner can be 
prepared. 
Spray Drying 
Spray drying is a continuous single step process which leads to both particle 
formation and drying and it was proposed for scaling up the liposome 
production process. Atomization of the sample, drying of the spray droplets 
and collection of the solid product are the main steps involved in this method 
(Shaji and Bhatia, 2013). At first lipids are mixed in organic solvents and the 
dispersion is pumped into the drying chamber through a spray nozzle leaving 
the sample atomized. Then the sample is dried in a concurrent air flow and 
collected in a reservoir. The dried lipids powder have to be hydrated in order 
to obtain multilamellar liposomes. Despite the numerous advantages in using 
this technique in terms of time and energy consuming, many are the 
difficulties in achieving stable liposomes. Different research groups have 
used this technique to produce loaded drug liposomes successfully, other 
have found many problems with respect to their stability. Silva and 
collaborators have obtained two populations of beta-carotene loaded 
liposomes, with average particle sizes around 300 and 1500 nm (Silva et al.). 
Sweeney and coworkers have used efficiently Spray-freeze-dried method to 
produce liposomal ciprofloxacin powder for inhaled aerosol drug delivery 
(Sweeney et al., 2005). Instead, Karadag and coworkers have recently 
confirmed the difficulty in prepare functional liposomal powders using 
conventional wall materials. In order to avoid thermal and environmental 
liposomes instability they adopted the “Layer-by-Layer” (LbL) depositing 
method, coating the surface of anionic lecithin liposomes with a cationic 
chitosan and adding maltodextrin as wall material to facilitate spray drying. 
When liposome were coated no liposomes aggregation or breakdown was 
observed and stable vesicles about 500 nm were achieved (Karadag et al., 
2013). 
Membrane Contactor  
Membrane contactor technique have already been used for the preparation of 
polymeric and lipidic nanoparticles and, most recently, it has been proposed 
for the preparation of liposomes. In 2011 Jaafar-Malej and coworkers have 
described a new method for liposome preparation based on both the 
principles of the ethanol-injection and membrane contactor methods. They 
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prepared liposomes 150-286 nm in size by mixing lipids in ethanol and 
pressing the obtained phase, at temperatures above the melting point of the 
lipids, through a membrane with a specified pore size, allowing the 
formation of multiple microflow streams. An aqueous phase flowed 
tangentially to the membrane surface leading to the formation of vesicles as 
the two miscible phases interdiffuse, hydrating the phospholipids (Jaafar-
Maalej et al., 2011). In 2012 Laouini and coworkers have utilized this 
technique to produce 100 nm spironolactone loaded liposomes achieving an 
encapsulation efficiency of 93 % (Laouini et al., 2012a). 
Heating method  
This method consists in mixing lipids and glycerol with aqueous solution, 
along with the material to be encapsulated, in a heat-resistant flask at a 
temperature above the Tc of the lipids and under an inert atmosphere. Has 
been demonstrated that liposomes and nanoliposomes can be formed by the 
heating method (HM) which have been successfully employed for gene 
transfer applications (Mozafari et al., 2002). Mozafari, in 2005, had modified 
the HM improving liposome monodispersity and storage stability. The 
variation apported to the so called “Mozafari method” consists in add lipids 
to a preheated mixture of nisin and a polyol such as glycerol in a heat-
resistant flask. The suspension is then leaved to stabilize at temperatures 
above the Tc under an inert atmosphere (Mozafari, 2010). Glycerol acts as 
isotonising and disperdant agent stabilizing liposomes and there is no need to 
remove it from the preparation. The particle size depends on the 
phospholipid nature, charge, the speed of the stirring and the shape of the 
reaction vessel thus the liposome dimension can be controlled (Laouini et al., 
2012b).  
Microfluidic method 
Microfluidic method is a relatively new technology used for the production 
of liposomes, this technique gives the possibility to control the lipid 
hydration process. The method can be classified in continuous-flow 
microfluidic and droplet-based microfluidic methods, according to the way 
in which the flow is manipulated (Yu et al., 2009). In 2004, Jahn and 
collaborators have described a microfluidic hydrodynamic focusing (MHF) 
method which operates in a continuous flow mode. In this technique a 
stream of isopropyl alcohol containing the dissolved lipids is 
hydrodynamically focused in a microchannel cross junction between two 
aqueous buffer streams. Monitoring the flow rates, thus controlling the lipids 
solution/buffer dilution process, dimension of liposomes can be controlled. 
They determined also that the liposomes size can be controlled by altering 
the ratio of the flow rate in the side inlet channels compared to the center 
inlet channel (Jahn et al., 2004). In 2006, Tan and coworkers have described 
a microfluidic based method to control liposome vesicles formation. The 
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method is based on a microfluidic device in which channel junctions are 
used in order to generate droplets which sizes is controlled by monitoring the 
flow rate. An expanding nozzle is used to control the breakup location of the 
droplet generation process. By this way monodispersed submicron droplets 
were achieved (Tan et al., 2006). Many variants of microfluidic method have 
been described in literature (Pradhan et al., 2008) such as 3D microfluidic 
hydrodynamic focusing in a concentric capillary array described in 2014 by 
Hood and collaborators (Hood et al., 2014). In this thesis the microfluidic 
method has been coupled with the ethanol injection method and a simil-
microfluidic apparatus has been developed as detailed in Chapter 4 (4.2 
section). 
Supercritical Fluid method 
In recent years dense gas technique was proposed for liposomes 
manufacturing in order to overcome the issues of both conventional 
techniques (i.e. use of organic solvent, use of multiple steps, problems 
associated to the stability of the final liposomal product) and new techniques 
such as the heating method and the membrane contactor which used high 
temperature (Meure et al., 2008). Great interest has been directed to the use 
of supercritical fluid (SCF) technology as new way to produce liposomes. 
SCF-CO2 is a not toxic and not inflammable solvent which has low critical 
temperature (31 °C) and pressure (7.38 MPa) (Parhi et al.) thus it can be 
used to avoid the degradation of thermolabile substances to be encapsulated. 
In 1997 Frederiksen and collaborators used supercritical carbon dioxide for 
the preparation of liposomes containing fluorescein isothiocyanate-dextran 
(FITC-dextran) and zinc phthalocyanine tetrasulfonic acid (TSZnPc) 
choosed as water soluble model substances. They used an apparatus 
consisting of two main parts: the high-pressure and the low-pressure 
sections. First lipids were dissolved under pressure in supercritical carbon 
dioxide, and then exposed to a low-pressure in which the solution is 
expanded and simultaneously mixed with the aqueous phase. The addiction 
of 7% absolute ethanol to carbon dioxide at controlled temperature and 
pressure resulted in the production of liposomes encapsulating the water 
soluble molecules, of 200 nm in size (Frederiksen et al., 1997). There are 
many different methods in utilizing SCF (Sekhon, 2010), as the scRPE 
above mentioned as a variation of REV technique for liposome production 















































4. Novel developed techniques 
for liposomes production  
In this chapter two novel developed 
techniques, the Ultrasound assisted Thin 
Film Hydration method and a Simil-
microfluidic approach for lipid 
nanostructured vectors production are 
presented along with their layout, principles 
and main phenomenological aspects 
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4.1 Ultrasound assisted Thin Film Hydration: layout, 
principles and phenomenological aspects 
4.1.1 Generalities 
As seen in Chapter 2, the use of liposomes in several fields of biotechnology, 
as well as of pharmaceutical and food sciences, is continuously increasing: 
they could be used as carriers for drugs and other active molecules of 
industrial relevance. Among other characteristics, one of the main relevant 
features to their target applications is the liposome size. From a 
pharmaceutical point of view liposomes dimensions influence liposomes 
time of circulation in the blood stream and/or their permeability through 
membrane fenestration in tumour blood vessels, from a nutraceutical point of 
view nanometric liposomes are able to improve taste, flavor, stability, 
absorption and bioavailability of nutients. 
On this basis, a versatile and reliable technique able to produce liposomes of 
different sizes to be used for disparate applications has been developed. In 
that regard, the Thin Film Hydration method (discussed in Chapter 3, 3.1.2.1 
paragraph), which produce micrometric structures, was revisited by adding 
an ultrasound assisted step in order to prepare, in a versatile manner, 
nanometric structures with the desired dimensions. 
In particular, the size of liposomes is determined during the production 
process, decreasing due to the addition of ultrasound energy. The energy is 
used to break the lipid bilayer into smaller pieces, then these pieces close 
themselves in spherical structures. 
Here, the mechanisms of rupture of the lipid bilayer and of the sphere's 
formation was studied and modeled accounting for how the energy, supplied 
by ultrasounds, is stored within the layers, as elastic energy due to the 
curvature and as energy due to the edge, and accounting for the kinetics of 
bending phenomenon. An algorithm to solve the model equations was 
designed and the relative calculation code was written. A dedicated 
preparation protocol, which involves active periods during which the energy 
is supplied and passive periods during which the energy supply is set to zero, 
was defined and applied. The model predictions compares nicely with the 
experimental results, by using the energy supply rate and a time constant as 
fitting parameters. Working with liposomes of different sizes as starting 
point of the experiments, the key parameter is resulted to be the ratio 
between the energy supply rate and the initial surface area. 
4.1.1.1 Principles of the ultrasound process and benefits 
Ultrasound is a mechanical vibration phenomenon having a frequency above 
the range of human hearing (> 20 KHz). When ultrasound is adsorbed by a 
media, acustic vibrations increase kinetic energy, producing an instantaneous 
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temperatures and pressures rise. The explanation of the process can be found 
in cavitation-wave hypothesis, proposed in 1960. According to this 
hypothesis, when pressure changes, there is a formation of cavities at liquid-
gas intarface. The collapse of these cavities generate shock waves bubbles 
capable of resonance vibration and producing vigorous eddying or 
microstreaming. The stresses associated with the propagation of ultrasonic 
waves may be converted into thermal energy or into chemical energy. 
Ultrasound assisted processes can be used for a disparate industrial 
applications, i.e. to homogenize, atomize, disperse, deagglomerate and sizing 
particles, emulsify, disintegrate cells and extracting protein or enzymes from 
them, to increase reaction speed, to clean, to degass liquids. For example 
ultrasonic atomization take advantage by ultrasound-phenomenon to break 
up a liquid film into fine droplets. In this case the phenomenology of the 
droplets formation process can be explained with  cavitation-wave 
hypothesis or with the capillary wave hypothesis (Avvaru et al., 2006) which 
analyze the behaviour of a liquid on the solid surface vibrating basing on 
Taylor instability criteria (Kull, 1991). When the vibration have a frequency 
of 30 Hz, above a threshold value of amplitude, on the liquid surface 
capillary waves, made of crests and troughs, are formed. At higher values of 
amplitude liquid droplets, separated from the waves crest, are formed 
(Abramov, 1999).  
In general, ultrasonication is an easy and scalable process which shows 
competitive energy costs, applicable in a vast range of fields and for 
disparate applications. 
Regardig the particles size reduction, it takes advantage from ultrasound 
process ability to break up lipid structures. In case of nanoliposomes the 
energy is used to break the lipid bilayer into smaller pieces, then these pieces 
close themselves in spherical structures producing SUVs. In comparison 
with other sizing techniques, the ultrasonic once shows great potential due to 
reducing time spent and easiness in use. Ultrasonic process not need a 
number of passages of liposome suspension through a membrane such as 
extrusion method and not high pressure have to be used (see 3.1.2.2 
paragraph). Furhermore, the final dimension of particles are not fixed to the 
pore size of the membrane but it is possible to change the vesicles size 
according to the application requirements. This is possible controlling the 
duty cycle, the discontinuous process by which the liquid sample is 
sonicated in periodic time intervals followed by switch off in energy supply. 
Finally, due to the critical importance to have a sterile environment during 
loaded SUVs production, another advantage is that sonotrode tip is simpler 
to clean and sterilize. 
The process parameters influencing the sizing process are the ultrasonic 
amplitude (%), the power (W), the number of sonication cycles and the time 
of sample exposure to ultrasound, as below detailed. 
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4.1.2 Experimental section 
4.1.2.1 Materials 
L-a-Phosphatidylcholine (PC) from egg yolk (CAS no. 8002-43-5), L-a-
phosphatidyl-DL-glycerol sodium salt (PG) from egg yolk lecithin (more 
than 99% pure), cholesterol (CHO) (CAS no. 57-88-5), potassium phosphate 
monobasic (CAS no. 7778-77-0) and sodium hydroxide (CAS no. 1310-73-
2) were purchased from Sigma Aldrich (Milan, Italy) as dried powders and 
used without further purification. All the other chemicals and reagents such 
as chloroform (CAS no. 67-66-3), ethanol (CAS no. 64-17-5), methanol 
(CAS no. 67-56-1) (Sigma Aldrich – Milan, Italy) used were of analytical 
grade. 
4.1.2.2 Layout 
Figure 3 shows a schematization of nanoliposomes production process 
through the ultrasound assisted Thin Film Evaporation technique developed. 
 
Figure 3. Process schematization of nanoliposomes production through the 
ultrasound assisited Thin Film Hydration method; the main steps are 
reported: lipids/organic solvent solution (1) is introduced in a rotary 
evaporator (D-1) where solvents are evaporated (2) leading to the formation 
of a dryied lipid film (3) which is then hydrated (4) and stirred (D-2) After 
this step a suspension containing MLVs is produced and submitted to a duty 
cycle sonication process (Z-1) thus producing SUVs (5), finally recovered 
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The set-up is composed by four main sections: a feeding section, a solvent 
evaporation section, a liposomes production section and a recovery section. 
In particular the production section is constituted by a rotary evaporator 
(Heidolph, Laborota 4002 Control), where micrometric vesicles are 
prepared, and an ultrasonic source (VCX 130 PB Ultrasonic Processors of 
Sonics & Materials Inc., CT, USA; maximum power 130 W; frequency 20 
kHz; sonotrode tip length 137 mm; sonotrode tip diameter 3 mm), which 
gives nanoliposomes as output product. 
For liposomes production at nanometric scale at first lipids are dissolved in 
organic solvents (chloroform/methanol) eventually containing the 
hydrophobic drug to be encapsulated; after mixing, the solution is vacuum 
dryied for 3 houres at 50 °C while rotating at 30 rpm in a water bath. The 
dried lipid film which is generated is then hydrated at room temperature with 
water or other hydration solution eventually containing the hydrophilic drug 
to be encapsulated and continuously stirred at 60 rpm. A suspension 
containing MLVs is produced, maintained at room temperature for 2 hours 
and then sonicated (treated volume: 1 mL) by applying a duty cycle 
purposely developed. The duty cycle is a discontinuous process by which the 
liquid sample is sonicated in periodic time intervals followed by switch off 
in energy supply. It consists in 2 ten-second irradiation rounds (amplitude 
45%), each followed by a twenty-second pause in order to prevent thermal 
vesicle disruption thus obtaining large vesicles, on micrometric scale, 
smaller then the starting once. In particular, taking into account their size 
and the phenomenology at the base of liposomes formation (detailed in 
4.1.2.4 paragraph), in this thesis, the large vesicles obtained from the first 
two rounds of duty cycle sonication will be named Large Unilamellar 
Vesicles (LUVs) due to the presumed presence of one lipid layer composing 
their structures. The sample is then stored overnight at 4°C and protected 
from light in order to stabilize the produced LUVs. Subsequently, in order to 
obtain SUVs, after the stabilization phase, the sample is sonicated again, at 
45% amplitude (percentage of maximum deliverable power), up to four more 
rounds as detailed in the next paragraph. 
4.1.2.3 Liposomes preparation 
SUVs were prepared by using the ultrasound assisted Thin Film Hydration 
technique and applying a dedicate protocol of sonication as before described. 
Briefly, unloaded liposomes were prepared dissolving PC (40 mg), CHO (16 
mg) and PG (4 mg) at 10:8:1 (mol:mol) ratio into 1 mL of 
chloroform/methanol 2:1 (vol/vol) solvent mixture. After vigorous pipetting, 
the solvent mixture was removed by evaporation in a rotary evaporator 
(Heidolph, Laborota 4002 Control) and the achieved lipid film was vacuum-
dried for 3 hours at 50°C in a water-bath. The dried lipid film was then 
hydrated at room temperature with 7 mL of PBS (pH 7.4), pre-warmed until 
50 °C, and adequately stirred. To prepare phosphate buffer solution (PBS) 
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potassium phosphate monobasic 0.2 M and sodium hydroxide 0.2 M were 
dissolved in distilled water to obtain a pH 7.4 PBS final solution. After 
hydration, a solution of Multi Lamellar Vesicles (MLVs), was obtained. The 
sample was maintained at room temperature for 2 hours and then 1 mL of 
the solution was subjected to a sonication step in order to get Large 
Unilamellar Vesicles (LUVs). Then, the LUVs sample was stored at 4°C for 
one night, protected from light, in order to allow vesicles stabilization. In 
order to obtain Small Unilamellar Vesicles (SUVs), more sonication steps 
were carried out. Design variables of this protocol are the number of 
sonication steps as well as the “amplitude” of sonication, i.e. the power level 
at which the ultrasound applicator was activated. Both the LUVs and the 
SUVs productions therefore involved sonication steps. Each sonication step 
was designed by this way: the ultrasounds were applied to 1 mL of solution 
for ten seconds, followed by twenty seconds of time during which the 
ultrasound applicator was switched off, in order to allow the sample cooling 
and to avoid thermal degradation. Liposomes size was measured by Photon 
Correlation Spectroscopy (PCS) using the Zetasizer Nano ZS instrument 
(Malvern, UK) that incorporates noninvasive backscatter (NIBS) optics. A 
detection angle of 173 degrees was used to permit size measurements of 
turbid samples like liposomes suspensions. The resulting particle size 
distribution was plotted as number of liposomes versus size. All the 
measurements were performed in triplicate, thus the results were expressed 
as average values. 
4.1.2.4 Modelling 
In order to describe what happens to the double layer of lipids which 
constitutes the liposomes, both the thermodynamics as well the kinetics of 
the process have been studied and thus modeled. From the energetic point of 
view (thermodynamic) the free energy of the membrane is mainly given by 
two fractions: the elastic energy due to membrane curvature and the tension 
energy due to the edge of the layer. Indeed, at the boundary of a bilayer the 
polar heads have to be arranged as a semi-circle, in order to connect the two 
monolayers (Helfrich, 1974). The elastic energy has been estimated by 
Helfrich (Helfrich, 1973) as proportional to the second power of twice the 
mean surface curvature, 1 𝑅⁄ , and to Gaussian surface curvature, 1 𝑅2⁄ ; 
through the main elastic moduli, 𝑘𝑐 and ?̅?𝑐; the edge energy are assumed to 
be proportional to the length of the bilayer edge (Helfrich, 1973, Fromherz, 
1983), by the edge tension parameter, 𝛾. On the basis of simple geometrical 
reasoning (Fromherz, 1983); a disc initially of radius 𝜌𝐷, with a surface area 
𝐴𝐷 = 𝜋𝜌𝐷
2 , which is (partially) bended toward forming a sphere (equivalent 
in area, then with a sphere radius 𝑅𝑆 = 𝜌𝐷 2⁄ ), has an edge length equal to 
𝐿 = (2𝜋𝜌𝐷
2 )√1 − (𝜌𝐷
2 4𝑅2⁄ ). Summarizing, for 𝑁 vesicles with a mean 
curvature 1 𝑅⁄ , the total free energy could be estimated by equation (4.1): 
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Therefore, the thermodynamic of the process (“how much” the liposome 
formation is possible) could be described once the number and the size of the 
starting discs, 𝑁 and 𝜌𝐷, as well as the curvature of the vesicle, 1 𝑅⁄ , are 
known; after the estimation of the material parameters (2𝑘𝑐 + ?̅?𝑐) and 𝛾. 
The kinetic of the process (“how fast” the discs bends, “how fast” they’re 
broken, and “how fast” the spheres were opened and flattened) could be 
described taking into account for the rate of energy addition as well as 
considering the bending process (during which the free energy decreases) as 
a first order phenomenon (Fromherz, 1983), in which the radius of curvature 
changes proportionally to the difference between actual curvature and the 
minimum curvature (corresponding to a closed sphere of radius 𝑅𝑆). In 
formulas, this means that the energy change is described by: 
d𝑔
d𝑡
= ?̇? (4.2) 







The rate of energy addition, ?̇?, and the time-constant of the bending process, 
𝜏𝑐, are process parameters to be determined. The energy supplied to a sphere 
causes the sphere to open and to flatten (a decreases in curvature, an increase 
in radius 𝑅). When energy is supplied to a flat disc, which is characterized 
by an infinite radius of curvature, this energy is no more used to decrease the 
curvature, but to break up the disc giving rise to smaller flatten bilayer 
fragments. 
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Figure 4. The phenomena which take place during liposome formation 
Summarizing, the phenomena which take place during liposome formation 
are depicted in Figure 4, whereas the process of modelling is reported as the 
flow-sheet in Figure 5. In Figure 4 the phases in which ultrasonic energy is 
supplied are described by full line arrows; the phases “of relaxation” during 
which no energy is supplied are described by dashed line arrows. The 
coalescence phenomenon, which causes small disks to give large disks, is 
not modelled since it should take place on a time scale considerably longer 
than the one observed here. The full duration of the process is divided in 
several time-steps, ∆𝑡, and then the integration of the ODEs (4.2 and 4.3) 
was numerically carried out, accounting for the duty-cycle of energy 
supplying. The energy for flat bilayer fragments break-up was indeed 
supplied in a non-continuous mode, allowing alternate phases of disc break-
up, heat dissipation and membrane bending. The process modelling requires 
to calculate, for each time-step, the free energy, 𝑔, the disc radius, 𝜌𝐷, 
curvature, 𝑅, and the numbers of liposomes, 𝑁. 
 The process is considered to start from a single (𝑁0 = 1) LUV 
(Large Uni-lamellar Vesicle) of radius 𝑅𝑆0 (corresponding to a total 
area 𝐴0 = 4𝜋𝑅𝑆0
2 ). Under this condition the initial radius of 
curvature is equal to the sphere radius (𝑅0 = 𝑅𝑆0); the disc 
equivalent (with the same area) to the sphere, will have the initial 
radius 𝜌𝐷0 = √4𝑅𝑆0
2 = 2𝑅𝑆0; and the free energy, given by equation 
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 During the phase in which no energy is supplied, the curvature 
increases and the radius of curvature 𝑅 decreases, according with eq. 
4.3 (in Figure 5, the ODE is numerically solved according an Euler’s 
scheme. Since the model is not given only by a couple of ODEs, but 
it requires also several choices regarding the calculation path, the 
simplest numerical scheme, the Euler’s one, has to be selected. 
Anyway, the stability and the accuracy of the scheme have been 
tested reducing the time-step size until the solution remained 
unchanged). In this phase, the disc radius and the number of 
liposomes remain constant, whereas the free energy is calculated by 
eq. 4.1. 
 When the energy is supplied, first of all eq. 4.2 has to be solved 
(once more, in Figure 5 the ODE is numerically solved according to 
an Euler’s scheme). Then, two different paths have to be followed 
according to the actual curvature. 
 If the configuration is not planar (curvature different from zero, 
radius of curvature finite), the spheres open, i.e. the curvature 
decreases (the radius of curvature increases). The radius of curvature 
has to be calculated by eq. 4.1. Again, during this phase the disc 
radius and the number of liposomes remain constant. 
 At last, in presence of planar configuration, the energy supplied is 
used to increase the edge length. The length of the edge could be 
calculated from the eq. 4.1, therefore 𝐿 = 2𝑁𝜋𝜌𝐷 = 𝑔 𝛾⁄ . Since the 
total surface area remains constant, 𝐴0 = 𝐴 = 𝑁𝜋𝜌𝐷
2 ; the disc radius 
and the number of liposomes could be obtained from these two last 
equations: 𝜌𝐷 = 2𝐴𝛾 𝑔⁄  and 𝑁 = 𝐴 (𝜋𝜌𝐷
2 )⁄ , as reported in Figure 5. 
The process is then described by repeating the calculation scheme for 
each time step, on the basis of the duty cycle imposed to the sample 
(?̇? = ?̇?(𝑡)). 
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Figure 5. The model calculation flow-sheet 
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4.1.3 Results and discussion 
4.1.3.1 Part 1: Model testing 
First of all, the response of the model to external stimuli has been checked 
by applying a fictitious ultrasound duty cycle. The duty cycle is built 
applying a power term, ?̇?0, for ten seconds, followed by a “pause” in energy 
supply for other twenty seconds. The cycle is repeated twice (for a total of 
ninety seconds). There is the need for periods during which the energy 
supply is switched off in order to avoid a continuous heating of the sample. 
In the proposed model the power is intended to be fully delivered to the 
membrane, therefore actually it is a (very small) fraction of the energy 
supplied by ultrasound applicator to the sample. 
 
Figure 6. Output of the calculation model for the simulated test 
The dimensionless forcing term, ?̇?(𝑡) ?̇?0⁄ , is reported in Figure 6 as the first 
graph starting from the top: it is depicted with a behavior as a square wave, 
even if actually the transition between on and off is somewhat more slow 
and less stiff. Starting from the top, in Figure 6 these graphs have been 
reported: the already discussed duty cycle; the radius of curvature, 𝑅 in µm; 
the radius of the disc equivalent to the sphere, 𝜌𝐷 in µm; the number of 
liposomes, 𝑁; and the total free energy, 𝑔 in J. In order to perform the 
simulation, the material parameters have been taken from literature to be 
𝑘𝑐=2.3∙10
-19
J; ?̅?𝑐=0 J; 𝛾=7.0∙10
-20
 J/nm. The initial radius of the LUV was 
taken to be 𝑅𝑆0 =1 µm, giving an initial equivalent disk radius of 𝜌𝐷0= 2 µm. 
The initial energy of the structure with these choice results 𝑔0 = 8𝜋𝑘𝑐 = 




 J. The two parameters which need to carry out the simulation were 
arbitrarily chosen to be ?̇?0 = 10
-15
 W and 𝜏𝑐 = 3 s. 
 At the beginning of the simulated test, roughly for a second the 
radius of curvature increases (as it is visible in the second graph), 
meaning that the initial LUV is being opened. In this period, the 
supplied energy was used just to increase the free energy of the 
membrane (the elastic energy actually decreases, while the edge 
energy increases), therefore the equivalent disc does not change its 
size, and the number of liposomes remains constant as well on its 
initial value (which is one). The third and the fourth graphs (from 
the top in Figure 6) then show two constant value initial segments 
(since the abscissa is just one second, these segments are just 
recognizable in the graphs). During this phase, the total free energy, 
reported in the fifth graph from the top, increases from its initial 
value, 𝑔0 which is of the order of 10
-18
 J, toward values within the 
range reported in the fifth graph. The rate of this first phase is 
dictated by the value of the power parameter ?̇?0 (the higher the 
power, the faster the de-bending of the sphere). 
 During the following nine seconds, while the energy is being 
supplied, it is possible to see that: from the second graph, the radius 
of curvature remains constant on a very high value (actually the 
membrane is flat, the radius of curvature should be infinite); from 
the third graph, the radius of the equivalent disc starts to decrease 
and, from the fourth graph, the number of structures increases, both 
these phenomena are due to the fact that the membrane is being 
disrupted by the ultrasound energy; from the fifth graph, the total 
free energy increases, being stored in the structures as edge energy. 
The magnitude of the phenomena which happen during this phase 
are also dictated by the value of the power parameter ?̇?0 (the higher 
the power, the higher the number of discs produced and the smaller 
their size). 
 At the end of first ten seconds of energy supply, roughly 𝑁 = 130 
discs with a radius 𝜌𝐷 = 176 nm have been obtained (the radius of 
the sphere equivalent to the disc being 𝑅𝑆 = 𝜌𝐷 2⁄  = 88 nm), and the 
energy has reached a maximum roughly equal to 10
-14
 J. During the 
following twenty seconds the relaxation process starts, and the discs 
bend themselves toward the spherical configuration, since the total 
free energy in that configuration is lower (the elastic contribution 
being lower than the edge contribution). During this phase, thus, the 
radius of curvature decreases (the curvature increases) and the total 
free energy decreases. The kinetic of such process being dictated by 
eq. 4.3 and by the value of the time-constant parameter 𝜏𝑐 (the 
smaller the time-constant, the faster the bending process). As 
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expected, during the bending phase no more entities were produced 
and their size remains constant (𝑁 and 𝜌𝐷 are constants). 
 Starting from the thirtieth seconds, the cycle starts again. During 
about the first five seconds (up to 35 s), the discs open (𝑅 increases), 
the entities do not change number and size (𝑁 and 𝜌𝐷 remain 
constants), the total free energy increases. 
 During the remaining of supply-energy phase (about five more 
seconds), the entities were flat discs, and then the energy was used 
to disrupt them: the curvature does not change, the number of entity 
increases and their size decreases. The total free energy still 
increases. 
 From forty to sixty seconds, the relaxation phase takes place: the 
discs bend toward sphere, thus the radius of curvature decreases, and 
the total free energy decreases, too. The number and the size of 
entities remain constant. During this phase, the diameter of the 
attainable liposomes is roughly equal to 124 nm (during the 
corresponding first phase it was 176 nm), their number is increased 
to about 250. 
 Once more, starting from the sixtieth seconds, the cycle starts again. 
This time the energy supplied was almost all used to open the 
spheres (they’re a lot and very small now, and thus they require a lot 
of energy to be opened), and thus just a little decrease in entity’s size 
(and a little increase in entity’s number) was attained. Roughly, 280 
liposomes with a diameter of 120 nm were obtained. 
Even if fictitious, this “experiment” is a lot informative and useful to 
understand both the role and the relevance of the model parameter as well as 
the behavior of the real systems. For example, it is evident that – if this 
situation was real – a second cycle of ultrasound application is useful in 
order to reduce liposome size, but a third cycle could be avoided. Of course, 
with the aim of point out a real and useful model, a comparison of its 
calculation against real experimental data is mandatory.  
4.1.3.2 Part 2: Experimental results description and 
interpretation 
Two different tests were designed and carried out in order to validate the 
proposed model. 
1. For the first kind of test (identified as the Run 1), the starting point 
was a solution containing LUVs, with a diameter within the 
micrometric scale (𝐷𝐷0 = 1.4 micron), obtained starting from the 
hydrated lipid bilayer (the MLVs solution), by a single step of 
sonication. The LUVs solution, after the night of rest (see 
Experimental section for preparation details) was then subjected to 
further one, two or three steps of sonication, in order to produce 
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SUVs, for a total time of sonication of ten, twenty or thirty seconds 
of application. These three tests (identified as Run 1.a, 1.b and 1.c) 
were carried out at a constant level of power (amplitude 45%, 
nominal power 58 W). 
 
Figure 7. Output of the calculation model for real test Run 1 
2. For the second kind of test (Run 2), the starting point was a solution 
containing SUVs, therefore with a diameter already within the 
nanometric scale, even if in presence of a large standard deviation, 
which can be interpreted as a large distribution of initial diameters 
(𝐷𝐷0 = 70 nm ± 40 nm). This initial SUVs solution, working at three 
different levels of power (Runs 2.a, 2.b and 2c), was subjected to 
further one, two or three steps of sonication (Runs 2.x1, 2.x2 and 
2.x3 with x = a, b or c); all relevant parameters, including power 
levels and obtained liposome diameters, are reported in Table 4. It is 
worth to note that: i) the level of used power does not affect 
significantly the size of the liposome; and ii) increasing the number 
of ultrasound application cycles changes a little the liposome size, 
whereas decrease the standard deviation of experimental data (i.e., 
the repetition of the ultrasound application causes the narrowing of 
the size distribution). 
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Table 4. Summary of experimental results 
 
Results of the simulation of the Run 1 are reported in Figure 7, which 
organized the same way of Figure 6, showing (from the top) the ultrasound 
duty cycle, the liposome radius, the radius of the equivalent disc, the number 
of liposomes and the energy for each liposome/disc of lipid bilayer. The 
general behavior of each variable is the same already discussed for Figure 6. 
The simulation has been carried out using the same values for parameters 
already listed in the simulation of Part 1 (𝑘𝑐 = 2.3∙10
-19
 J; ?̅?𝑐 = 0 J; 𝛾 = 
7.0∙10
-20
 J/nm), and using the remaining two (?̇?0 and 𝜏𝐶) as fitting 
parameters, by comparison of the calculation results with the final diameters 
of the observed liposome, as reported in Table 4. The value obtained are: ?̇?0 
= 1∙10
-15
 W, 𝜏𝐶 = 2.8 s. The comparison between experimental data and 
calculated values is reported in Figure 8, which shows a nice agreement 
between the two series of data. It is worth to note that, even if the use of 
fitting parameters could drive the model toward the correct prediction of 
experimental data, the model itself is robust enough to account for the 
unexpected experimental observed behavior: the first ultrasound cycle 
causes a large decrease in sphere size (from 1400 nm to 86 nm), the second 
cycle causes another noticeable decrease (from 86 nm to 51 nm), whereas 
the third cycle does not change the size (51 nm is very close to 49 nm, within 
the measurement error). This could lead to the conclusion that the model is 
able to reproduce all the physical phenomena which take place during the 
process. 
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Figure 8. Experimental and calculated liposome diameters for Run 1 
The calculations related to the Run 2 (precisely the data of Run 2.a, i.e. the 
test performed using the ultrasound amplitude of 30%, corresponding to 
nominal power of 39 W) are summarized in Figure 9, which is organized the 
same way of Figure 6 and Figure 7.  
 
Figure 9. Output of the calculation model for the real test Run 2.a 
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The comparison between calculated values and experimental data is reported 
in Figure 10 for Run 2.a, and once more it shows a nice agreement between 
the two series of data: the calculated values falls well inside the confidence 
range given by standard deviation of experimental data. The fitting 
parameters value are ?̇?0 = 2.3∙10
-18
 W and 𝜏𝐶 = 4.8 s. Since the level of 
power resulted to not affect the liposome size, there is no need for further 
optimization/comparison with the results of Run 2.b and/or 2.c. 
 
Figure 10. Experimental and calculated liposome diameters for Run 2.a 
While the fitted values for the time constant, 𝜏𝐶, are of the same order of 
magnitude (2.8 s for Run 1 and 4.8 s for Run 2), the fitted values for the rate 
of energy supply, ?̇?0, is quite different (roughly three orders of magnitude). 
Actually, the relevant parameter should be not the rate of energy supply but 
its ratio with the surface area of the lipid bilayer, 𝐴0. For Run 1, this value is 








. It is 
evident that a single value of this parameter, ?̇?0 𝐴0⁄ , can describe both the 
tests. 
As far as observed until now, the model is descriptive, i.e. it is able to 
describe how the size of liposome – made of the materials used in this thesis 
– changes if the ultrasonic energy duty cycle is varied. In order to point out a 
fully predictive model, a deeper knowledge of the parameters nature is 
required. I.e., the physical meaning of the ratio ?̇?0 𝐴0⁄  as well as of the time 
constant, 𝜏𝐶, have to be clarified and the effects of process parameters 
(sample volume, ultrasonic probe size and efficiency, amplitude and power 
of the US source, nature of the lipid bilayer) on the model parameters 
(?̇?0 𝐴0⁄  and 𝜏𝐶) have to be investigated. 
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4.1.4 Remarks 
A versatile and reliable technique able to produce liposomes of different 
sizes to be used for disparate applications has been developed. The Thin 
Film Hydration method was successfully revisited by adding an ultrasound 
assisted step in order to produce nanometric structures, with the desired 
dimensions, starting from the micrometric ones. 
The phenomenological aspects involved in vectors constitution have been 
highlighted along with the mechanisms of bilayer rupture/nanovesicles 
formation. In that regard, a dynamic model able to describe the curvature of 
a lipid bilayer under the effect of ultrasonic energy was proposed and tested. 
The model is based on the calculation of bilayer free energy due to the 
curvature (elastic contribution) and due to the layer limits (edge 
contribution). The supply of energy by sonication exposure can cause the 
spherical vesicles opening or the disc rupture (increasing of the edge length). 
During the rest phase, while no ultrasonic energy is supplied, the bilayer 
curves toward the spherical form in order to minimize the free energy. The 
dynamic of such processes was described as a first order phenomenon and 
the model was numerically solved using the rate of energy supply, ?̇?0, and a 
time constant, 𝜏𝐶, as fitting parameters. The fitting was carried out by 
comparison with experimental data produced by a preparation protocol 
detailed on purpose. The model was found able to calculate successfully size 
of spherical vesicles (liposomes), on the nano-metric scale, produced by 
cycles of sonication. Two different groups of tests, performed starting from 
LUVs (Large Uni-Lamellar Vesicles) and from SUVs (Small Uni-Lamellar 
Vesicles), allowed to identify as key parameters the time constant and the 
rate of energy supply for unit of bilayer surface area, ?̇?0 𝐴0⁄ . The model, 
because of the presence of fitting parameters, cannot be defined as a 
predictive tool, but it was found able to reproduce all the observed features 
of the real preparation process. 
Due to its easiness, reliability, versatility and its great potential in reducing 
time spent, the ultrasound process developed and modelled was also used for 
liposomes homogenization operation during vesicles production through a 
simil-microfluidic approach detailed in the next section. In that regard, a 
simil-microfluidic apparatus was developed in order to produce higher 
volumes of lipid vectors, potentially on production scale, directly with 
nanometric size. 
Finally, different active molecules of industrial relevance were encapsulated 
in nanoliposomes through the developed technique as detailed in the 
“Applications” section. 
Part of this work has been reported in:  
Barba A.A., Bochicchio S., Lamberti G., Dalmoro A., “Ultrasonic energy in 
liposome production: process modelling and size calculation”, Soft Matter, 
2014, 10 (15), 2574 – 2581.  
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4.2 Simil-microfluidic liposome preparation method: 
layout, principles and phenomenological aspects 
4.2.1 Generalities 
Due to their biocompatibility, safety and delivery efficacy, the demand of 
liposomes based products to be used in pharmaceutical and nutraceutical 
field has risen together with the need of large-scale and low environmental 
impact techniques capable to produce significant amounts of liposomes in a 
short time and without the use of drastic conditions. Indeed, according to the 
Paris Agreement on climate change (Abeysinghe and Barakat, 2016), 
innovation must go hand in hand with the developing of green products, 
improving the business processes and scaling-up investments through greater 
energy and material efficiencies (Burck et al., 2014). The energy efficiency 
and emissions reduction in the industrial sectors are the crucial point. 
As seen in “State of the art” section, nowadays there is a wide set of 
possibilities to produce lipid-based drug delivery systems through the use of 
conventional or more recently discovered techniques (Meure et al., 2008, 
Wagner and Vorauer-Uhl, 2010, Bangham and Horne, 1964). However, 
despite the leaps and bounds made with the novel technologies in the last 
few years, the majority of these methods are characterized by high energy 
request, long times of process, the use of toxic solvents together with a low 
productivity. In particular, the most used techniques, such as the Ethanol 
Injection (Pons et al., 1993) or the Thin Film Hydration method discussed in 
the previous section, are bench-scale techniques characterized by bulk 
discontinuous processes. Microfluidics is a relatively new technology used 
for the production of liposomes on nanometric scale (Yu et al., 2009). This 
last gives the possibility to produce, in a continuous manner, Small 
Unilamellar Liposomes (SUVs) with a precise control on liposomes 
dimensional features by modulating the flows at micrometric scale, anyway 
the method is characterized by elevated costs of microfabrication and low 
product volumes in output. 
To overcome these limitations, in this thesis microfluidics based methods, 
which are expensive for special devices needed and microfabrication costs, 
have been transposed to a millimeter scale and coupled with the Ethanol 
Injection method, drastically reducing the production costs and increasing 
the yields. 
With the aim to have a control on flow, typically chaotic in a bulk phase 
which is instead laminar, and thus controllable, in a microfluidic system, 
starting from a work of Pradhan and collaborators (Pradhan et al., 2008), in 
which a syringe pump driven microfluidic device was used to produce 
liposomes, the design and the developement of a new semicontinuous bench 
scale apparatus for a massive nanoliposomes production, overcoming the 
limits imposed by the syringe volumes, has been done. The process basically 
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consists in the realization of a contact between two flows, lipids/ethanol and 
water solutions, inside a tubular device, where interdiffusion phenomena 
allow the formation of lipid vesicles. Furthermore in this thesis, taking into 
account that size and size distribution are key parameters determining 
liposomes performance as carrier systems in both biomedical applications 
(i.e. influencing liposomes time of circulation in the blood stream and/or 
their permeability through membrane fenestration in tumour blood vessels 
(Sawant and Torchilin, 2012)) and nutraceutical applications (i.e. improving 
taste, flavor, stability, absorption and bioavailability of nutraceuticals (Reza 
Mozafari et al., 2008, Bochicchio et al., 2016a) similarly as done by Jahn 
and collaborators for a microfluidic hydrodynamic focusing (MHF) platform 
(Jahn et al., 2004), a dimensional control of the produced nanoliposomes 
was demonstrated by tuning not only the flow rates, as done by Jahn 
research group, but also the lipids concentration. In the light of what 
previously explored and modelled (4.1 section), ultrasonic energy, and its 
developed duty cycle protocol (Barba et al., 2014), was used as 
intensification tool in nanoliposomes production through the simil-
microfluidic apparatus. The duty cycle sonication process was successfully 
scaled up and used for particles homogenization operation as below 
described. 
4.2.2 Experimental section 
4.2.2.1 Materials 
L-α-Phosphatidylcholine (PC) from soybean, Type II-S, 14-23% choline 
basis (CAS n. 8002-43-5) and ethanol of analytical grade (CAS n. 64-17-5) 
were purchased from Sigma Aldrich (Milan, Italy). 
4.2.2.2 Layout  
Figure 11 shows a schematization of nanoliposomes production process 
through the semicontinuous simil-microfluidic apparatus fabricated. The set-
up is constituted by five main section: a feeding section, a pumping section a 
production section, an homogenization section and, finally, a recovery 
section. 
In particular, the feeding section consists in two lines: the first is made up by 
a stirred tank filled with a lipids/ethanol solution (number 1 of Figure 11), in 
which is eventually dissolved an hydrophobic active principle, conveyed in a 
silicon tube (667-8441 RS Components, Northants, UK). This latter has an 
internal diameter of 1.6 mm and a length of 610 mm, is made of silicone and 
is suitable for food and pharmaceutical applications (operating temperature 
range from -50 to 200° C). 
The second line includes a stirred tank filled with the hydration solution 
(number 4 of Figure 11), which can be pure water or an aqueous solution 
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containing the hydrophilic active principle, conveyed in a flexible silicone 
tube (00392400, RS Components, Northants, UK) with an internal diameter 
and length of 5 mm and 360 mm, respectively. 
The pumping section is composed by two single head peristaltic pumps 
(Verderflex OEM mod. Au EZ) indicated as elements G-1 and G-2 in Figure 
11 with a polyamide, acetal and stainless steel pump head and a permanent 
magnet gear-motors. 
In particular, among the several pumping systems (gear pumps, piston 
pumps, syringe pumps, gravity systems, pressurized canisters), peristaltic 
pumps were chosen for their several advantages: they are able to pump 
different kinds of fluid; the treated fluid does not interact directly with the 
pump components thus the cleaning and the maintenance operations are 
easily performed; they are able to modulate large amount of fluids and to 
keep them constant; finally they are suitable for large-scale processes 
(Dalmoro et al., 2014). 
The lipids/ethanol solution tube ends with a 0.6 mm internal diameter needle 
(Eurospital Spa, mod. Euroset 34 Fly 23G Latex Free) inserted into a silicon 
tube of 3 mm internal diameter and 185 mm length (00392200, RS 
Components, Northants, UK) which is an extension of the water tube. This is 
the production section sketched in Figure 11 and indicated as element I-1. In 
this section an interdiffusion of the two pushed liquids occurs leading to the 
formation of liposomes on nanometric scale. 
Briefly, the process starts when lipids/ethanol and water solutions are pushed 
through peristaltic pumps into the production section, where liposomal 
vesicles are formed directly on nanometric size. The formed hydroalcoholic 
solution is recovered in a tank and stirred. Finally, in order to homogenize 
the vesicles for a better particles size distribution, aliquots of the liposomal 
suspension are subjected to the duty cycle sonication process previously 
developed and modelled (Barba et al., 2014), by applying a duty cycle 
consisting of 5 ten-second irradiation rounds each followed by a 20 second 
pause in order to prevent thermal vesicle disruption. In particular, a 3 mm 
probe was used in the homogenization process by treating 1 ml sample 
aliquots at 45 % amplitude of sonication in duty cycle (130 W, 20 kHz) as 
before done for nanoliposomes production through the ultrasound assisted 
Thin Film Hydration method (4.1 section). 
In that regard, the homogenization section was subsequently scaled up by 
using a titanium probe of 6 mm diameter acting directly on 110 ml sample 
production batch and changing some of the sonication key parameters as 
detailed in 4.2.2.5 paragraph. Figure 11 shows exactly the apparatus plant 
configuration directly with the integration of the ultrasound assisted 
homogenization section scaled up. 
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Figure 11. Process schematization of nanoliposomes production through the 
semicontinuous simil-microfluidic apparatus; the main sections are 
reported: feeding, pumping, production, homogenization and recovery. 
From the tanks (D-1, D-2) lipids/ethanol and water solutions are pushed 
through peristaltic pumps (G-1, G-2) to the production section (I-1) were 
nanometric vesicles are formed. The hydroalcoholic solution (7) is 
recovered in a tank (D-3) and subjected to a duty cycle sonication process 
(Z-1). Finally the suspension (8) is recovered and characterized 
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Flow regime evaluation  
First of all, taking into account that a microfluidic system is characterized by 
a laminar flow regime, the fluid dynamic nature of the simil-microfluidic 
apparatus was evaluated. 
In the simil-microfluidic set up developed, through the use of constructive 
expedients (millimetric tubes, peristaltic pumps, injection needle) the 
reproduction of the laminar flow regime was possible being all the Hagen-
Poiseuille assumptions satisfied (Bird et al., 2007) as detailed in the results 
section (4.2.3.1 paragraph). 
At first the Reynolds number was found for all the conditions used. In 
particular, for all the volumetric flow rates tested (10:1, 15:1, 20:1 and 40:1 
Vhs/Vls), the Reynolds number (Re) of the organic and the polar phases was 




     (4.4) 
where ρ is the fluid density, V is the volumetric flow rate of the fluid, μ is its 
dynamic viscosity and D is the diameter of the tube. For the determination of 
the fluid dynamic conditions some approximations were done: the organic 
phase was referred only to ethanol, the polar phase only to water and the 
liposomal suspension was referred to a water-alcohol solution, their 
chemical-physical and transport properties (density and viscosity) were 
determined at room temperature. In detail, for the polar phase a tube 
diameter of 5 mm was considered and the density and the viscosity of the 




 Pa·s, respectively. For the 
organic phase, a 1.6 mm diameter tube was considered and the density and 
the viscosity of the ethanol at room temperature were considered to be equal 
to 789 kg/m
3
 and to 1.2·10
-3
 Pa·s, respectively. For the hydroalcholic 
suspension the liposomal section production tube of 3 mm was considered 
and the chemical-physical and transport properties of the mixture were 
approximated to those of the water being the concentration of ethanol in the 
suspension very small for all the volumetric flow rates ratio (Vhs/Vls) tested, 
with a maximum of 9 % v/v of ethanol for the 10:1 Vhs/Vls up to the 2.5 % 
v/v of ethanol used at 40:1 Vhs/Vls. 
Moreover, in order to neglect the end effects and thus fulfill another 
assumption of Hagen-Poiseuille, the “entrance length” (Le), after the 
lipid/ethanol tube entrance in that of water, was calculated as 𝐿𝑒 = 0.035 ∙
𝐷 ∙ 𝑅𝑒 . In particular, the Le was calculated taking into account the lower 
and the higher Reynolds numbers obtained and the 3 mm diameter of the 
tube where the hydroalcholic solution streams. Notably, a certain entrance 
region is needed for the buildup to the parabolic profile thus the piping 
length, in which the two phases interdiffuse, has to be longer than the 
“entrance length”. 
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4.2.2.3 Liposomes preparation 
Once defined the geometric parameters, those of process such as the 
volumetric flow rates, the lipid concentration and the sonication conditions 
adopted were investigated in order to establish their control on the 
nanoliposomes dimensional features. For this purpose samples of unloaded 
liposomes were produced at different conditions and then characterized. The 
morphological characterization was performed by using optical microscopy 
(Axioplan 2- Image Zeiss) for fluorescence imaging, a 100 X oil immersion 
objective was used to visualize the vesicles. Rhodamine B was used for 
microscope fluorescence observations. 
Dimensional characterization of vesicles was performed by Dynamic Light 
Scattering analysis (Zetasizer Nano ZS, Malvern, UK). The resulting particle 
size distribution was plotted as number of liposomes versus size. The 
Polydispersity Index (PDI) was calculated for all the preparations. Statistical 
analysis of experimental data (size and PDI) were analyzed using Student's t-
test and one-way analysis of variance (ANOVA), and differences were 
considered statistically significant at p < 0.05. 
Volumetric flow rate ratio modulation 
In order to study the influence of the lipid concentration and the volumetric 
flow rate ratio on liposomes size and size distribution, liposomes were at 
first prepared by maintaining constant the PC concentration in the 
hydroalcoholic solution at 0.15 mg/ml and varying the volumetric flow rates. 
This latter, defined as the hydration solution volumetric flow rate (Vhs) to 
the lipid solution volumetric flow rate (Vls), was varied (10:1, 15:1, 20:1 and 
40:1 Vhs/Vls) maintaining constant the Vls at 4 ml/min and changing the 
Vhs (40 ml/min, 60 ml/min; 80 ml/min and 160 ml/min). Briefly, for this 
purpose, 16.5 mg of PC were dissolved in 10 ml of ethanol to achieve the 
lipid solution, while deionized water (100 ml) was used as hydration 
solution. The two liquids were pushed into their respective silicon tubes 
through the use of peristaltic pumps following the process previously 
described and schematized in Figure 11. 
Lipid concentration modulation 
After the volumetric flow rate ratio optimization, maintaining constant at 
10:1 the Vhs/Vls ratio, the lipid concentration in the final hydroalcoholic 
solution was changed (0.15, 1, 4 and 5 mg/ml) and the liposomes size and 
size distribution were analyzed again. 
Aliquots (1 ml) from all the produced samples were then taken and subjected 
to the homogenization process (Barba et al., 2014). 
The effects of volumetric flow rate ratio and PC concentration on liposomes 
size and size distribution were studied with and without the ultrasound 
contribution. 
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4.2.2.4 Process productivity evaluation 
In order to have an idea of the productivity of the process through the simil-
microfluidic apparatus developed, liposomes number for unit volume of 
solution obtained at different operative conditions was evaluated. In 
particular the number of vesicles formed for unit volume in the final 
hydroalcoholic solution, at the different volumetric flow rates ratio tested 
and PC concentrations used, was valued for sonicated and not sonicated 
samples. The number of liposomes for unit volume (Nlip) was analytically 
calculated as done by Encapsula Nanosciences, a liposome formulator and 




     (4.5) 





) is the number of lipids present in one 













    (4.6) 
where d is the vesicles diameter size (nm), h is the thickness of the bilayer 
(nm) and a is the hydrophilic portion surface area (nm
2
).  
For unilamellar vesicles made from phosphatidylcholine the bilayer 
thickness is about 5 nm while the hydrophilic portion surface area is 
equivalent to 0.71 nm
2
 thus the equation 4.6 can be simplified as follows: 

















, expressed in 1/nm
2
. 
4.2.2.5 Scale up of the ultrasound assisted homogenization 
process  
To move from a production scale of a few milliliters to a greater production 
batches (of the order of hundred milliliters) the homogenization section was 
scaled up. In particular, the 3 mm sonotrode tip was replaced by a 6 mm tip 
acting directly on the entire volume of the liposomal suspension (110 ml per 
batch), thus the plant configuration described in 4.2.2.2 paragraph was 
adopted. 
In particular, in order to obtain, with the new plant configuration, the same 
final nanoliposomes dimensional features previously achieved by sonicating 
1 mL aliquots of sample, keeping constant the duration of each cycle (10 s) 
and the time in which the ultrasound is not applied (20 s) and operating with 
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an amplitude of 100%, the ultrasound power and the number of cycles 
required to sonicate a 110 ml volume of liposomal suspension were 
determined. In particular, starting from a volume of unloaded nanoliposomes 
suspension of 1 ml, using an amplitude of 100 %, the energy supply by one 
sonication cycle of 10 seconds was determined. Considering the linearity 
between the power and the volume of sonication, the power required to 
sonicate 110 ml of liposomal suspension was determined, then the number of 
duty cycle sonication rounds able to provide the necessary power has been 
obtained experimentally. In particular, unloaded nanoliposomes were 
produced by mantaining constant the optimized conditions (10:1 Vhs/Vls; 5 
mg/ml lipids/final hydroalcoholic solution) and by submitting the samples to 
different sonication rounds: 0, 15, 30 and 60 duty cycle rounds were applied, 
then vesicles were characterized in terms of size and size distribution. 
4.2.3 Results and Discussion 
4.2.3.1 Simil-microfluidic apparatus  
A new semicontinuous bench scale apparatus for nanoliposomes production 
was successfully designed and developed, overcoming the limits imposed by 
the conventionally used techniques. In particular, by coupling the ethanol 
injection method with the microfluidic principle and transposing them on a 
micrometric scale it was possible to achieve a massive nanoliposomes output 
in an easy and cheap way. In a work of Pradhan and collaborators (Pradhan 
et al., 2008) a syringe pump driven microfluidic device was developed to 
produce nanoliposomes, in this thesis the semicontinuous bench scale 
apparatus was designed by replacing the syringe pumps by the peristaltic 
once, allowing the production of larger volumes and by injecting the lipid 
phase directly into the polar phase without the help of any tubes connection 
systems. Moreover, microfluidics based methods, such as the MHF platform 
made by Jahn et al. (Jahn et al., 2004), which are expensive for special 
devices needed and microfabrication costs, have been transposed to a 
millimeter scale, drastically reducing the production costs and increasing the 
yields. 
The simil-microfluidic approach had also permitted to overcome the limit of 
bulk phase methods in which is difficult to control the liposomes 
dimensional features instead carefully modulated in this thesis with a further 
ultrasound assisted homogenization step. Finally, the simil-microfluidic 
apparatus had allowed to successfully produce ferrous sulfate loaded 
nanoliposomes to be used in nutraceutical application as detailed in 
“Application” section (Chapter 5). 
Flow regime evaluation and phenomenological aspects 
Like in a microfluidic system, due to the millimetric scale of the channels 
and the low volumetric flow rates, the flow in the simil-microfluidic 
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apparatus developed is laminar in opposition to the chaotic onces 
characterizing the bulk phases. Indeed, results obtained relatively to the flow 
regime evaluation have shown that all the Hagen-Poiseuille assumptions 
were satisfied (Bird et al., 2007). First of all Reynolds number results are 
reported in Table 5. 
Table 5. Reynolds number relative to the polar phase, the organic phase and 
the hydroalcholic solution at the different volumetric flow rates ratio tested 
V, ml/min 𝑹𝒆 












For all the conditions tested, the polar and the organic phases exhibit a 
laminar flow regime in the feeding section, likewise the hydroalcholic phase 
in the production section. In particular, the Reynolds number, which was 
found to be less than 2100 for all the volumetric flow rates conditions tested, 
changes from 311.4 to 1160 moving from 10:1 Vhs/Vls to 40:1 Vhs/Vls. 
This result shows that the blending between the two phases is governed by 
diffusion mechanisms. 
Apart from the Reynolds number, the other Hagen-Poiseuille assumptions 
were also satisfied. In particular, operating at constant temperature and 
pressure, the fluids were considered incompressible and the flow was 
considered to be steady being, except for the startup moment, the volumetric 
flow rates mantained constant during the entire production process. 
Moreover, the fluid is considered Newtonian because the behavior of the 
hydroalcholic suspension was approximated to that of water which is a 
Newtonian fluid. 
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Finally, the piping length in which the two phases interdiffuse is longer than 
the “entrance length” needed to buildup the parabolic profile. In particular a 
32.7 mm and a 121.8 mm entrance lengths were found at the lower and the 
higher Reynolds number tested, respectively. This lengths are lower than 
that of the pipe (150 mm) where interdiffusion phenomena occured. 
From a phenomenological point of view, liposomes formation is governed 
by the molecular diffusion between two phases: the organic solvent, in 
which the lipids are solubilized, and the water; this latter simultaneously 
diffuses into the organic solvent in order to reduce its concentration below 
the critical value required for the lipids solubilization. During the diffusion 
process, lipid vesicles on nanometric scale start to form through a 
mechanism called "self-assembly", according to the theory of Lasic et al. 
(1988): lipids dissolved in an organic solvent are in the form of bilayer 
fragments (Phospholipid Bilayer Fragments, BPFs), the interdiffusion of the 
water and the organic solvent reduces the solubility of the lipids in the 
solvent causing thermodynamic instability of BPFs edges, inducing the 
curvature and the closure of bilayer fragments which allow the formation of 
liposomal vesicles (Lasic and Papahadjopoulos, 1998). In particular, for a 
microfluidic system, liposomes formation happens at the interfaces between 
the alcoholic and water phases, when they start to interdiffuse in a direction 
normal to the liquid flow stream. Changes in flow conditions result in a size 
variations of the insertion section of the organic phase reflecting on the 
vesicles dimensional features. In particular, increasing the volumetric flow 
rates ratio, the size of the insertion section of the organic phase decreases; 
this leads to a major dilution of the organic phase limiting the formation of 
long BPFs thus inducing the production of liposomal structures of small 
dimensions. In general, it was shown that the variation in shear forces at the 
interface of the two fluids have no conseguence on liposomes structure. In 
particular, mantaining constant the volumetric flow rates ratio and changing 
both the buffer and the lipids alcoholic solutions volumetric flow rates, Jahn 
and collaborators have demonstrated that is not the magnitude of the shear 
forces between the parallel layered stream in having significant impact on 
liposomes size and size distribution as the stream width (which depends on 
the volumetric flow rates ratio) (Jahn et al., 2007). In Figure 12 a schematic 
representation of the liposome formation process through the microfluidic 
approach is presented. 
 
Figure 12. Representation of the liposome formation process by a 
microfluidic approach 
  Novel developed production techniques  
  59 
In general, local fluctuations of the lipid concentration in a bulk solution 
make difficult to control the size and the polydispersity of the produced 
vesicles. On the contrary, the presence of intubated laminar flows with the 
relative matter diffusive transport allows to minimize the fluctuations of the 
lipid concentration inside the tubes and to modulate the size and the size 
distribution of the final vesicles. 
4.2.3.2 Unloaded nanoliposomes production: process 
parameters effect on dimensional features 
Small Unilamellar Vesicles (SUVs) directly on a nanometric scale were 
produced through the developed simil-microfluidic apparatus, without the 
use of any toxic solvents and drastic conditions (i.e. high temperature and/or 
pressure). In Figure 13 the SUVs obtained are shown. In particular, to the 
light of nanoliposomes size obtained (detailed in the next subparaghaph) 
vesicles presented in the fluorescence microscopy images are called SUVs 
even if aggregates and/or large vesicles produced together with SUVs, 
although few, are well and more visible in the captured images. 
 
Figure 13. Fluorescence microscopy images of lipid vesicles labelled with 
Rhodamine B dye and visualized with a 100 X objective 
Effect of volumetric flow rate ratio  
The volumetric flow rate ratio exerts a strong influence on the final vesicles 
dimensional features as also found by Jahn and collaborators for a 
microfluidic hydrodynamic focusing platform (Jahn et al., 2004).  
In fact, it was shown that increasing the ratio between the water volumetric 
flow rate to the lipids-ethanol volumetric flow rate the liposomes dimension, 
reported in Figure 14 A, do not change in a statistical manner (p > 0.05) 
while the PDI value increases as showed in Figure 14 B. 
In particular, for not sonicated samples, PDI is worsened when flow rate 
ratio increases from 20 to 40 (it is kept statistically constant between 10 and 
20); for sonicated samples, PDI is worsened going from a flow rate of 10 to 
15; for higher flow rates it is kept constant. 
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Specifically, not sonicated liposomes of 49 nm in size were obtained by 
operating with a 10:1 Vhs/Vls ratio and vesicles even smaller were achieved 
with a 15:1 and 20:1 Vhs/Vls, up to a diameter of 33 nm for liposomes 
obtainined by using a 40:1 Vhs/Vls, the higher volumetric flow rate ratio 
tested. An opposite trend is visible for the PDI of not sonicated samples, 
whose 0.36 value obtained from the 10:1 Vhs/Vls becomes 0.73 when a 40:1 
Vhs/Vls ratio was used, index, the latter, of an highly polydispersed sample. 
The ultrasound assisted process applied reduces the liposomes PDI for all the 
flow rates explored except for the 15:1. The duty cycle sonication has a key 
role in the liposomes homogenization by reducing the polydispersity of the 
sample, optimizing the size distribution; i.e. for the 40:1 Vhs/Vls the PDI is 
nearly halved (Figure 14 B). 
 
Figure 14 A) Sonicated and not sonicated liposomes diameter size at 
different volumetric flow rates ratio. B) Polydispersity Index (PDI) of 
sonicated and not sonicated liposomes at different volumetric flow rates 
ratio. Results are expressed as average of three determinations and reported 
along with the standard deviation 
Effect of lipid concentration  
It was observed that at equal flow rates ratio, when the lipids concentration 
increases the liposomes size (Figure 15 A) and PDI values (Figure 15 B) 
remain statistically constant (p > 0.05); just for sonicated samples, PDI is 
worsened when concentration increases from 0.15 to 1, then it is kept 
constant. The sonication process has confirmed to be efficacy for liposomes 
homogenization ameliorating liposomes dimensional distribution for 
concentrations 4 and 5 mg/ml (values statistically significant, p<0.05); i.e. 
for the 5 mg/ml concentration, after the homogenization step, the PDI 
decreases from 0.32 to 0.29 (Figure 15 B). 
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Figure 15 A) Sonicated and not sonicated liposomes diameter size at 
different PC concentrations in the hydroalcoholic solution. B) Polydispersity 
Index (PDI) of sonicated and not sonicated liposomes at different PC 
concentrations in the hydroalcoholic solution. Results are expressed as 
average of three determinations and reported along with the standard 
deviation 
4.2.3.3 Productivity of the process 
The number of liposomes for unit volume, index of the productivity of the 
process, was calculated for all the conditions tested. It was demonstrated that 
the number of liposomes increases for sonicated samples. It is important to 
note that the sonication always enhances the productivity of the process with 
a maximum of 57 % more liposomes produced with a 40:1 Vhs/Vls ratio 
(Figure 16 A) and a plus of 67 % considering the 5 mg/ml PC concentration 
(Figure 16 B). 
 
Figure 16 A) Sonicated and not sonicated liposomes number (Nlip) for unit 
volume of solution obtained at different volumetric flow rates ratio. B) 
Sonicated and not sonicated liposomes number (Nlip) for unit volume of 
solution obtained at different PC concentrations in the hydroalcoholic 
solution 
Summerizing, the results relative to the unloaded vesicles production have 
shown that the liposomal vesicles with the best size distribution were 
produced by using a volumetric flow rate ratio of 10:1 Vhs/Vls and a 
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concentration of lipids equal to 5 mg/ml. The duty cycle sonication process 
was effective in homogenize the vesicles as well as to increase the 
productivity of the process as showed for all the operative conditions tested. 
4.2.3.4 Scale up of the ultrasound assisted homogenization 
process 
In order to scale up the ultrasound assisted homogenization process, keeping 
constant the duty cycle irradiation time and using the 6 mm tip with a 100% 
amplitude, the power to be delivered and thus the number of sonication 
cycles able to amplifying the sound wave on the entire batch volume 
produced (110 ml) generating the same dimensional features founded for 
sonicated sample aliquots (1 ml) was found. 
In particular, being the power of sonication equal to 4.7 W for 1 ml of 
sample volume and considering the linearity between the power and the 
number of sonication rounds at fixed volume (Figure 17), the power 
theoretically required to sonicate 110 ml was about 500 W; such power has 
been operatively obtained by using 15 rounds of duty cycle sonication. 
 
Figure 17. Linearity between the number of duty cycle sonication rounds 
applied and the power supplied to 110 ml nanoliposomes suspension 
The effect of different times of sample exposure to ultrasound on the 
vesicles dimensional features was studied after 0, 15, 30 and 60 rounds of 
duty cycle sonication, results are reported in Figure 18. 
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Figure 18 A) Liposomes diameter size after different number of duty cycle 
sonication rounds. B) Polydispersity Index (PDI) of liposomes after different 
number of duty cycle sonication rounds. Results are expressed as average of 
three determinations and reported along with the standard deviation 
As a result of the homogenization process scale-up, it was possible to 
observe a reduction of both liposomes diameter size (Figure 18 A) and PDI 
(Figure 18 B) as an effect of sonication. In particular, starting from 82 nm 
not sonicated vesicles (0 rounds) the average size was reduced to 66, 70 and 
52 nm respectively after 15, 30 and 60 duty cycle sonication rounds. With 
regard to the polydispersity index, the sonication was always effective in 
homogenize the liposomal suspensions for all the operating conditions 
tested. In particular, samples obtained by using 60 rounds of duty cycle 
sonication (52.4 ± 1.05 nm; 0.29 ± 0.01 PDI) showed a significant reduction 
of the standard deviation and can be compared with those obtained on a 
small scale, operating with 1 ml sample aliquot and the 45% amplitude, 
having an average size of 52.18 ± 8.93 nm and a PDI of 0.29 ± 0.01 (4.2.3.2 
paragraph). However, depending on the application requirements, 15 rather 
than 60 duty cycle rounds can be used.  
In conclusion, the homogenization step has proved to be an effective and 
easily scalable method therefore was included in the production process by 
using the simil-microfluidic apparatus configuration as schematized in 
Figure 19. 
 
Figure 19. Three main units of the simil-microfluidic set-up: a production 
unit according to the simil-microfluidic approach, an ultrasound assisted 
homogenization and recovery unit, a storage unit 
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4.2.4 Remarks 
A massive production of nanoliposomes is possible due to the developed 
simil-microfluidic bench scale apparatus with a precise control on particles 
dimensional distribution by varying the liquids volumetric flow rate ratio. In 
particular, increasing the ratio between the water volumetric flow rate to the 
lipids-ethanol volumetric flow rate the liposomes PDI increases; at equal 
flow rates, when the lipids concentration increases the liposomes PDI is 
keept constant. Ultrasonic energy was used to enhance homogenization of 
the hydroalcoholic bulk and, as expected on the bases of previous studies, its 
duty cycle application efficaciously promoted vesicles disaggregation. The 
ultrasound assisted homogenization has also proved to be a reliable and 
scalable process intensification tool. The simil-microfluidic apparatus 
developed is ables to produce nanoliposomes through a sustainable large 
scale process, avoiding the use of toxic solvents and drastically reducing 
process time and costs. 
 
Part of this work has been reported in: 
Bochicchio S.; Dalmoro A.; Recupido F.; Lamberti G.; Barba A.A.; 
“Nanoliposomes production by a protocol based on a simil-microfluidic 
approach”, accepted as publication in “Lecture Notes in Bioengineering 







In this chapter, all the applications 
concerning the use of the Ultrasound 
assisted Thin Film Hydration method and 
the Simil-microfluidic technique developed 
are presented. The aim is focused on the 
production of nano-liposomal carriers 
loaded with different kinds of active 
molecules: micronutrients (vitamins and 
ferrous sulfate) for nutraceutical 
applications and therapeutic agents (peptide 
and NABDs) for pharmaceutical 
applications. Each application is briefly 
described introducing the appliance field, 
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5.1 Liposomal vectors for vitamins delivery 
5.1.1 Generalities 
Liposomes are efficient nutrient delivery systems which are able to ensure a 
controlled and targeted release to foodstuffs due to their thermodynamic 
stability (Fernández-García et al., 2007, Kwak, 2014, deAssis et al., 2014). 
The possibility of producing nanostructured materials for controlling the 
bioavailability of nutrients with strong biological activity has great industrial 
relevance for optimizing product formulation (food supplements, vitamin 
dosage systems) and processing, thus contributing to people’s health and 
well-being (Sanguansri and Augustin, 2006, Lopez-Rubio et al., 2006, 
Soottitantawat et al., 2005, Emamifar et al., 2010, deAssis et al., 2012, 
deAssis et al., 2014). 
Recently, much attention has been paid to using the nanoliposomes as 
carriers of bioactive ingredients in food and nutrition for encapsulating 
antioxidants (Azevedo et al., 2013, LIU et al., 2013, Isailović et al., 2013, 
Gupta and Abu-Ghannam, 2011, Toniazzo et al., 2014). In fact, using 
liposomes as antioxidant vitamin carriers represents a promising approach 
for developing new functional food formulations and solving the vitamin 
stability issues which strongly hinder their application. 
Vitamin B12, α-Tocopherol and Vitamin D2 were used due to their great 
antioxidant potential and different hydrophilic-lipophilic and solubility 
properties. 
Few are the information regarding the encapsulation of ergocalciferol and 
vitamin B12 in liposomes, a little bit more can be found in literature for α-
tocopherol encapsulated in liposomes (Rovoli et al., 2013) but data are 
completely missing in relation to the production of liposomes smaller than 
80-100 nm in size encapsulating vitamins.  
In this thesis nanoliposomal vectors (NLV) with high encapsulation 
efficiency of vitamins were produced for a controlled release purposes. 
Taking into account the benefits in obtaining the smallest nanoliposome with 
the highest vitamins encapsulation efficiency, the ultrasound assisted Thin 
Film Hydration method developed (4.1 section) was used. The main 
challenge of this approach was to test the versatility of the developed 
preparative protocol to achieve tailored liposomes in terms of size and 
encapsulation efficiency in relation to three used vitamins, different in size 
and solubility. By using the developed technique (Barba et al., 2014) the 
production of 40-50 nm SUVs containing ergocalciferol, vitamin B12 and α-
tocopherol was performed emphasizing that vitamins encapsulation 
efficiency for NLV smaller than 50 nm was never tested before. 
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5.1.2 Materials 
L-α-Phosphatidylcholine (PC) from egg yolk (CAS n. 8002-43-5), 
Cholesterol (CHO) (CAS n. 57-88-5), L-αPhosphatidyl - DL glycerol 
sodium salt (PG) from egg yolk lecithin (over 99% pure), vitamin B12, B12, 
(CAS n. 68-19-9), α-tocopherol, TC (CAS n. 10191-41-0), ergocalciferol, 
D2, (CAS n. 50-14-6), potassium phosphate monobasic (CAS n.7778-77-0) 
and sodium hydroxide (CAS n. 1310-73-2) were purchased from Sigma 
Aldrich (Milan, Italy) as dried powders and used without further 
purification. All the other chemicals and reagents such as chloroform (CAS 
n. 67-66-3), ethanol (CAS n. 64-17-5), methanol (CAS n. 67-56-1) (Sigma 
Aldrich, Milan, Italy) used were of analytical grade. 
5.1.3 Methodology and sperimental set-up 
5.1.3.1 Preparation of MLVs and SUVs loaded with vitamin B12  
Unilamellar liposome vesicles were prepared by means of the Thin Film 
Hydration method (Meure et al., 2008, Bangham and Horne, 1964) by 
sonication. In short, PC (40 mg), CHO (16 mg) and PG (4 mg) at 10:8:1 
(mol:mol) ratio were dissolved at 50 °C in 2 mL of chloroform/methanol 2:1 
(vol/vol). The solvent was removed by evaporation in a rotary evaporator 
(Heidolph, Laborota 4002 Control) and the lipid film produced was vacuum-
dried for 3 hours at 50°C in a water bath. The dried lipid film was then 
hydrated at room temperature with 2 mL of pre-warmed PBS (pH 7.4) 
containing vitamin B12 (14.32 mg) and continuously stirred at 60 rpm. The 
molar ratio of vitamin to the total amount of lipids was 1:10 (mol:mol). A 
phosphate buffer solution (PBS) was prepared by dissolving potassium 
phosphate monobasic 0.2 M and sodium hydroxide 0.2 M in distilled water 
thus obtaining a pH 7.4 PBS final solution. This buffer solution was used for 
carrying out liposome production and vitamin load and stability tests. 
The preparation containing MLVs was maintained at room temperature for 2 
hours. Part of this sample was used to assay morphology, size and 
entrapment efficiency of MLVs. Most of the sample was then sonicated at 
45% amplitude (treated volume: 1 mL) by applying a duty cycle consisting 
in 2 ten-second irradiation rounds (amplitude 45%), each followed by a 
twenty-second pause in order to prevent thermal vesicle disruption thus 
obtaining Large Vesicles (LVs). The sample was stored overnight at 4°C and 
protected from light to stabilize the produced LVs. In order to obtain SUVs, 
after the stabilization phase, the sample was then sonicated at 45% amplitude 
(percentage of maximum deliverable power) for four more rounds. 
The above-described sonication protocol was carried out with VCX 130 PB 
Ultrasonic Processors of Sonics & Materials Inc., CT, USA instrument 
(maximum power 130 W, frequency 20 kHz; sonotrode tip length 137 mm; 
sonotrode tip diameter 3 mm) as described in 4.2.2.2 paragraph. The 
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dedicated protocol of duty cycle sonication is schematized in Figure 20 A, 




Figure 20. Ultrasonic irradiation protocol (duty cycle, A) and its effect on 
liposomal structures size (from Multilamellar Vesicles –MLVs- to Small 
Unilamellar Vesicles –SUVs-, B). In Figure A, starting with MLVs, following 
two irradiation rounds (all irradiation rounds are of 10 seconds and are all 
followed by a 20-second pause) Large Unilamellar Vesicles-LUVs with 
micrometric diameter size are obtained as showed by LUVs size distribution 
in Figure B. In Figure A, starting with LUVs, after three and four more 
irradiation rounds (50 and 60 seconds), SUVs of nanometric size are 
obtained as showed by SUVs size distribution in Figure B.  
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Table 6. Process parameters adopted in Multiamellar Vesicles (MLVs) and 
Small Unilmellar Vesicles (SUVs) preparation, achieved loading and 
encapsulation efficiency. Results are expressed as average of three 
determinations; SD is the standard deviation 
Process parameter MLV SUV 
Sonication duty cycle (s)  
2 + 4 irradiation 
rounds 
Fraction of maximum power (%)  45 
Frequency (KHz)  20 
Treated volume (mL) 2  1 
Encapsulation efficiency (%) and Standard Deviation (SD) 
Vitamin B12 (%, SD) 72.0 ± 0.00 56.2 ± 8.51 
α-Tocopherol (%, SD) 95.0 ± 7.07 76.3 ± 14.20 
Ergocalciferol (%, SD) 81.5 ± 2.12 57.5 ± 13.9 
Theoretical load (%)   
Vitamin B12 (%) 19.2 19.2 
α-Tocopherol (%) 2.9 2.9 
Ergocalciferol (%) 19.9 19.5 
Effective load achieved (%)and Standard Deviation (SD) 
Vitamin B12 (%) 14.6 ± 0.65 11.76 ± 3.67 
α-Tocopherol (%) 2.8 ± 0.70 2.2 ± 0.12 
Ergocalciferol (%) 16.8 ± 1.23 11.9± 4.11 
5.1.3.2 Preparation of MLVs and SUVs loaded with vitamin α-
tocopherol 
The preparation of SUVs containing α-tocopherol was carried out using the 
Thin Film Hydration method followed by sonication, as above described. In 
short, PC (120 mg) and CHO (3 mg) at 20:1 molar ratio and α-tocopherol 
(3.70 mg) were dissolved in 2 mL of chloroform/methanol 2:1 (vol/vol). The 
solvent was removed by evaporation and the dried lipid film was hydrated 
with 3 mL of PBS (pH 7.4) at room temperature and adequately stirred. The 
molar ratio of α-tocopherol to the total amount of lipids was 1:20 (mol:mol). 
The preparation containing MLVs was treated by applying the duty cycle 
described above for vitamin B12-containing liposomes. 
Chapter 5   
70 
5.1.3.3 Preparation of MLVs and SUVs loaded with vitamin 
ergocalciferol 
The lipid composition used for SUVs loaded with ergocalciferol was PC (60 
mg) and CHO (1.5 mg) at 20:1 molar ratio. The molar ratio of ergocalciferol 
(14.92 mg) to the total amount of lipids was 1:2 (mol:mol). The Thin Film 
Hydration method followed by sonication was used for producing 
ergocalciferol loaded SUVs as described for the other vitamins. 
5.1.3.4 Physicochemical characterization of vesicles 
Bright field imaging 
The morphological and dimensional characterizations of MLVs were 
performed with optical microscopy (Axioplan 2- Image Zeiss) for bright 
field imaging. A 100 X oil immersion objective was used to visualize the 
vesicles.  
Particle sizes  
A dimensional analysis of microscope images, performed with the software 
ImageJ was combined with a Dynamic Light Scattering analysis for MLV 
and SUV dimensional characterization. In particular, Dynamic Light 
Scattering analysis were performed by using the ZetasizerNano ZS 
(Malvern, UK) which incorporates noninvasive backscatter (NIBS) optics. 
The detection angle of 173 degrees, able to measure the particles size of the 
concentrated, turbid sample was used. The resulting particle size distribution 
was plotted as the number of liposomes versus size. All the measurements 
were performed in triplicate. The results were expressed as average values. 
5.1.3.5 Evaluation of vitamins encapsulation and stability test 
Encapsulation efficiency and load 
With the aim to measure the encapsulated vitamin, liposomes were lysed by 
ethanol and the entrapped vitamin was assayed by UV spectroscopy. In 
short, a given amount of each kind of loaded liposomes, prepared as above 
described, was washed three times with PBS and centrifuged. The recovered 
precipitates (loaded liposomes) were added with ethanol to promote the lysis 
of the liposomal bilayers and the suspension was undergone to UV 
spectrophotometric assay performed using Lambda 25 UV/VIS 
Spectrophotometer (PerkinElmer, Monza, Italy). An absorption spectrum 
from 200 nm to 600 nm was always investigated for all vitamins 
formulations and the maxima wavelengths, typical for each loaded vitamin: 
at λ=361nm for liposomes containing vitamin B12, at λ=290 nm for 
liposomes containing α-tocopherol and at λ=265 nm for liposomes 
containing ergocalciferol, was considered. The vitamins amounts were 
determined using a calibration curve prepared for all kinds of vitamins in the 
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different solvent used. A control with unloaded liposomes in the same 
absorption spectrum was performed.  
For all formulations, encapsulation efficiency (e.e.) was determined as the 
percentage of detected encapsulated vitamin in liposomes to the initial 
amount of vitamin included in the formulation; it was calculated using the 
following equation: 
 e. e. (%) = (
𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑣𝑖𝑡𝑎𝑚𝑖𝑛,   𝑚𝑔
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑖𝑡𝑎𝑚𝑖𝑛 𝑎𝑚𝑜𝑢𝑛𝑡,𝑚𝑔
) × 100 (5.1) 
Vitamin loads were determined through the ratio: 
 load (%) = (
𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑣𝑖𝑡𝑎𝑚𝑖𝑛,   𝑚𝑔
𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑒𝑠,   𝑚𝑔
) × 100 (5.2) 
In particular, the theoretical load is referred to the initial amount of vitamin 
included in the formulation (divided by the total mass); the effective one is 
referred to the assayed vitamin amount (divided by the total mass). 
Stability test 
In order to evaluate the ability of the liposomal structures to retain their 
loading outside the cell environment, stability tests were performed 
observing vitamins release in PBS solution (pH 7.4) at 37°C (investigated 
time: about 10 days). In short, given amounts of loaded liposomes were put 
in measured volumes of PBS solution, then aliquots were removed from 
each sample at given time and centrifuged at 13000 rpm for 30 minutes at 
4°C (Beckman Coulter Avanti J-25I, Ramsey, Minnesota, USA) to 
precipitate the liposomes. After centrifugation the supernatant was carefully 
removed without disturbing the pellet and the precipitated liposomes were 
washed three times with PBS solution in order to be sure that all un-
encapsulated vitamins were removed. After each centrifugation and wash 
steps the supernatants were collected for UV spectrophotometric analysis. 
Vitamin B12 in supernatant was determined by carrying out a UV 
spectrophotometric analysis using PBS as blank, while α-tocopherol and 
ergocalciferol in supernatant were determined using 90 mL/100 mL ethanol 
as blank. The recovered pellet was re-suspended in ethanol in order to lyse 
the liposomes and the entrapped vitamin contained in the precipitated 
liposomes was assayed, via UV spectrophotometric analysis, using ethanol 
as blank. All the measurements were performed in triplicate. 
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5.1.4 Results  
5.1.4.1 MLVs production from lipidic film via ultrasonic 
irradiation: loading and characteristics 
Bright field imaging 
Bright field imaging was used in order to clarify the structure of vitamin 
B12, α-tocopherol and ergocalciferol loaded MLVs. As shown in Figure 21, 
spherical, separated and defined liposomes were obtained for each 
formulation. 
 
Figure 21. Optical microscope pictures (in bright field, Obj. 63X) of loaded 
MLVs 
Particle sizes measurement  
The dimensional analysis of microscope images prior to vesicle sonication 
showed micrometric MLVs in all samples. The diameter sizes were 5.77 ± 
1.23 m for vitamin B12-liposomes, 3.89 ± 1.72 m for α-tocopherol-
liposomes and 2.96 ± 1.97 µm for ergocalciferol-liposomes as summarized 
in Table 7. 
Table 7. Structures size of loaded Multilamellar Vesicles (MLVs) and Small 
Unilamellar Vesicles (SUVs). Results are expressed as average of three 












diameter size ± 
SD 
MLVs 5.770 m ± 1.23 3.890 m ± 1.72 2.960 µm ± 1.97 
SUVs 0.051 m ±0.028 0.040 µm ±0.009 0.048 µm ± 0.037 
 
  
   
vitamin B12 liposomal vesicles α-tocopherol liposomal vesicles ergocalciferol liposomal vesicles 
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Determination of MLVs encapsulated vitamin B12, α-tocopherol and 
ergocalciferol 
For all formulations high effective loads (the theoretical load can be taken in 
account as reference) were obtained. The results of MLVs loads 
determination are reported in Table 6. 
For all formulations, high encapsulation efficiencies were obtained; in 
particular, e.e. achieved for MLVs were 72.0 ± 00 % for vitamin B12, 95.0 ± 
7.07 % for α-tocopherol and 81.5 ± 2.12 % for ergocalciferol. The results of 
MLV encapsulation efficiency are also summarized in Table 6 (and 
compared with vitamin e.e. in SUVs). 
Stability test and evaluation of vitamin B12, α-tocopherol and 
ergocalciferol release 
Liposomes loaded with vitamin B12, α-tocopherol and ergocalciferol 
underwent a stability test to evaluate the timing of drug release in similar 
conditions to the intracellular environment. Liposomes were found to be 
stable at 37°C in PBS (pH 7.4) media release over a 10-day period. 
5.1.4.2 SUVs production from lipidic film via ultrasonic 
irradiation: loading and characteristics 
Particle sizes  
A Dynamic Light Scattering analysis carried out after six total sonication 
rounds showed nanometric SUVs with diameter size of 51 ± 28 nm for 
vitamin B12-liposomes, 40 ± 9 nm for α-tocopherol-liposomes and 48 ± 37 
nm for ergocalciferol-liposomes (Table 7). 
Determination of SUVs encapsulated vitamin B12, α-tocopherol and 
ergocalciferol 
For all formulations high effective loads (the theoretical load can be take in 
account as reference) were obtained. The results of SUVs loads 
determination are reported in Table 6. 
The encapsulation efficiency achieved for SUVs was 56.2 ± 8.51 % for 
vitamin B12, 76.3 ± 14.02 % for α-tocopherol and 57.5 ± 13.9 % for 
ergocalciferol. The results of SUVs encapsulation efficiency are summarized 
in Table 6. 
Evaluation of vitamin B12, α-tocopherol and ergocalciferol release 
(stability test) 
SUVs loaded with vitamin B12, α-tocopherol and ergocalciferol underwent a 
similar stability test to MLVs under the same physiological conditions 
described above. SUVs were found to be stable over a 10-day period as 
shown in Figure 22. Retained vitamin profiles show that the encapsulated 
molecules are well confined in the nanoliposomal structures (pellet). 
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Figure 22. Vitamins retention in nanoliposomes (SUVs) and released in 
PBS. Full symbols: squares, triangles and circles are referred to B12, 
tocopherol and ergocalciferol, respectively, and represent vitamin retained 
in the pellet. Open symbols: squares, triangles and circles are referred to 
B12, tocopherol and ergocalciferol, respectively, and represent the vitamin 
losses in phosphate buffer solution 
5.1.5 Discussion 
5.1.5.1 Thin film hydration technique assisted by ultrasonic 
irradiation 
Stable, highly loaded liposomal structure were carried out by means of an 
efficient ultrasound-assisted procedure. The rupture of the MLV lipid bilayer 
with ultrasonic energy produces smaller pieces which enclose themselves in 
nanometric liposomal structures (the process is shown in Figure 4 of 4.1 
section) whose size depends on irradiation time, amplitude, frequency and 
on the volume of the sample treated. 
As shown in Table 8, liposome diameter sizes are correlated to the number 
of sonication rounds applied: starting with MLVs, following two irradiation 
rounds (all irradiation rounds are of 10 seconds and are all followed by a 20-
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second pause) LUVs with 1.416 ± 0.117 μm diameter size are obtained. 
Starting with LUVs, following two more sonication rounds, SUVs of 86 ± 
33 nm in size are produced; after three more sonication rounds and four 
more irradiation rounds, SUVs of 51 ± 28 nm and 49 ± 26 nm are obtained, 
respectively. 
Table 8. Large Unilamellar Vesicles (LUVs) and Small Unilamellar Vesicles 
(SUVs) mean diameter size and Standard Deviation (SD) after sequential 
sonication rounds. Triplicate measurements were performed 
Sample Mean diameter size ± SD 
LUVs: 2 Starting batch 1.416 m ± 0.117 
SUVs:  Batch 2 
  Batch 3 
  Batch 4 
86 nm ± 33 
51 nm ± 28 
49 nm ± 26 
In Figure 20 the ultrasonic irradiation protocol used (Figure 20 A) is 
compared with the liposome size measurements carried out after sample 
irradiation (Figure 20 B). In Figure 20 A, the first two duty cycle sonication 
rounds which produce LUVs, correspond to the first two curves in Figure 20 
B; the last two irradiation rounds which produce SUVs, correspond to the 
last two curves in Figure 20 B. As previously reported, one of disadvantages 
of size reduction process by sonication is the poor control in size-uniformity 
of SUVs. This is due to the dimensional heterogeneity of MLVs produced by 
the Thin Film Hydration technique. 
The main advantage of the duty cycle sonication, applied in association with 
the traditional TFH method, is that there is no fixed constraint to the pore 
size of the membrane and the size of the vesicles can be changed according 
to the application requirements. SUVs of the right size can be obtained in a 
few seconds by simply modulating the duty cycle starting from micrometric 
liposomes. Furthermore, due to the importance of producing SUVs in a 
sterile environment, another advantage is that sonotrode tips are easier to 
clean and sterilize compared to membranes. 
In this thesis SUVs with 40-51 nm in size containing vitamins with elevated 
encapsulation efficiency were obtained in a few seconds by modulating the 
duty cycle (irradiation protocol) starting from micrometric liposomes. This is 
possible applying the dedicated radiative protocol developed defining 
several operative parameters (power of ultrasound, amplitude, number of 
rounds and their duration) as described in 4.2 section (Barba et al., 2014). 
Moreover, if it is compared with similar liposomes production methods, the 
developed protocol is more easy and rapid. For example, nanoliposomes 
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production process used by Mohammadi and coworkers (Mohammadi et al., 
2014) is similar to that used in this study but involves three stages (thin film 
hydration - homogenization – sonication) and gives particles of 82–90 nm in 
size entrapping D3, vitamin with similar features to those of ergocalciferol.  
On the basis of all these advantages duty cycle sonication method can be 
easily scaled up to industrial scale for control the mean size of liposomes for 
SUVs production without affecting their load efficiency. This is what was 
done in the second part of the PhD project as described in “Scale up of the 
ultrasound assisted homogenization process”, 4.2.3.4 paragraph. 
Moreover, the high encapsulation efficiency of both hydrophilic and 
hydrophobic vitamins found in MLVs decreases but in a not considerable 
manner after the size reduction process, making this ultrasound-assisted 
technique useful for obtaining highly loaded nanoliposomes. 
Finally, in order to carry out a comparison between the vitamins load 
achievable with the developed technique and the vitamin load achievable by 
breaking unloaded preformed liposomes (classic encapsulation approach), 
vitamin B12 was encapsulated within liposomes by producing unloaded 
MLVs, hydrating the lipidic film with PBS without vitamin B12 and then 
irradiating the sample (with the same parameters and duty cycle sonication 
protocol described above) in a PBS solution containing vitamin B12. Using 
this second approach the vitamin B12 encapsulation efficiency in SUVs was 
40%, which was much lower compared to the value of 56.2 % achieved for 
B12 encapsulation with the ultrasound-based TFH technique. Therefore the 
new approach appears to be a promising technology for obtaining highly 
loaded nanoliposomal formulations, boosting bioactive antioxidant delivery 
and providing process optimization in terms of possibilities of size range and 
production times. 
5.1.5.2 Vitamins solubility and SUVs load analysis  
Both hydrophilic and hydrophobic vitamins are easily destabilized by 
variations in temperature, oxygen, light and humidity (Azevedo et al., 2013). 
The encapsulation in liposome enables us to improve the stability of water-
soluble vitamins and assure the bioavailability of liposoluble vitamins with 
absorption limitations, at the same time thus protecting them during storage 
and in the physiological environment as mentioned in 2.2.1 paragraph 
regarding the critical issues in nutraceutical agents delivery. 
Liposomes are able to incorporate hydrophilic and hydrophobic vitamins: 
hydrophilic vitamins can be encapsulated in the interior aqueous 
compartment, while lipophilic and amphiphilic vitamins can be incorporated 
into the liposome bilayer. As shown in Table 9, since vitamin B12 is 
hydrophilic it is mainly entrapped in the liposome aqueous core while α-
tocopherol and ergocalciferol, hydrophobic molecules, are entrapped in the 
liposome lipid bilayer. Both the incorporation and the release of hydrophilic 
and hydrophobic vitamins (the main features of used vitamins and obtained 
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SUVs are summarized in Table 9) are influenced by the lipid composition of 
SUVs resulting in various levels of drug incorporation efficiency. 
Table 9. Main vitamins properties and Small Unilamellar Vesicles 
characterization 
Properties Vitamin B12 α-Tocopherol Ergocalciferol 
Average mass (Da)* 1355.36 430.71 396.65 
Stokes radius (nm)* 0.85 0.43 0.46 
Solubility in H2O 
(mg/mL)*- 20°C - 
12.5 0.021 0.050 
Encapsulation 
Efficiency (%) 
56.2 ± 8.51 76.3 ± 14.2 57.5 ± 13.9 
Total mass of vitamin 
(mg) in supernatant 
and pellet 
14.32 ± 1.08 3.70 ± 0.41 14.92 ± 3.29 
Mass of vitamin (mg) 
in supernatant 
6.70 ± 1.36 0.92 ± 0.44 6.56 ± 3.48 
Mass of vitamin (mg) 
in pellet 
7.62 ± 1.24 2.78 ± 0.22 8.36 ± 0.19 
Vitamin retention area 
(grey filling) in the 
liposomal structures 
   
*Source: ChemSpider Search and share chemistry at http://www.chemspider.com 
Cholesterol plays an important role in liposome formulations for bilayer 
stability; in Tabandeh & Mortazavi (Tabandeh and Mortazavi, 2013) it was 
observed that drug encapsulation efficiency is also directly related to 
cholesterol molar ratio due to its competition with α-tocopherol. The 
composition of the lipid bilayer as well as the incorporation of the right 
amount of cholesterol are essential for the encapsulation efficiency of 
hydrophobic molecules. In particular, a study on encapsulation efficiency of 
α-tocopherol in MLVs produced by the TFH method was done by varying 
the molar ratio of α-tocopherol and that of cholesterol (Tabandeh and 
Mortazavi, 2013). In this thesis 1:20 molar ratio of α-tocopherol to egg 
lecithin was selected as the optimum amount for the production of MLVs 
with the highest encapsulated amount of α-tocopherol in its active form. 
Moreover, among the different molar ratios of cholesterol investigated by 
Tabandeh & Mortazavi (1:20, 1:10, 1:1 cholesterol to lecithin mol:mol), 1:20 
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molar ratio of cholesterol was selected as the optimum formulation. Using 
these optimum ratios of cholesterol and α-tocopherol and the thin film 
hydration method they have obtained MLVs with 86 % e.e. but not in small 
unilamellar vesicles. 
In this thesis, starting from 1:20 molar ratio of α-tocopherol to the total 
amount of lipids and maintaining at 1:20 the molar ratio of cholesterol to 
phosphatidylcholine, MLVs of 3.9 μm in size with an e.e. of 81.5 % have 
been produced, obtaining high encapsulation efficiency in agreement with 
Tabandeh & Mortazavi. 
In another study, based on thin-film hydration-sonication method, 
Mohammadi and coworkers (Mohammadi et al., 2014) have encapsulated in 
nanoliposomes the hydrophobic active molecule vitamin D3. In particular, in 
contrast with what has been said about the key role of cholesterol in 
hydrophobic vitamins encapsulation, they have showed that changing the 
lecithin to cholesterol ratio (60:0, 50:10, 40:20, 30:30 w/w) the 
encapsulation efficiency does not change for nanoliposomes encapsulating 
vitamin D3. In their study the e.e. was more than 93%, in liposomes of 82–
90 nm in size, for all formulations tested and they showed that changes in 
cholesterol amount have an effect only on the stability, in particular, on the 
zeta potential of empty liposomes. 
In the present study it has been shown that α-tocopherol and ergocalciferol 
hydrophobic vitamins can be encapsulated with high encapsulation 
efficiency in SUVs with a diameter range of 40-48 nm using 
phosphatidylcholine and cholesterol at 20:1 molar ratio. The SUVs range 
size obtained, which can be easy achieved by the two operative steps, thin 
film hydration - sonication, could be particularly interesting for intravenous 
vitamin therapy. 
In the production of MLVs and SUV encapsulating vitamin B12 has been 
used 1:4 w/w ratio of vitamin B12 to the total amount of lipids taking into 
account the best vitamin/lipids ratio find in a work of Liu and Park (Liu and 
Park, 2010) in which ascorbic acid (vitamin C), another water-soluble 
vitamin, was encapsulated in chitosan-coated nano-size liposomes with a 
maximum loading efficiency about 96.5% when 1:1 weight ratio of vitamin 
C to the total amount of lipids was used.  
It is important to note that the applied sonication duty cycle does not affect 
vitamins stability but plays a role, as above discussed, on the encapsulation 
efficiency and in turn on vitamin loads.  
In Table 9 it is shown that the initial amount of each vitamin (total mass of 
vitamin) was perfectly assayed in supernatant (mass of vitamin in 
supernatant) and pellet (mass of vitamin in pellet) phases collected at the end 
of sonication procedure from MLVs to SUVs (a purposely test of mass 
balance was performed). 
In Table 9 it is shown the effect of sonication action on encapsulation 
efficiency and on vitamin loads for the prepared MLVs and SUVs. The 
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sonication, inducing a cyclic opening and closing of liposomal bilayer, 
involves vitamin losses in the sonication bulk in amount related to the 
features of the entrapped vitamin (mainly the solubility).  
The SUVs obtained in this thesis are stable and did not release significant 
amounts of vitamins in PBS throughout the study period. The main 
consequence is that they may have a longer shelf life (i.e., a commercial 
product based on this formulation can be kept for long periods without 
deteriorating or releasing active components). 
5.1.6 Remarks 
Liposomes can be a highly efficient delivery system which is able to 
maintain accessible vitamin sources for new pharmaceutical and food 
industry applications. The high encapsulation efficiency of both hydrophilic 
and hydrophobic vitamins into SUVs and the obtainable nano-size by means 
of the developed ultrasonic assisted approach make liposomes optimal 
carriers biocompatible, stable and easy to reduce in size.  
In this study the new developed procedure, based on thin film hydration 
method followed by sonication cycles, was applied to prepare liposomes 
loaded with three vitamins with different hydrophobicity. All the kinds of 
liposomal structures produced were characterized in terms of encapsulation 
efficiency, size and stability in a relatively long period. The liposomes were 
obtained with tailored size ranging from 2.9 μm to 5.7 μm for MLVs 
obtaining, after sonication in duty cycle, SUVs in the average range of 40 
nm to 51 nm in size. High encapsulation efficiency was obtained in both 
MLVs, with a e.e. % of 72.0 ± 00 % for vitamin B12, 95.0 ± 7.07 % for α-
tocopherol and 81.5 ± 2.12 % for ergocalciferol, and SUVs, with a e.e. % of 
56.2 ± 8.51 % for vitamin B12, 76.3 ± 14.02 % for α-tocopherol and 57.5 ± 
13.9 % for ergocalciferol (the higher the vitamin hydrophobicity, the higher 
the encapsulation efficiency). A comparison between vitamin B12 load 
achievable with the developed technique and the vitamin load achievable by 
breaking unloaded preformed liposomes (conventional approach) showed an 
increase of encapsulation efficiency in SUVs from 40% to 56.2 %, 
confirming the effectiveness the of pointed out technique. 
 
Part of this work has been reported in: 
Bochicchio S.; Barba A.A.; Grassi G.; Lamberti G.; “Vitamin delivery: 
carriers based on nanoliposomes produced via ultrasonic irradiation”; LWT - 
Food Science and Technologies, 2016, 69, 9 -16 
  






5.2 Nanoliposomes vectors for ferrous sulfate delivery 
5.2.1 Generalities 
As in depth previously discussed for vitamins delivery (5.1 section), due to 
their unique properties of biocompatibility, biodegradability, low intrinsic 
toxicity and versatility, liposomes uses has been rapidly grown as new 
technology for food fortification (Kosaraju et al., 2006). In particular, size 
and size distribution are key parameters determining liposomes performance 
as delivery systems in nutraceutical applications by improving taste, flavor, 
stability, absorption and bioavailability of bioactive compounds, all features 
which are meliorate if the micronutrient is nanoencapsulated (Reza Mozafari 
et al., 2008, Srinivas et al., 2010, Putheti, 2015, Bochicchio et al., 2016a). 
Compared with micrometre-sized systems produced by traditional 
microencapsulation techniques, nanoparticles have a larger interfacial 
surface area and have the potential to improve the solubility, enhance the 
bioavailability and improve the controlled release of the bioactive principle 
(Singh, 2016). Moreover, nanoparticles may also have an elongated retention 
time in the small intestine when compared to the larger structures (Huang, 
2012). 
Food enrichment process was introduced with iron micronutrient in order to 
combat anemia, one of the most widespread nutritional deficiencies, 
affecting globally two billion people (Mellican et al., 2003). In 1993 the 
Special Commission for Enrichment of Foods was created by the Venezuela 
Government and, in the same year, a fortification program began in which 
maize and wheat flours were enriched with 20 and 50 mg of iron (as ferrous 
fumarate)/kg flour, respectively (Layrisse et al., 1996). Despite the success 
of iron fortification in addressing the prevalence of iron deficiency anemia, 
particularly in developing countries, this has been limited by the lack of a 
robust, simple, and easy-to-transfer fortification technology (Mehansho, 
2006). Regarding the supplementary micronutrient products present on 
market in the form of tablet or capsules their quality and variety have to be 
improved, increasing the availability and access of supplements in the 
commercial sector (Mora, 2002).  
In order to meliorate the supplementary iron products currently on the 
market, often composed by micrometric particles, sometimes containing the 
less absorbable ferric form of iron and obtained, in the most of the cases, by 
using ineffective production processes and drastic conditions, ferrous sulfate 
nanoliposomes were produced in this thesis by using the simil-microfluidic 
bench scale apparatus developed, presented in 4.2 section. 
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With the aim to give a contribution in the development of both an improved 
iron-nanoliposomal formulation and a simple, low cost and sustainable 
production method, at first the effect of different weight ratios of iron to the 
total formulation components (0.06, 0.035, 0.02 and 0.01 iron/total 
components weight ratio) on the final vesicles encapsulation efficiency was 
investigated. Then, a comparison in terms of vesicles final properties (mean 
diameter size, polidispersity index, zeta potential, charge and encapsulation 
efficiency) and the yields of the processes was realized between liposomes 
obtained by using the simil-microfluidic set up and the ones obtained by 
using the Ethanol Injection and the ultrasound assisted Thin Film Hydration 
method, at the same operative conditions. 
5.2.2 Materials 
L-α-Phosphatidylcholine (PC) from soybean, Type II-S, 14-23% choline 
basis (CAS n. 8002-43-5), Cholesterol (CHO) (CAS n. 57-88-5), Rhodamine 
B dye (CAS 83-68-9-Sigma-Aldrich, Milan, Italy), ferrous sulfate 
heptaidrate (CAS n. 7782-63-0), ascorbic acid (CAS n. 50-81-7), ethanol of 
analytical grade (CAS n. 64-17-5), Triton X100 (CAS n. 9002-93-4), 
hydrochloric acid (CAS n. 7647-01-0), hydroxylamine hydrochloride (CAS 
n. 5470-11-1), ammonium acetate (CAS n. 631-61-8), glacial acetic acid 
(CAS n. 64-19-7) and 1,10-Phenantroline (CAS n. 66-71-7) were purchased 
from Sigma Aldrich (Milan, Italy). 
5.2.3 Methodology and sperimental set-up 
5.2.3.1 Preparation of iron loaded nanoliposomes 
Production through the simil-microfluidic apparatus 
Ferrous sulfate loaded nanoliposomes were produced by using the simil-
microfluidic bench scale apparatus developed whose layout and main 
process steps are described in 4.2 section. 
The optimized conditions of 10:1 (Vhs/Vls) volumetric flow rate ratio and 5 
mg/ml lipids in the final hydroalcoholic solution were used for liposomes 
preparation. Briefly, a lipid/ethanol solution was obtained by dissolving 470 
mg of PC and 94 mg of cholesterol in 10 ml of ethanol. Cholesterol was used 
at 2.5:1 (mol/mol) PC/CHOL ratio and was added to the formulation in order 
to stabilize the loaded vesicles. Ferrous sulfate heptaidrate and ascorbic acid 
were dissolved in 100 ml of deionized water which was used as hydration 
solution. Ascorbic acid was added as an anti-oxidant to preserve the ferrous 
ion against oxidation in a ferrous/acorbic acid weight ratio of 1:6 (w/w). It 
has been shown that the co-addition of ascorbic acid and iron in a 2:1 molar 
ratio (6:1 weight ratio) increases iron absorption from foods 2- to 3-fold in 
adults and children (Stekel et al., 1986b, Stekel et al., 1986a, Lynch and 
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Stoltzfus, 2003). In particular, four different formulations were produced 
which differ from each other for the ferrous sulfate/total formulation 
components (lipids, ascorbic acids and ferrous sulfate) weight ratio (w/w) 
used. Starting from a 0.06 ferrous sulfate/total components weight ratio, 
selected from Xia et Xu (2005) (Xia and Xu, 2005), nanoliposomes were 
also produced by using a 0.035, 0.02 and 0.01 ferrous sulfate/total 
components (w/w) ratio and maintaining constant all the other chemical and 
process parameters adopted. In order to have a comparison with the ferrous 
sulfate loaded particles, unloaded nanoliposomes were produced by 
adoperating the same formulation and process conditions but using, as 
hydration solution, pure deionized water without the addition of ascorbic 
acid and iron.  
Production through the classical bench scale techniques  
The conventional Ethanol Injection (EI) method (3.1.2 section) and the 
ultrasound assisted Thin Film Hydration (TFH) technique developed (4.1 
section) were adopted for the production of ferrous sulfate loaded 
nanoliposomes in order to have a comparison in terms of productivity with 
those achieved by the use of the simil-microfluidic semicontinuous apparatus 
fabricated. In particular, the fourth formulation with a 0.01 ferrous 
sulfate/total components (w/w) ratio was produced with both the techniques. 
Ethanol Injection  
Using the EI technique, ferrous sulfate loaded and unloaded nanoliposomes 
were prepared by dissolving 470 mg of PC and 94 mg of cholesterol in 10 ml 
of ethanol. After stirring, the ethanol/lipid solution was sprayed by means of 
a 10 ml syringe (needle of 0.8 mm) in a 100 ml of deionized water 
containing ferrous sulfate (5.64 mg) and ascorbic acid (33.8 mg) at 6:1 
(w/w) to achieve loaded nanoliposomes. Liposomes suspension was stirred 
for 10 min and left stabilize at room temperature for two hours. Finally, 
aliquots (1 ml) of the obtained vesicles were subjected to the duty cycle 
sonication size reduction process, according to the procedures previously 
described (4.1.2.2 paragraph). By this way nanoliposomes were produced by 
maintaining at 5 mg/ml the lipid concentration in the final hydroalcoholic 
solution and at 10:1 (v/v) the volume ratio between the hydration solution to 
the lipid solution as done by using the simil-microfluidic apparatus in 
optimized conditions. 
Ultrasound assisted Thin Film Hydration 
The ultrasound assisted TFH method was also used to produce 
nanoliposomes maintaining constant the lipid concentration. Briefly 47 mg 
of PC and 9.4 mg of CHOL at 2.5:1 (mol/mol) ratio were dissolved in 1 mL 
of chloroform/methanol at 2:1 (vol/vol). The solvent was removed by 
evaporation at 50 °C for 3 h in a rotary evaporator (Heidolph, Laborota 4002 
Control, Bergamo, Italy) under reduced pressure until a lipid film was 
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produced. The dried lipid film was then hydrated at room temperature with 
11 mL of deionized water containing ferrous sulfate (0.62 mg) and ascorbic 
acid (3.72 mg) at 6:1 (w/w). The preparation containing Multilamellar 
Vesicles (MLVs) was maintained at room temperature for 2 h and, 
subsequently, sample aliquots (1 mL) were subjected to the ultrasound 
assisted size reduction process, in the mode previously described for the 
other production techniques adopted. 
5.2.3.2 Physicochemical characterization of vesicles 
Morphology 
The morphological characterizations of unloaded and ferrous sulfate loaded 
nanoliposomes were performed with optical microscope in fluorescence field 
(Axioplan 2- Image Zeiss, Jena, Germany) equipped with a software to 
capture the images. The Rhodamine B dye was used to visualize lipid 
vesicles. A 100 x oil immersion objective was used. 
Size and zeta potential 
Size and zeta potential determinations of unloaded and ferrous sulfate loaded 
vesicles were performed by using the Zetasizer Nano ZS (Malvern, UK) 
with noninvasive backscatter (NIBS) optics. The detection angle of 173 
degrees was used. The resulting particle size distribution was plotted as 
number of liposomes versus size. The Polydispersity Index (PDI) was 
calculated for all the preparations. All the measurements were performed in 
triplicate. The results were expressed as average values. 
5.2.3.3 Evaluation of iron encapsulation and stability test 
Encapsulation efficiency (EE) 
From all the samples produced, aliquots were taken and 
spectrophotometrically analyzed in order to measure the real encapsulated 
and the unencapsulated amount of ferrous sulfate. For this purpose 2 ml 
aliquots were centrifuged at 30000 rpm (Beckman Optima L-90K, SW 55 Ti 
rotor) for 1 h at 4 ° C in order to remove the supernatant from the 
precipitated nanoliposomes (pellet). The supernatant volume, stored for the 
subsequent ferrous sulfate determination, was measured and replaced with 
the same volume of Triton X100 at 1% (v/v) in order to lyse the 
nanoliposomes pellet and to analyze the encapsulated ferrous sulfate. 
Iron determination was performed by the 1,10-Phenanthroline assay. Briefly, 
to 400 μl aliquot of supernatant, 200 µl of 37 % (v/v) hydrochloric acid were 
added to acidified the solution together with 100 μl of 10 % (v/v) 
hydroxylamine hydrochloride used as a reducing agent. After 10 minutes, 1 
ml of ammonium acetate buffer solution, previously prepared by dissolving 
50 g of ammonium acetate in 30 ml of deionized water and 140 ml of glacial 
acetic acid, was added together with 200 μl of 1,10-Phenantroline at 0.5 % 
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(v/v). The steps were repeated for the pellet dissolved in Triton X 100. The 
total volume for each test tube was then increased to 10 mL with deionized 
water. Blanks reagents were prepared in the same manner but using pure 
water or Triton X100 in place of the samples. An absorption spectrum from 
200 nm to 600 nm was investigated for all the samples and the maximal 
wavelength of 510 nm, typical of the 1,10-Phenantroline-Fe
2+
 ions complex, 
was considered. The iron amounts was determined by using a ferrous sulfate 
calibration curve previously prepared with the same 1,10-Phenantroline 
colorimetric determination. The UV spectrophotometric assay was 
performed by using Lambda 25 UV/VIS Spectrophotometer (PerkinElmer, 
Monza, Italy). 
The encapsulation efficiency (e.e.) was determined as the percentage of 
ferrous sulfate encapsulated in nanoliposomes to the initial amount of 
ferrous sulfate included in the formulation and was calculated using the 
equation 5.3: 
 e. e. (%) = (
𝐹𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑒𝑙𝑙𝑒𝑡,𝑚𝑔
𝐹𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑒𝑙𝑙𝑒𝑡+ 𝐹𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡,𝑚𝑔
) × 100  (5.3) 
Iron loads were determined through the ratio: 
 𝐿𝑜𝑎𝑑, % =
  𝐹𝑒,𝑚𝑔
  𝐹𝑒 + 𝑎𝑠𝑐𝑜𝑟𝑏𝑖𝑐 𝑎𝑐𝑖𝑑 +𝑙𝑖𝑝𝑖𝑑𝑠,𝑚𝑔
× 100  (5.4) 
In particular, the theoretical load is referred to the initial amount of iron 
included in the formulation and divided by the total mass while the effective 
one is referred to the iron amount effectively presents in the nanoliposomes 
(pellet) divided by the total mass. 
Stability test 
The stability of the produced nanoliposomes with the best iron encapsulation 
efficiency (fourth formulation) was tested in conditions simulating those of 
food storage. The samples were maintained at 4 °C for a period of about 15 
days in deionized water and the mass of iron present in the supernatant and 
in the pellet was quantified at established time. Briefly, given amounts of 
loaded nanoliposomes were put in measured volumes of deionized water. 
Subsequently, after 6 h, 22 h, 46 h, 70 h, 130 h e 346 h sample aliquots were 
taken and centrifuged under the same operating conditions described for the 
encapsulation efficiency determination. The mass of iron present in both the 
supernatant and the pellet solutions were determined, at each time, by the 1, 
10-Phenantroline method through UV spectrophotometric assay. All the 
measurements were performed in triplicate. 
 
Chapter 5   
86 
5.2.4 Results and Discussion 
5.2.4.1 Iron loaded nanoliposomes production  
Simil-microfluidic apparatus production process 
The simil-microfluidic bench scale apparatus developed has allowed to 
successfully produce iron loaded nanoliposomes in the desired range size by 
using the optimized conditions. The method has permitted to produce 
ferrous-sulfate nanostructured vectors without the use of drastic conditions, 
such solvents and/or high pressure, currently used in literature and also at 
industrial scale for iron-particles manufacturing by using discontinuous 
processes such Reverse Phase Evaporation, Thin Film Hydration and 
Homogenization-Freeze Thawing methods, this last used for the commercial 
microencapsulated iron Biofer® (Lipotech) production (Kosaraju et al., 
2006, Xia and Xu, 2005, Abbasi and Azari, 2011, De Paoli and Hager, 
1996). A part of the drastic conditions used, limits in the output volumes of 
final product, usually ranging from 10 to 60 mL with the above mentioned 
techniques, represent another crucial problems directly linked with high 
commercial costs of supplemental products which, for this reason, are not jet 
widely used as a very proper therapies. With the simil-microfluidic set up 
developed, by using the ultrasound as tool for the process intensification, it 
is possible to obtain a massive output with the minimum of energy, costs and 
time: one batch of 110 mL iron-liposomal suspension can be produced in 
few minutes with the possibility to restart the process in a semi-continuous 
manner. Once again the chemical engineering approach of process 
intensification together with the use of not drastic condition has led to the 
production of suitable nanovector. 
Formulation efficacy 
Scientific works about iron encapsulation in lipid particles for nutraceutical 
applications show some failing in terms of formulation such an unbalanced 
ascorbic acid/iron (AA/Fe) weight ratio compared to that recommended by 
the World Health Organization (WHO) (Dary and Hurrell), which is the 6:1 
w/w used in this thesis, and the frequent use of the less absorbable form of 
iron: the ferric form (Santiago, 2012).  
For example, a 1:15 weight ratio of ascorbic acid to ferrous sulfate was used 
by Xia and Xu (Xia and Xu, 2005) and also by Abbasi and Azari (Abbasi 
and Azari, 2011) while a 1:1.5 AA/Fe weight ratio was used in another work 
by Kosaraju and collaborators (Kosaraju et al., 2006). Even if referring to the 
products already on the market and most frequently used for the treatment of 
iron deficiencies it can be note that formulations are unbalanced in 
iron/ascorbic acid ratio, for example SunActive®, a TAIYO International 
product for iron fortification, contains a 4:1 w/w A.A./Fe, furthermore the 
ferric pyrophosphate is used in this formulation. Biofer®, a Lipotech 
microencapsulated iron product, contains 1:15 AA/Fe w/w. Sideral and 
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Sideral Forte, a Pharmanutra products, are formulated with the less 
absorbable ferric pyrophosphate form and contains from 1:4 to 1:2 w/w 
Fe/A.A, this last used in Sideral Forte, for the treatment of severe anemias. 
Moving from the nutraceutical field towards the food sector, the optimized 
formulation containing the liposomal ferrous form could be used also for 
food fortification. In that regard iron food fortification is recognized as a 
strategy to control childhood anemia: i.e. the frequent use of cow’s milk in 
Latin America, including Brazil, during infancy, and iron fortification of this 
vehicle is an inexpensive alternative to increase iron levels in children 
(Lamounier et al., 2010), about that Torres and collaborators have observed 
a decreases of anemia when 1 liter/day of fluid milk fortified with 3 mg of 
chelate amino acid iron were administered to children (Torres et al., 1996).  
Considering to enrich a milk with the ferrous sulfate nanoliposomes 
produced through the use of the simil-microfluidic apparatus developed, and 
considering the formulation with the maximum e.e. achieved (Table 11), it 
would be possible to obtained in just few minutes (one batch) a milk 
suspension with an iron concentration of 56.4 mg/L that would be enough to 
meet the daily requirement of iron for an entire family. Indeed, the 
Recommended Dietary Allowances (RDAs) for iron considering an adult is 
of 8 mg for males and of 18 mg for females (Food and Board, 2002) thus 
250 ml of enriched milk daily would be sufficient for one person. 
5.2.4.2 Iron loaded nanoliposomes characterization 
Morphology 
In order to obtain information about morphology, fluorescence imaging was 
used. As showed in Figure 23 spherical and separated liposomes were 
achieved with all the formulations tested. 
 
Figure 23. Fluorescence microscopy images of ferrous sulfate lipid vesicles 
labelled with Rhodamine B dye and visualized with a 100 X objective 
Size and zeta potential  
The objective of a fortification technology development is to deliver 
bioavailable active molecule, such iron, via commonly consumed foods and 
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beverages without compromising their taste, appearance and stability. In 
particular, the iron solubility is very dependent on the size and the shape of 
the iron-particles complexes, characteristics which are governed by the 
manufacturing process (Mehansho, 2006). In that regard, particles of 
nanometric scale are required to maintain the transparency of clear 
beverages during enrichment: carrier have to be small enough so as not to 
scatter light and be detected by naked eye (Danino et al., 2014). The nano-
scale plays a crucial role also for other forms of iron supplementation such 
oral formulations, the first choice to replace normal iron levels. In this case, 
the size of nanoparticle systems has a remarkable influence on carriers 
uptake after their administration: in many works has been proved that 
nanostructured delivery systems yield an increases in drug uptake, enhancing 
the intestinal absorption of the active principle (Desai et al., 1996, Hussain et 
al., 2001). Despite the crucial role of particle size in iron delivery is 
confirmed by several studies, few are those in which dimensional features 
are clearly showed while the major of works not provide this information; 
also the commercial products not specify the carriers dimensions. In this 
thesis an accurate analysis of iron-vesicles dimensional features and surface 
charge, produced by the simil-microfluidic apparatus, was done and the 
results obtained from the sonicated and not sonicated samples are presented 
in Table 10. 
Table 10. Sonicated and not sonicated liposomes diameter size, 
polydispersity index (PDI) and zeta potential produced at different weight 
ratio of ferrous sulfate to the total formulation components. Results are 
expressed as average of three determinations and reported along with the 




0.06 w/w 0.035 w/w 0.02 w/w 0.01 w/w 
Not sonicated samples size and PDI 











PDI ± SD 0.41 ± 0.03 0.45 ± 0.04 0.76 ± 0.034 0.69 ±0.08 0.080616376 0.40 ± 0.03 
Sonicated samples size and PDI 

















Samples zeta potential 
Zeta 
Potential 
(mV) ± SD 
-57.87 ± 
1.13 
-41.05 ±0.7 -20 ±1.16 - 19±0.55 
-35.87 ± 
2.05 
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In reference to the not sonicated samples, it can be observed that the 
diameter size of unloaded nanoliposomes (about 72 nm) is smaller than the 
ferrous sulfate loaded form. The increases of loaded vesicles average 
dimension, which is about 103-154 nm range in size, is indicative of the fact 
that a certain amount of iron and ascorbic acid is encapsulated within the 
vesicles. Regarding the polydispersity index of the samples it was remained 
almost unchanged for the unloaded vesicles and for the 0.06 (w/w) and the 
0.01 (w/w) formulations (PDI about 0.4) while some aggregates were 
founded for the 0.035 (w/w) and the 0.02 (w/w) samples with a PDI value of 
about 0.7 (Table 10). Considering the sonicated samples it can be note that 
the sonication has a crucial role in reducing the size of the iron loaded 
liposomes confirming what previously seen for the unloaded structures: i.e. 
the average liposomes diameter size of the first formulation (0.06 w/w) is 
decreased of about the 44 % after the ultrasound assisted step (from 127 nm 
to about 48 nm in size). This is true for all the tested samples. With regard to 
the polydispersity index, the sonication is effective again: ever taking into 
account the first iron-loaded formulation the PDI, initially of 0.45, becomes 
0.38 after the ultrasound assisted homogenization step. The reduction in 
vesicles size and PDI by passing from the not sonicated to the sonicated 
samples was always found for all the samples tested (Table 10). 
Moreover, it is important to note that size and PDI values obtained for the 
not sonicated unloaded liposomes with the addition of cholesterol (72 nm; 
0.4 PDI) are near to the value obtained for the not sonicated unloaded 
nanoliposomes formulated with only PC, without cholesterol, (81 nm size; 
0.32 PDI) by using the same process conditions: 10:1 Vhs/Vls and a 5 mg/ml 
PC concentration in the final hydroalcholic solution. The same comparable 
values were found for the PC-CHOL sonicated unloaded samples (50 nm 
size and a 0.2 PDI) and the PC sonicated unloaded sample (52 nm in size 
and a 0.3 PDI) (4.2 section). This comparison point out the reliability and the 
reproducibility of the developed set-up and the operating conditions used.  
Another important parameter to take into account in the development of drug 
delivery systems to be used in nutraceutical applications is the zeta potential 
(), a stability index of the nanoliposomes suspensions. In order to avoid the 
nanostructures aggregation, resulting in a precipitation and loss of product 
stability, carriers should have a  > 30 mV, when the zeta potential drops 
below this value the system becomes unstable and begins forming larger 
complexes as the attractive forces prevails (Schatzlein, 2013). Here, 
negatively charged vesicles were produced for all the iron/total formulation 
components (w/w) ratio tested (0.06, 0.035, 0.02 and 0.01 weigh ratio). In 
particular, the zeta potential value for unloaded liposomes was negative (-
57.87 ± 1.13 mV) due the presence of polyunsaturated fatty acids (linoleic 
and olei acids) composing the phosphatidylcholine vesicles. Moreover, being 
the negative charges of the liposomal bilayer able to trap the cationic ferrous 
sulfate by electrostatic interactions, as a consequence of the presence of 
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positive charged iron ions, the vesicles surface becomes less negative for 
loaded liposomes (Table 10). In particular it seems that for the 0.035 (w/w) 
and for the 0.02 (w/w) formulations the electrostatic interactions have 
conrned more the outer vesicles surface then the inner part, being the zeta 
potential less negative (about -20 mV) respect to the other formulations 
(from -36 to - 41 mV  range) where iron is mostly entrapped in the 
liposomes core (see Table 10). 
Encapsulation efficiency (EE) 
Due to its rapid oxidation-reduction (redox) reactions, iron administration is 
almost always accompanied by undesired effects related to taste, appearance, 
and bioavailability. In order to develop an effective iron fortification 
technology or iron supplement therapy it is of critical importance border the 
micronutrient into the liposomes aqueous core so as to limit the components 
that cause undesirable organoleptic properties and influence iron 
bioavailability. 
In order to make iron unreactive during its administration and storage, 
ferrous sulfate was isolated from the external environment and oxidizing 
agents by encapsulation in nanoliposomal structures produced by using 
different weight ratio of iron to the total formulation components. According 
with Xia and Xu, it was observed that increasing ferrous ion concentration 
there is a decreases of encapsulated ferrous ion amount when deionized 
water is used as hydrating medium (Xia and Xu, 2005). Nevertheless, it is 
important to underline that by using the Reverse-Phase Evaporation (REV) 
method and maintaining the same hydration medium and iron species used in 
this thesis, they have obtained an e.e. of about 5% and 16 % respectively for 
a 0.06 and a 0.04 w/w iron/total components used. As visible from Table 11, 
in this thesis a 22 % e.e. and a 42 % e.e. were achieved by using respectively 
a 0.06 and a 0.035 w/w iron/total formulation components through the use of 
the simil-microfluidic apparatus developed. In general, the decreases in iron 
e.e. by increasing the ferrous sulfate concentration can be explained by the 
fact that the ferrous sulfate is a strong electrolyte and for major load values 
the ionic strength, defined as the concentration of ions present in a solution, 
increases, resulting in a reduction of the encapsulation capacity in the 
aqueous phase (solution of iron and ascorbic acid) [56]. In virtue of these 
considerations, loaded nanoliposomes characterized by higher iron/total 
formulation components weight ratios were studied observing an increased 
e.e. in particular of 52 % by using a 0.02 w/w iron/total components and of 
about the 97 % with the 0.02 w/w iron/total components formulation (Table 
11).  
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Table 11. Theoretical load, effective load and encapsulation efficiency (e.e.) 
of sonicated liposomes produced at different weight ratio of ferrous sulfate 
to the total formulation components. Results are expressed as average of 















load ± SD 
(%) 
4.23 ± 0 3.41 ± 0 2.3 ± 0 0.98 ± 0 
Effective 
load ± SD 
(%) 
0.99 ± 0.031 1.28 ± 0. 32 1.22 ± 0. 2 0.93 ± 0.13 
e.e. ± SD 
(%) 
22.33 ± 0.58 42.14 ± 6.74 52.2 ± 1.41 96.63 ± 2.7 
In general, better e.e. results respect to the literature works has been obtained 
by the use of a simple and rapid technique and just deionized water as 
hydration medium. Indeed, by means of the last formulation, it was possible 
to obtain stable liposomes with a diameter of 76 nm and an encapsulation 
efficiency of 97 %. In a work of Kosaraju and collaborators a preparation of 
Fe/AA-loaded liposomes below 250 nm in size was obtained for Fe/AA 
concentrations of 7.5/5 % (w/w) by using Emultop ® obtaining a maximum 
of 57 % e.e. with an homogenization process (Kosaraju et al., 2006). In some 
cases, higher ferrous sulfate e.e. were obtained in liposomes by using citric 
acid sodium phosphate buffer solution as hydration medium and Tween 80 
in the lipid formulation but the liposomes dimensions are in the micrometer 
scale (Abbasi and Azari, 2011).  
Regarding the ferrous sulfate loads achieved, from Table 11 it can be 
observed that the 0.035 w/w Fe/total components formulation showed the 
major effective load, about the 1.3 %, along with an encapsulation efficiency 
of about 42 %. 
Stability test 
The stability of the produced iron loaded nanoliposomes with the best 
encapsulation efficiency (0.01 w/w Fe/total formulation components) was 
tested in conditions simulating those of iron enriched food (such milk or fruit 
juice) storage. The samples, maintained at 4 °C for a period of about 15 days 
in deionized water, were found to be stable as can be observed from the 
Figure 24. 
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Figure 24. Iron retained in nanoliposomes and released in deionized water. 
The open symbols are referred to the ferrous sulfate mass retained in the 
pellet, the full symbols represent the iron losses in deionized water 
The trend of the mass of iron presents in the pellet and in the supernatant at 
different time remains constant during an observation period of 130 h (about 
6 days). At the last observation, after 346 h (about 15 days), approximately 
the 24 % of the total ferrous sulfate was released in the supernatant, probably 
due to oxidation phenomena occurred to lipids. In general, liposomal 
structures showed a good ability in retain the iron mass in their core 
structures, proving to be useable for food iron enrichment application. 
5.2.4.3 A comparison between the simil-microfluidic apparatus and 
the classical bench scale techniques  
Iron liposomes produced with the simil-microfluidic set-up were compared 
with ferrous sulfate loaded vesicles produced with the conventional 
techniques by using the same operating conditions and the 0.01 w/w Fe/total 
components formulation. In Table 12 the results relative to structures size, 
PDI, zeta potential and encapsulation efficiency of iron-nanoliposomes are 
presented for the tree methods adopted. 
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Table 12. Size, PDI, zeta potential and encapsulation efficiency (e.e.) of 
ferrous sulfate loaded nanoliposomes produced adopting the 0.01 w/w 









Size (nm) ± SD 76.29±16.4 49.85±1.79 74.53±9.81 
PDI ± SD 0.37±0.029 0.30±0.021 0.52±0.039 
Zeta Potential 
(mV) ± SD 
-35.87±2.05 -30.2±1.27 -37.27±2.26 
e.e. ± SD (%) 96.63± 2.7 97.98± 2.17 100±0 
The liposomal dimensional features are comparable except for a slight 
reduction in liposomes size observed by using the ultrasound assisted Thin 
Film Hydration method and an increases in PDI by using the Ethanol 
Injection method. Zeta potential values as well as the encapsulation 
efficiencies remains high and mostly similar, with a 100 % of e.e. by using 
the EI technique. The strength of the simil-microfluidic apparatus resides 
therefore in the process time and yield, in the use of not drastic conditions 
(toxic solvents or high pressure/temperature are avoided), in the controllable 
final liposomes dimensional features by modulating the starting flow 
conditions. 
In particular, the conventional Thin Film Hydration method (Bangham and 
Horne, 1964) followed by the ultrasound assisted size reduction process 
(Barba et al., 2014), used in this thesis also for the production of SUVs 
encapsulating different kind of vitamins (5.1 section), peptides (5.3 section) 
and Nucleic Acid Based Drugs (NABDs) (5.4 and 5.5 sections), despite 
giving the possibility in achieving liposomes on nanometric scale due to the 
versatility of the size reduction process developed, with high loads for the 
most of the active molecules used, suffers of the impossibility to scale up the 
process. The volumes in output are small with long process times. Indeed, 
also if considering the higher capacity of a standard size round bottom flask 
commercially available, the resulting volume of product obtainable in a 
given time (usually 3-4 hours are necessary just to the solvent evaporation 
step) is small and finite, the situation is not different for the ethanol injection 
technique which, despite being a more rapid method, presents a maximum 
syringe volume of 50 ml, moreover the process is discontinuous and not 
controllable. The semicontinuous apparatus developed has not limits in the 
production, in particular in just 2.5 minutes it is possible to produce 110 ml 
of iron-nanoliposomes solution. As visible in Table 13, through the use of 
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the developed apparatus the yield of the process, intended as the ratio of the 
number of liposomes produced in one batch for unit volume (see 4.2.2.4 
paragraph, eq. 4.5) to the time spent for their production, is about 2.3 * 10
14
 
(1/ml h) while with the conventional technique the yield decreases becoming 
about 9*10
9 
(1/ml h) and 5.4*10
11
(1/ml h) respectively when the Thin Film 
Hydration and the Ethanol Injection methods are adopted. 
Table 13. A comparison in terms of process yield between the use of the 
simil-microfluidic set-up and the classical bench scale methods in 
nanoliposomes production. A volumes of 110 ml (one batch volume), 3000 
ml (maximum round bottom flask volume) and 50 ml (maximum sysringe 
volume) were considered for Simil microfluidic set-up, ultrasound assisted 
TFI and the EI techniques, respectively with a production time of 2.5 min, 10 












No limits 3000 50 
Yield for a 
batch, 1/(ml h) 
2.27*10
14
 8.98 * 10
9




A massive production of nanoliposomes is possible due to the developed 
apparatus with a precise control on particles size and size distribution by 
varying the liquids volumetric flow rate ratio or lipids concentration. Ferrous 
sulfate loaded nanoliposomes with high encapsulation efficiencies (up to 97 
% e.e.) and good dimensional features (127-135 nm for not sonicated and 
48-76 nm for sonicated liposomes) were successfully produced through the 
use of the simil-microfluidic apparatus developed, obtaining an elevated 
process yield if compared to the classical bench scale techniques. Taking 
into account that “less waste” and “less energy” are the central topics of food 
manufacturers, the apparatus developed could will make iron-nanoliposomal 
based nutraceutical products cheaper due to a more efficient and sustainable 
production process, avoiding the use of toxic solvents and drastic conditions. 
The simil-microfluidic apparatus developed could have a great impacts on 
the nutraceutical-processing industries reducing process time and costs.  
Part of this work has been reported in: 
Bochicchio S.; Lamberti, Barba A.A., “Phenomenological and formulation 
aspects in tailored nanoliposomes production”, chapter in book Liposomes, 
InTech Ed, 2017, in press.  
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5.3 Nanoliposomes vectors for peptide delivery 
5.3.1 Generalities  
The use of peptides in the development of new therapeutic strategies is 
becoming increasingly important due to their multifunctionality. Indeed, 
peptides can be used as vaccines, as cell-penetrating molecules or as new 
therapeutics for a lot of different diseases. In paticular, in 2015 the results 
relative to a Phase IIB Trial of BLP25 Liposome Vaccine have been 
published (Fosgerau and Hoffmann, 2015). As therapeutics agents, peptides 
could be used for the cure of a vast array of diseases but the lack of effective 
vectors limits their use (Tan et al., 2010). The susceptibility to enzymatic 
degradation make peptides high degradable molecules, characterized by in 
vitro and in vivo instability, immunogenicity and short half-life (Patel et al., 
2014b). 
The developement of suitable drug delivery systems is a key to improve 
peptides pharmacokinetic properties and to achieve a controlled and targeted 
release which resuts in a revolutionary new clinical approach for the 
treatment of different diseased states as cancer, multiple sclerosis, diabetes, 
hepatitis, rheumatoid arthritis, leukemia, infectious diseases and Heart 
Failure (HF) (Huang and Wang, 2006, Patel et al., 2014a, Li et al., 2012, 
Park et al., 2011). 
In that regard, G protein-coupled receptor kinase 2 (GRK2) is a kinase which 
role is relevant in the physiology of various organs/tissues including the 
heart and blood vessels (Carotenuto et al., 2013). It was demonstrated that 
GRK2 levels are increased in HF (Carotenuto et al., 2013, Iaccarino et al., 
2005) thus the inhibition of this kinase represents a potential way to treat 
several cardiovascular pathologies (Harding et al., 2001). 
The KRX29 is a novel small cyclic peptide designed on the HJ loop of 
GRK2, where its kinase activity resides. It inhibited potently and selectively 
the GRK2 activity, being more active than its linear precursor. In a cellular 
system, this peptide confirms the beneficial signaling properties of a potent 
GRK2 inhibitor. 
Although its small dimension (8 amino acids) KRX29 low absorption, 
instability in physiological environments and short half-life requires the 
encapsulation in suitable carriers in order to overcome these limits. In this 
thesis, with the aim to increase the potential therapeutic of the KRX29 
peptide, tailored nanoliposomes as suitable delivery vectors for this GRK2 
inhibitor have been designed and produced. 
Three different liposomal formulations, by changing the charge ratio (-/+) 
between the negative charged phosphatidilglicerol and the positive charged 
peptide KRX29, were investigated. In particular, the liposomal vectors were 
designed using a 1:1, 7:1 and 13:1 (-/+) charge ratios and produced by the 
thin film hydration method followed by the sonication sizing process, the 
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new method described in 4.1 section (Barba et al., 2014), in order to achieve 
nanoliposomes with predictable and reproducible size distributions. The 
liposomes charge effect on both peptide encapsulation and recovery 
efficiencies was studied through an analytical HPLC protocol expressly 
developed for this purpose. Moreover, the peptide loading on encapsulation 
and recovery efficiencies in the produced liposomes was also tested together 
with the stability of peptide-liposome complex in Tris-HCl solution 
simulating extracellular conditions. This study thus represents a mile stone 
for future in-vivo investigations to prove the effectiveness (and its 
performance as inhibitor) of the encapsulated peptide. 
5.3.2 Materials 
Peptide KRX29, which main properties can be found in Table 14, was 
manufactured as described in the next paragraph. L-α-Phosphatidylcholine 
(PC) from egg yolk (CAS n. 8002-43-5), Cholesterol (CHO) (CAS n. 57-88-
5), L-αPhosphatidyl - DL glycerol sodium salt (PG) from egg yolk lecithin 
(over 99% pure), Tris(hydroxymethyl)aminometane hydrochloride (CAS 
n.42861) and sodium chloride (CAS n. S9888) were purchased from Sigma 
Aldrich (Milan, Italy) as dried powders and used without further 
purification. All the other chemicals and reagents such as chloroform (CAS 
n. 67-66-3), ethanol (CAS n. 64-17-5), methanol (CAS n. 67-56-1)(Sigma 
Aldrich- Milan, Italy), used were of analytical grade. 
5.3.3 Methodology and sperimental set-up 
5.3.3.1 Peptide KRX29 synthesis 
Peptide KRX29 synthesis was performed according to the solid phase 
approach using standard Fmoc methodology in a manual reaction vessel 
(Atherton, 1989). Nα-Fmoc-Asp(Allyl)-OH and Nα-Fmoc-Lys(Alloc)-OH 
were used as lactam precursors .The first amino acid was linked on to the 
Rink resin (0.75 mmol/g) previously deprotected by a 25% piperidine 
solution in DMF for 30 min. The following protected amino acids were then 
added stepwise. Each coupling reaction was accomplished using a 3- fold 
excess of amino acid with HBTU and HOBt in the presence of DIPEA (6 
equiv). The Nα-Fmoc protecting groups were removed by treating the 
protected peptide resin with a 25% solution of piperidine in DMF and the 
deprotection protocol was repeated after each coupling step. 
After linear assembly, cyclization was performed as described in literature 
(Grieco et al., 2001).
 
The N-terminal Fmoc group was removed and the 
peptide was released from the resin with TFA/iPr3SiH/H2O (90:5:5) for 3 h. 
The crude peptides were purified by preparative RP-HPLC and purity 
monitored by analytical HPLC. Molecular weights were confirmed by ESI-
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MS. 
Table 14. Peptide KRX29 chemico-physical properties 
Peptide name KRX29 
Peptide sequence KLLRrHDI 
Chemical formula C46H82N18O9 
Peptide Molecular Weight, uma 1031.6 
Peptide Molecular Weight   
+trifluoroacetic acid (TFA), uma 
1601.6 
Hydrophobic portion, % 38 
Hydrophilic portion, % 62 
Net charge at pH 7.0 + 3 
Isoelectric point (IET) 11.48 
5.3.3.2 MLVs and SUVs preparation at different charge ratio 
Multi lamellar vesicles (MLVs) were prepared by means of the Thin Film 
Hydration method followed by sonication in order to finally get suitable 
Small Unilamellar Vesicles (SUVs). The negative charged PG was used as 
one of the formulation component in order to electrostatically react with the 
positive charged KRX29 peptide. To this purpose, three different liposomal 
formulations were produced by changing the PG/KRX29 (-/+) charge ratio; 
in particular a 1:1, 7:1 and 13:1 (-/+) charge ratio formulations were 
prepared. Using the same lipid compositions, unloaded MLVs and SUVs 
were also produced in order to get a comparison with the loaded liposomal 
samples. 
In short, for a 1:1 charge ratio formulation, PC (75 mg), CHO (9 mg) and PG 
(6.3 mg) at 11:3:1 (mol:mol) ratio were dissolved in 3 mL of 
chloroform/methanol 2:1 (vol/vol). Part of the solvent was removed by 
evaporation in a rotary evaporator (Heidolph, Laborota 4002 Control, 
Bergamo, Italy) under reduced pressure until a lipid film was produced. 
Then any traces of the solvent were removed by evaporation maintaining the 
sample under reduced pressure for 3 hours, at 50 °C. The dried lipid film 
was then hydrated at room temperature with 3 mL of pre-warmed deionized 
water containing 1 mg/ml of peptide KRX29 for loaded liposomes 
production and with pre-warmed deionized water without peptide for 
unloaded liposomes. Both the loaded and unloaded formulations were stirred 
in a continuous manner for 30 minutes at 60 rpm. MLVs produced starting 
from the 7:1 (-/+) and the 13:1 (-/+) charge ratio formulations were prepared 
as above described for the 1:1 (-/+) PG:KRX29 liposomes but varying the 
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lipids and peptide amounts used, as reported in Table 15. In particular, for 
the 7:1 (-/+) charge ratio formulation PC, CHO and PG were used at 4:1:3 
(mol:mol) ratio while for the 13:1 (-/+) formulation, PC, CHO and PG were 
used at 2.5:1:2 (mol:mol) ratio.  
Table 15. Liposomal formulations for KRX29 encapsulation with different 











1:1 25 3 2.1 1 
7:1 20 2.5 15 0.95 
13:1 16 3 11 0.4 
For all the formulations, the preparations containing MLVs were maintained 
at room temperature for 2 hours. Part of the unloaded and loaded liposome 
samples were used to characterized MLVs in terms of morphology and size; 
loaded MLVs were also characterized in terms of amount of peptide 
recovered, load and encapsulation efficiency. Most of the sample was then 
sonicated at 45% amplitude (treated volume: 1 mL) by applying a duty cycle 
consisting in 2 ten-second irradiation rounds (amplitude 45%), each 
followed by a twenty-second pause in order to prevent thermal vesicle 
disruption thus obtaining Large Unilamellar Vesicles (LUVs). The samples 
were stored overnight at 4 °C and protected from light. The samples were 
then sonicated at 45% amplitude (percentage of maximum deliverable 
power) for three more rounds in order to obtain SUVs (the duty cycle 
sonication protocol is in dept described in 4.1 section). The process 
parameters in MLV and SUV preparation are summarized in Table 16.  
Table 16. Process parameters adopted in Small Unilmellar Vesicles (SUVs) 
preparation, starting from Multilamellar Vesicles (MLVs) 
Process parameters From MLV to SUV 
Sonication duty cycle (s) 2 + 3 irradiation rounds 
Fraction of maximum power (%) 45 
Frequency (KHz) 20 
Treated volume (mL) 1 
5.3.3.3 MLVs and SUVs physicochemical characterization  
Bright field imaging 
Morphological and dimensional characterizations of unloaded and loaded 
MLVs, produced with the different formulations, were performed by optical 
microscopy (Axioplan 2- Image Zeiss, Jena, Germany) for bright field 
imaging. A 63 X objective was used to visualize the vesicles. 
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Particle sizes and zeta potential 
The dimensional analysis of microscope images, performed with the 
software ImageJ, was combined with the Dynamic Light Scattering analysis 
for MLV and SUV. In particular, Dynamic Light Scattering analysis was 
performed by using the ZetasizerNano ZS (Malvern, UK) which 
incorporates noninvasive backscatter (NIBS) optics. A detection angle of 
173 degrees was used to measure the particles size of the concentrated 
samples. For each formulation tested, the resulting particle size distribution 
was plotted as the number of liposomes versus size. Zeta potential was also 
determined in Light Scattering for both unloaded and loaded SUVs. All the 
measurements were performed in triplicate. The results were expressed as 
average values.  
5.3.3.4 Determination of encapsulation efficiency, peptide 
KRX29 recovery and achieved loading 
For each formulation tested, encapsulation efficiency, peptide recovery and 
load in liposomes were evaluated by Reversed Phase High Performance 
Liquid Chromatography (RP-HPLC) analysis. In brief, 150 µl of MLVs 
sample were centrifuged at 10500 rpm for 30 minutes at 4 
°
C and all 
supernatant was removed. The same was for SUVs, in this case 200 µl of 
sample were centrifuged at 30000 rpm overnight at 4 
°
C and all supernatant 
was removed. For both MLVs and SUVs samples, the recovered 
supernatants were diluted 1:3 v/v with 100 % ethanol and then injected into 
RP-HPLC. Subsequently, 300 µl and 400 µl of 100 % ethanol were added 
respectively to the MLVs and SUVs pellets. The samples were vortexed 
until the lipid pellets broke up and then analyzed by RP-HPLC. Peptide 
quantifications were carried out by external standard calibration with a 
satisfactory linearity (R
2
 >0.998). The calibration curve was performed for 
peptide in distilled water, the retention time of peptide in ethanol and buffer 
solution was also analyzed resulting the same. High performance liquid 
chromatography was performed on a Shimadzu HPLC consisting of an 
autosampler, a dual wavelength absorbance UV detector, set to 215 nm. The 
mobile phases employed were: solvent A (water + 0.1% TFA) and solvent B 
(acetonitrile + 0.1% TFA); using a linear gradient from 5% to 90% B over 
14 min, the separation was carried out using an Ascentis Express Peptide 
ES-C18 column 50 mm х 3.0 mm, 2.7µm (Supelco), at a flow rate of 0.800 
mL/min.  
For MLVs and SUVs formulations produced at the different charge ratio, the 
encapsulation efficiency (e.e.) was determined as the percentage of peptide 
encapsulated in liposomes to the initial amount of peptide included in the 
formulation and was calculated using the following equation: 
 e. e. (%) = (
𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,   𝑚𝑔
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑎𝑚𝑜𝑢𝑛𝑡,   𝑚𝑔
) × 100 (5.5) 
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where the amount of peptide encapsulated in liposome was calculated 
subtracting the amount of peptide present in the supernatant of the 
centrifuged sample from the total amount of peptide included in the 
formulation. 
The effective loads of peptide into liposomes, ever for MLVs and SUVs 
formulations produced at the different charge ratio, were calculated as 
follows: 
 load (%) = (
𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,   𝑚𝑔
𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑒𝑠,   𝑚𝑔
) × 100 (5.6) 
In particular, the theoretical load is referred to the initial amount of peptide 
included in the formulation (divided by the total mass); the effective one is 
referred to the assayed peptide amount (divided by the total mass). 
The effective amount of peptide accounted for in MLVs and SUVs 
formulations after extraction was calculated as follows: 
 recovery (%) = (
𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑,   𝑚𝑔
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑎𝑚𝑜𝑢𝑛𝑡,   𝑚𝑔
) × 100 (5.7) 
where peptide recovered is the total amount of peptide KRX29 extracted 
from supernatant and pellet of centrifuged samples. 
5.3.3.5 MLVs at constant charge ratio but with different peptide 
concentration: preparation and characterization 
In addition to the charge ratio, another key parameter affecting the 
encapsulation efficiency is the amount of peptide used in liposomes 
production. During the lipid film hydration the bilayer, getting in contact 
with the hydration solution containing the peptide, closes to form MLVs. 
During this process the amount of peptide that remains entrapped in the 
liposomes may changes on the basis on how concentrated the hydration 
solution is. In order to investigate the influence of the KRX29 concentration 
on the encapsulation efficiency another formulation was produced 
maintaining this time constant the PG/KRX29 charge ratio at 1:1 (-/+) but 
hydrating the lipid film with the double of peptide mass (2 mg/ml) as 
indicated in Table 17.  
Table 17. Composition of two 1:1 charge ratio formulations with different 
amount of peptide KRX29 
PG/KRX29 










1:1 25 3 2.1 1 
1:1 22 3 4.2 2 
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The peptide amount was changed maintaining the same formulation charge 
ratio in order to observe the differences in encapsulation efficiency without 
the influence of electrostatic interactions, being this formulation 
characterized by a (-/+) charge balance. The final total lipids concentration 
was remained about the same (30 mg/ml) for both the formulations and 
MLVs were produced through the thin film hydration method as above 
described for the other formulations. 
The final liposomes sample was characterized in terms of encapsulation 
efficiency, peptide recovery, load and stability evaluated by RP-HPLC 
analysis as before described for the other samples. 
5.3.3.6 Stability test 
Stability test of loaded liposomes was assayed in order to evaluate the ability 
of the nanoliposomes in retaining KRX29 at extracellular environment 
simulated conditions. Tris-buffered saline solution (TBS) was prepared 
dissolving Tris(hydroxymethyl)aminometane hydrochloride 0.01 M and 
sodium chloride 0.15 M in distilled water, obtaining a pH 7.4 TBS final 
solution. This solution was used as medium for the peptide-liposome 
complex stability test. 
Release profile of peptide in Tris-HCl solution medium (pH 7.4) was thus 
studied testing the 1:1 (-/+) charge ratio formulation produced, containing 2 
mg/ml of peptide. This formulation was choice for the stability test due to its 
higher peptide recovery efficiency (the amount of peptide accounted for (%)) 
respect to the 7:1 (-/+) and the 13:1 (-/+) charge ratio formulations. 
In short, 850 µl of loaded liposomes sample were centrifuged at 10500 rpm 
for 30 min at 4 °C, subsequently the supernatant was carefully removed and 
replaced with the double of volume of Tris-HCl medium (1.7 ml). The 
sample was then putted in an incubator set at 37 °C with an orbital shaker 
and maintained in agitation at 60 rpm for 72 h. At predetermined intervals, 
250 µl aliquots of loaded liposomes were taken from the sample and 
centrifuged at 10500 rpm for 30 min at 4 °C (Beckman Coulter Avanti J-25I, 
Ramsey, Minnesota, USA) to precipitate the liposomes. After each 
centrifugation the supernatants were collected for HPLC analysis. The 1:2 
v/v dilution of the sample with Tris-HCl was taken into account during the 
peptide quantification. All the measurements were performed in triplicate. 
The percent of KRX29 released in the supernatant was calculated using the 
following equation: 
KRX29 released (%) = (
 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 ,   𝑚𝑔
𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑎𝑚𝑜𝑢𝑛𝑡,   𝑚𝑔
) × 100(5.8) 
where the peptide amount in supernatant is referred to the amount of KRX29 
recovered at different times (after 45 minutes, 3 h, 24 h, 48 h and 72 h) in the 
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aliquots collected after centrifugation and the encapsulated peptide amount 
in liposome was calculated as described in 5.3.3.4 paragraph. 
5.3.4 Results 
5.3.4.1 MLVs and SUVs at different charge ratio 
5.3.4.1a Physicochemical characterization 
Bright field imaging 
Bright field imaging was used to observe the structure of both unloaded and 
peptide KRX29 loaded MLVs, prepared starting from the different charge 
ratio formulations. As shown in Figure 25 spherical, separated and defined 
liposomes were obtained for the three different formulations tested. 
 
Figure 25. Optical microscope pictures (in bright field, Obj. 63 X) of KRX29 
loaded liposomes at the different tested charge ratios  
Unloaded and loaded MLVs and SUVs at different PG/KRX29 charge ratios 
were then analyzed for dimensional characterization. For all formulations, 
unloaded MLVs with a micrometric range size of 5 - 6.4 µm and KRX29 
loaded MLVs with 7.2 - 11.7 µm range size were produced through the thin 
film hydration method. 
Starting from MLVs, after five total sonication rounds, SUVs with 
nanometric size were achieved for both unloaded and peptide KRX29 loaded 
liposomes. Data taken from a numerical size distribution have showed a 
range size of 19 - 21 nm for unloaded vesicles while for loaded SUVs a 22 - 
35 nm range size was observed. In Table 18 particles size results are 
summarized and presented along with polydispersity index (PDI) values. 
Results are expressed as average of three determinations with standard 
deviation. 
  
   
1:1 (-/+) charge ratio 7:1 (-/+) charge ratio 13:1 (-/+) charge ratio 
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Table 18. Size of unloaded and loaded Multilamellar Vesicles (MLVs) and 
Small Unilamellar Vesicles (SUVs) at the different PG/KRX29 studied 
charge ratios. PDI is the polydispersity index. Results are expressed as 
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Zeta Potential  
For all the different kinds of liposomal produced vectors, the DLS analysis 
showed, as attended, a negative zeta potential of unloaded and peptide 
loaded liposomes. In Table 19 all the results along with standard deviation 
are reported as average values of three determinations. 
Table 19. Zeta potential of unloaded and loaded Multilamellar Vesicles 
(MLVs) and Small Unilamellar Vesicles (SUVs) achieved using different 
PG/KRX29 charge ratios. Results are expressed as average of three 
determinations; SD is the standard deviation 
 1:1 (-/+)  7:1 (-/+)  13:1 (-/+)  
Unloaded 
liposomes 
-15.3 ± 0.6 -20.1 ± 1.62 - 41.9 ± 3.88 
KRX29 loaded 
liposomes 
-16.1 ± 0.37 -18.1 ± 3.51 -37.9 ± 0.4
 
5.3.4.1b Determination of encapsulation efficiency, peptide KRX29 
recovery and achieved loading 
Using the first 1:1 (-/+) charge ratio formulation, an encapsulation efficiency 
(e.e.) of 33.6 ± 0.32 % and of 37.7 ± 0.44 were obtained for MLVs and 
SUVs, respectively. With the same charge ratio formulation, peptide 
recoveries of 94.4 ± 0.78 % for MLVs and 80.6 ± 0.33 % for SUVs were 
also achieved.  
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Starting from the second formulation (7:1 (-/+) charge ratio) a significant 
increase in encapsulation efficiency was observed, obtaining an e.e. of 98.9 
± 1.53 %. and of 97.3 ± 0.34 % for MLVs and SUVs, respectively. On the 
contrary, peptide recoveries were reduced until to 46.6 ± 6.6 % for MLVs 
and 33.8 ± 12.5 % for SUVs.  
A slight increase in the encapsulation efficiency was still visible using the 
last 13:1 (-/+) formulation with an e.e. of 100 ± 0 %. for MLVs and an 98.8 
± 1.4 % for SUVs, with a peptide recovery of 22.07 ± 1.85 % and 21.8 ± 
0.64 % for MLVs and SUVs, respectively. All the results are summarized in 
Table 20. 
Table 20. Encapsulation efficiency and amount of peptide KRX29 accounted 
for in MLVs and SUVs loaded with KRX29 at the studied different charge 





(%) and Standard Deviation 
(SD) 
Amount of peptide KRX29 
accounted for (%) and 
Standard Deviation (SD) 
 MLVs SUVs MLVs SUVs 
1:1 (-/+) 33.6 ± 0.32 37.7 ± 0.44 94.4 ± 0.78 80.6 ± 0.33 
7:1 (-/+) 98.9 ± 1.53 97.3 ± 0.34 46.6 ± 6.6 33.8 ± 12.5 
13:1 (-/+) 100  ± 0 98.8 ± 1.4 22.07 ± 1.85 21.8 ± 0.64 
The results of theoretical and effective loads achieved for peptide KRX29, 
for small and large vesicles, are summarized in Table 21.  
Table 21. Theoretical load and effective load of MLVs and SUVs loaded 
with KRX29 at the studied different PG/KRX29 charge ratios. Results are 
expressed as average of three determinations; SD is the standard deviation 
PG-KRX29 
charge ratio  
Theoretical loading 
achieved(%) 
Effective loading achieved 
(%) and Standard 
Deviation (SD) 
 MLVs SUVs MLVs SUVs 
1:1 3.37 3.37 1.16 ± 0.01 1.3 ± 0.01 
7:1 2.23 2.23 2.21 ± 0.35 2.19 ± 0.38 
13:1 1.3 1.3 1.27 ± 0 1.24 ± 0.004 
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Moreover in Table 22 the peptide mass balances, accurately determined by 
dedicated HPLC protocol, were reported for each formulation. 
Table 22. Mass balance of KRX29 loaded in MLVs and SUVs at the studied 
different charge ratios. Results are expressed as average of three 
determinations; SD is the standard deviation 
KRX29 Mass Balance in 1 ml sample MLV SUV 
1:1 charge ratio formulation 
Total mass of peptide (mg) in supernatant 
 and pellet ± SD 
0.99 ± 0.008 0.84 ± 0.006 
Mass of peptide (mg) in supernatant ± SD 0.7 ± 0.004 0.65 ± 0.004 
Mass of peptide (mg) in pellet ± SD 0.29 ± 0.004 0.19 ± 0.002 
7:1 charge ratio formulation 
Total mass of peptide (mg) in supernatant  
and pellet ± SD 
0.40 ± 0.11 0.27 ± 0.06 
Mass of peptide (mg) in supernatant ± SD 0.008 ±0.01 0.017 ±0.02 
Mass of peptide (mg) in pellet ± SD 0.39 ± 0.12 0.26 ± 0.03 
13:1 charge ratio formulation 
Total mass of peptide (mg) in supernatant  
and pellet ± SD 
0.086 ± 0.002 0.084 ± 0.002 
Mass of peptide (mg) in supernatant ± SD 0.0 ± 0.0 0.01 ± 0.001 
Mass of peptide (mg) in pellet ± SD 0.086 ± 0.002 0.074 ± 0.001 
5.3.4.2 MLVs at constant charge ratio and different peptide 
concentration 
As it is shown in Table 23, using the 1:1 (-/+) charge ratio formulation with 
2 mg/ml of KRX29, MLVs with an encapsulation efficiency of 57 ± 0.04 % 
were achieved respect to the 33.6 ± 0.32 % e. e. obtained by using 1 mg/ml 
of peptide at the same charge ratio. 
Table 23. Encapsulation efficiency and amount of peptide KRX29 accounted 
for in MLVs loaded with different amounts of KRX29 at the same PG/KRX29 
charge ratio (1:1 -/+). Results are expressed as average of three 















(%) and SD 
1:1 1 33.6 ± 0.32 94.4 ± 0.78 
1:1 2 57 ± 0.04 72.9 ± 0.06 
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Moreover, the amount of peptide accounted for was decreased with the last 
formulation (Table 23) while the effective load was increased (Table 24) if 
compared to the first formulation. 
Table 24. Theoretical load and effective load of MLVs loaded with different 
amounts of KRX29 at the same PG/KRX29 charge ratio (1:1 -/+). Results 













achieved (%) and 
SD 
1:1 1 3.37 1.16 ± 0.01 
1:1 2 6.6 3.86 ± 0.002 
The differences in encapsulation and extraction efficiencies can be also 
observed in Table 25 where the mass balances for the first and the last 
formulations were reported. 
Table 25. Mass balance of KRX29 loaded in MLVs at the two studied 
different KRX29 concentrations. Results are expressed as average of three 
determinations; SD is the standard deviation 





1:1 charge ratio formulation 
Total mass of peptide (mg) in 
supernatant and pellet ± SD 
0.99 ± 0.008 1.5 ± 0.001 
Mass of peptide (mg) in supernatant ± 
SD 
0.7 ± 0.004 0.88 ± 0.001 
Mass of peptide (mg) in pellet ± SD 0.29 ± 0.004 0.6 ± 0.0008 
5.3.4.3 Stability test 
Liposomes batches undergone to the stability test were found to be stable for 
72 hours in stirred Tris-HCl solution at 37 °C. As it can be observed from 
Figure 26, after 3 h, a maximum of amount of peptide released was 
achieved.  
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Figure 26. Peptide release profile in Tris-HCl solution at 37°C 
The cumulative profile thus shows that only the 18 % of the encapsulated 
peptide was released. Indeed, after the 3 hours, only small differences in 
peptide amounts between the aliquots analyzed were assayed. These 
differences were reasonably due to the nature of the sample which being a 
suspension is not completely uniform in its liposomes content. 
5.3.5 Discussion 
As therapeutics agents, peptides could be used for the cure of a vast array of 
diseases but the lack of effective vectors limits their use (Tan et al., 2010). 
The awareness of the need of a delivery systems at first, and, then, the 
deeper understanding of the importance in having a tailored carriers, has led 
the scientific community to investigate about peptides encapsulation in 
different delivery systems (Belogurov et al., 2013, Mohan et al., 2015, Silva 
et al., 2013). In particular, in 2015, the results relative to a Phase IIB Trial of 
BLP25 Liposome Vaccine have been published. In their work, Butts and 
collaborators have produced BLP25 liposome vaccine consisting of BLP25 
lipopeptide, immunoadjuvant monophosphoryl lipid A, and three lipids 
(cholesterol, dimyristoyl phosphatidylglycerol, and dipalmitoyl 
phosphatidylcholine) forming a liposomal product. They have evaluated the 
effect of their prepared loaded system on survival and toxicity in patients 
with stage IIIB and IV of non–small-cell lung cancer (NSCLC). They have 
demonstrated the safety of the developed preparation, suggesting a potential 
survival advantage for patients (Butts et al., 2005). Taking into account the 
potential and the possible various applications in medical field of peptides, it 
comes clear the crucial importance in projecting suitable delivery systems 
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considering peptide features and exploring the different possible lipid 
formulations. Consequently, becomes evident the necessity in using a 
versatile and reliable production technique, able to produce tailored carriers 
without affecting the peptide integrity and thus its final biological activity. 
5.3.5.1 Effect of formulation 
The design of liposome formulation has a crucial importance in tailored 
peptide-nanovectors production. Lipid type and concentration, amount of 
peptide to be used and presence of charged molecules are all parameters 
which affect the liposomal final features such as shape, size, zeta potential, 
stability as well as encapsulation efficiency and peptide loading. Moreover, 
for best results in encapsulation efficiency, if both charged lipids and active 
molecules are used, a design of the right (+/-) charge ratio in the final 
formulation should to be done. 
In particular, in a work of Su and collaborators, it was underline the 
importance in take advantage of the charge ratio influence on liposomes-
peptide bonds to produce peptides physically coating liposomes. They have 
showed that the coating was mainly driven by the electrostatic interaction 
between the cationic peptides and the anionic lipids and can be used as a 
versatile method to attach peptides on liposomal bilayer (Su et al., 2014). In 
this thesis it was exploited the effect of different lipid/peptide charge ratios 
to encapsulate a new small cyclic peptide to achieve the best formulation 
with the higher encapsulation efficiency without overlook the effects of this 
formulation parameter on all the other liposomes final features such as the 
size, the zeta potential and the peptide load and recovery efficiency. 
5.3.5.1.a Effect of peptide/lipid charge ratio 
Unloaded and loaded liposomes size  
Numerous scientific studies have shown that the size and zeta potential of 
liposomes determine their in-vivo and ex-vivo performance, thus a good 
design first and a subsequent careful analysis of the data are fundamental 
steps in nanostructured vectors production (Mozafari, 2010, Chang et al., 
2011). 
Three peptide-liposomes formulations characterized by a different (-/+) 
charge ratio (1:1, 7:1, and 13:1 -/+) have been investigated in order to 
compare the obtained range size and zeta potential values. At first, for each 
formulation, unloaded MLVs and SUVs sizes were analyzed in order to 
compare the resulting range values with those obtained from KRX29 loaded 
small and large vesicles. A comparison between loaded and unloaded 
liposomes, maintaining constant the lipids type and their total concentration 
in the final formulation, is important to have an idea of peptide influence on 
the vesicles final size. First of all, it was observed that the use of negative 
charged PG in the formulation gives unloaded MLVs with a larger diameter 
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size. This can be visible by comparing the unloaded MLVs sizes obtained 
from the last two formulations (the 7:1 and the 13:1 -/+, whose diameter 
range size were respectively of 6.43 ± 2.5 µm and 6.28 ± 1.72 µm), with 
those obtained with the first formulation (1:1 -/+ sample with 5 ± 1.9 µm 
range size vesicles) where the amount of PG was drastically reduced. This 
can be explained due to the repulsive force generates between the charged 
lamellae: this condition involves the increase of the aqueous compartments 
and therefore the final vesicles diameter increases too (Sessa and 
Weissmann, 1968). 
It is interesting to note that unloaded MLV diameter size was smaller than 
that found for MLVs loaded with KRX29 peptide and this was true for all 
the tested formulations. For example, in the first formulation, the diameter of 
unloaded MLVs was 5 ± 1.9 µm while for loaded vesicles was 7.2 ± 2 µm 
and it was possible to observe the same trend for all MLVs and SUVs 
samples (results are summarized in Table 18). For example, taking into 
account ever the 1:1 (-/+) formulation, the unloaded SUVs diameter size of 
19 nm increases in the presence of peptide, becoming of 22 nm. The 
increasing in liposomes size can be explained due to the presence of peptide 
whose amphiphilic nature (KRX29 is constituted of 62 % hydrophilic and 38 
% hydrophobic portions, see Table 14) allows it to be in part encapsulated in 
the aqueous core and in part entrapped in the lipid bilayer of liposomal 
structures. This leads to a global increasing in the final liposome volume. It 
is important to underline the relevance in producing loaded vesicles of 
nanoscale dimension, mostly if the formulation had to be used for 
intravenous injection. In numerous scientific works it was demonstrated that 
the liposomes ability to permeate through membrane fenestrations of 
diseased blood vessels can be associated to their nanoscale dimensions 
(Godin et al., 2010, Truran et al., 2014, Tsiklauri et al.). This can be very 
useful in the treatment of linked to heart failure disease states and other 
cardiovascular pathologies being characterized by diseased blood vessels 
(Khurana et al., 2005). 
Zeta potential analysis of loaded liposomes  
Another important feature is the final liposomes surface charge. This value is 
an index of liposomes stability and could influence liposomes transfection 
efficiency inside tissues and cells. It was recently demonstrated that, despite 
their negative charge, anionic formulations have provided challenges of self-
assembly and transfection efficiency in the treatment of neuronal diseases. In 
particular, Tagalakis and collaborators have observed that anionic PEGylated 
siRNA nanocomplexes, unlike the cationic ones, were not only resistant to 
aggregation in the presence of serum but they also give a significant gene 
silencing when administered to rat brains (Tagalakis et al., 2014). 
In this thesis, the zeta potential was analysed before and after peptide 
encapsulation in order to understand the effect of KRX29 on the total surface 
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charge. Zeta potential values of the unloaded formulations were strongly 
negative whereas those with peptide became less negative, denoting the 
influence of peptide content on the final surface charge. This can be 
explained due to the positive peptide amino acid sequences, which decrease 
the electrostatic field of the negatively charged phosphatidylglycerol head 
groups, thus diminishing the zeta potential values. 
The total surface charge changed with about the same trend in the 7:1 (-/+) 
and 13:1(-/+) formulations, where a considerable amount of negative 
charged lipid was used and high encapsulation efficiency was also achieved. 
In particular, in the 7:1 (-/+) formulation the zeta potential decreases from - 
41.9 ± 3.88 mV of unloaded liposomes to -37.9 ± 0.4 mV for loaded 
liposomes and about the same decrease in zeta potential was assayed for the 
13:1 (-/+) formulation, with a -20.1 ± 1.62 mV for the unloaded form and -
18.1 ± 3.51 mV for the loaded one (see Table 19). No decrease in zeta 
potential was visible for the first 1:1 (-/+) formulation being this latter 
“neutral” since it was characterized by a charges balance between the 
negative PG and the positive KRX29. In this case only the phosphate groups 
of phosphatidylcholine give the weak negative charge (about -16 mV) to the 
final liposomes and the peptide, which is encapsulated with a low efficiency, 
has not influence.  
The zeta potential analysis can be useful for the best formulation choice in 
order to achieve stable nanoparticles. Taking into account that liposomes are 
stable when have  > 30 mV, for the 13:1 (-/+) loaded formulation a high 
zeta potential was achieved (-37.9 ± 0.4 mV), index of stable particles 
production. In this case, with the 13:1 (-/+) charge ratio it is possible to 
obtain the higher encapsulation efficiency (98.8 – 100 % e. e., see Table 20) 
with a favorable zeta potential. 
Peptide recovery, encapsulation efficiency and load analysis 
It has been shown that small differences in the spatial arrangement of amino 
acids can cause big changes in the interaction of peptides with lipid 
membranes, mostly affecting peptide orientation (Koller and Lohner, 2014). 
This can lead to a difficult recovery of the peptide from the final liposomal 
complex. Due to the different characteristics of peptides there is no a unique 
protocol for their extraction, on the contrary, this must be accurately studied 
according to the chemical nature of the amino acids which constituted the 
peptide sequence. In the work of Shariat et al., (Shariat et al., 2014) it was 
underline how the knowledge of the optimal methods for both encapsulation 
and peptide content determination in liposomes can accelerate the 
development of liposomal vaccine formulations. Indeed, they have explored 
the use of different encapsulation methods and different extraction methods 
for the delivery of a new designed peptide into liposomes, as an approach for 
breast cancer vaccine formulation. They found the maximal peptide recovery 
(92.6 ± 2.1 %) from liposomes using acidified isopropanol at 1:2 of sample 
to solvent ratio. 
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In this thesis, it was demonstrated that not only the solvent used but also the 
lipids/peptides charge ratio can influence peptide extraction helping to create 
more or less strong ties between the two molecules. By preliminary studies 
of peptide recovery, methanol and ethanol at different v/v ratio have been 
tested as extraction phase (data are not shown); at last ethanol as the 
extraction medium was selected in order to have the highest efficiency in 
peptide recovery from liposomes. In addition to the extraction solvent nature 
it was also demonstrated that the charge ratio strongly affected the peptide 
recovery: higher is the charge ratio between peptide and lipids, lower is the 
peptide extraction efficacy due to the strong electrostatic interaction (Figure 
27). 
 
Figure 27. Effect of PG/KRX29 (-/+) charge ratio on recovery efficiency 
On the contrary, higher is the charge ratio, higher is the encapsulation 
efficiency even if small differences were found in changing form the 7:1 (-
/+) to the 13:1 (-/+) formulation (Figure 28). 
 
Figure 28. Effect of PG/KRX29 (-/+) charge ratio on encapsulation 
efficiency 
In particular, as summarized in Table 20, taking into account the 7:1(-/+) 
formulation, the amount of peptide KRX29 recovered respect to the total 
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amount of used peptide was of 46.6 % for MLVs and of 33.8 % for SUVs 
corresponding to a 98.9 ± 1.53 % e. e. and 97.3 ± 0.34 % e.e. for MLVs and 
SUVs, respectively. When even more negative charges were used (13:1(-/+) 
formulation) the encapsulation efficiency was maxim, with a 100 % for 
MLVs and 98.8 ± 1.4 % e.e. for SUVs, but the amount of peptide KRX29 
recovered (%) was drastically decreased (22.07 ± 1.85 % for MLVs and 21.8  
± 0.64 % for SUVs). When finally a 1:1 charge ratio was used low 
encapsulation efficiency was found, 33.6 ± 0.32 % for MLVs and 37.7 ± 
0.44 % for SUVs (due to the neutralized charge) but almost the total amount 
of peptide used was recovered (94.4 ± 0.78 % from MLVs and 80.6 ± 0.33 
% from SUVs). These results underline the crucial rule of charge ratio in 
peptides carriers design based on liposomal structures. 
Theoretical and effective loads were also calculated for each formulation 
(results are summarized in Table 21) and a peptide mass balance was done 
for each formulation as reported in Table 22. 
The high encapsulation efficiency found in both MLVs and SUVs and the 
effective loads achieved have demonstrated the great efficacy in using a 13:1 
(-/+) charge ratio formulation. The use of an excess of thirteen negative 
charges respect to the positives one allows a very strong interaction between 
the phosphate groups of phosphatidylglycerol and the amine groups of 
peptide. This interaction can explain not only the elevated e.e. values but 
also limits in the peptide-lipids complex dissociation, resulting in a difficult 
peptide recovery. 
5.3.5.1.b Effect of peptide concentration  
As the charge ratio, also the peptide concentration should be carefully sought 
due to its influence on the liposomes encapsulation efficiency. In this thesis, 
starting from a neutral formulation (at 1:1 (-/+) charge ratio, negative PG and 
positive KRX29 charges are neutralized) it was demonstrated that when the 
peptide concentration is doubled the encapsulation efficiency (57 ± 0.04 % 
e.e.) increases of about 20 % respect to the 1 mg/ml peptide formulation 
(33.6 ± 0.32 % e. e.) (see Table 23). The explanation resides in a more 
concentrated solution, which gets in contact with the lipid film: when bilayer 
fragments start to close and form liposomes, a more concentrated solution 
remained entrapped inside the vesicles. This is true until a critical 
peptide/total lipids weigh ratio over that is not possible to further increase 
the encapsulation efficiency by increasing the peptide concentration because 
the quantity of phospholipids would not be enough to its full encapsulation. 
In that regard, Colletier and collaborators, have investigated the influence of 
the eggPC and POPC lipids concentration on the AChE protein 
encapsulation efficiency demonstrating that encapsulation is proportional to 
the number of lipids (Colletier et al., 2002). They have also demonstrated 
that encapsulation depends on electrostatic interactions between the enzyme 
peripheral surface and the polar head group of phospholipids. According to 
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this work and considering the results achieved, it was confirmed the crucial 
role played by the charge ratio in liposomes design that could help to 
increase encapsulation efficiency when the critical peptide/total lipids weigh 
ratio is already reached but is not enough to give the highest encapsulation 
efficiency. 
5.3.5.2 Efficacy of ultrasound assisted technique in KRX29-
liposomes production 
As well as the formulation choice, also the production process is of crucial 
importance. The encapsulation efficiency of peptides into liposomal vesicles 
is generally low and common methods used for encapsulating peptides not 
help to achieve better results (Shariat et al., 2014). In particular, the sizing 
process often limits the successful preparation of SUVs loaded vesicles, 
using both the extrusion method (a certain amount of peptide can be lost on 
filters) and the traditional sonication one (peptides can aggregates each other 
during sonication treatment) (Shariat et al., 2014). Thus, the development of 
the appropriate technique and the study of the main process parameters, to 
optimize both production stages and loading/stability of nanovectors, are of 
crucial importance. 
The ultrasound assisted Lipid Film Hydration technique was used for the 
production of MLVs and SUVs encapsulating KRX29 peptide. Starting from 
MLVs formulation, liposomes dimension has been related to the energy 
supply in order to obtain SUVs with the desired size, useful for peptides 
intravenous administration. As in depth described in 4.1 section for 
modeling studies, during the formation of smaller liposomes the ultrasonic 
energy used breaks the lipid bilayer of large vesicles (MLVs) into smaller 
pieces, then these pieces close themselves in spherical structures producing 
SUVs. As showed in Table 18, after five total irradiation rounds (the first 
two in order to get LUVs, then the other three after one night of vesicles 
stabilization) SUVs with a diameter range of 20-35 nm were produced. 
The developed technique has allowed to obtain high encapsulation efficiency 
values in MLVs and SUVs, demonstrating the efficiency of both lipid 
hydration and size reduction steps. In that regard, vesicles exposed to a total 
of five duty cycle sonication rounds maintain intact their content and no 
significant differences in the encapsulation efficiency were observed 
between MLVs and SUVs for all the investigated formulations (see Table 
20). It is important to underline that no peptide degradation products were 
visible through HPLC analysis after samples sonication steps, supporting the 
efficacy and the safety of the technique developed. 
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5.3.6 Remarks 
In this thesis, with the aim to increase the potential therapeutic of the 
KRX29 peptide, tailored nanoliposomes as suitable delivery vectors were 
designed and produced.  
The used thin lipidic film hydration/sonication technique has proved to be 
reliable and versatile to produce liposomal structure with tailored size, 
starting from several lipidic/peptide formulations. Indeed the adopted 
process parameters (ultrasonic frequency and amplitude, sonication time and 
rounds) and the use of different L-α Phosphatidyl - DL glycerol sodium salt 
concentrations have allowed to obtain stable nanostructured vectors having 
the desired features in terms of size and charge. 
The effect of liposomes charge on both peptide encapsulation and recovery 
efficiencies was then studied, through a dedicated analytical HPLC protocol, 
showing, as expected, an antithetical behavior. The higher encapsulation 
efficiency (about 100%) was achieved (both in SUVs and MLVs), using the 
higher charge ratio formulation (13:1 (-/+)). Viceversa the ability to recover 
the entrapped peptide was obtained for loaded systems (both SUVs and 
MLVs) at the lower charge ratio formulation (1:1 (-/+)). 
As the charge ratio, also the peptide concentration shows influence on the 
liposomes encapsulation efficiency. Finally, it has been demonstrated that 
when the peptide concentration is doubled the encapsulation efficiency 
increases of about 20% with respect to the used starting concentration of 1 
mg peptide/ml (57% vs 34%). 
 
Part of this work has been reported in: 
Bochicchio S.; Sala M.; Spensiero A.; Scala M.C.;. Gomez-Monterrey I.M.; 
Lamberti G.; Barba A.A.; “On the design of tailored liposomes for peptide 
delivery”, submitted 
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5.4 Nanoliposomes vectors for dsDNA delivery 
5.4.1 Generalities 
Nucleic Acid Based Drugs (NABDs) constitute a class of promising and 
powerful therapeutic new agents with limited side effects, potentially 
useable against a wide range of diseases, including cancer. Among them, the 
short interfering RNAs (siRNAs), represent very effective molecules. 
Despite their in vitro efficacy, the major drawback that limits siRNAs usage 
consists in a difficult delivery due to their very low stability in physiological 
fluids, and to their limited membrane-permeability through physiological 
barriers (see 2.2.1). On the other hand, liposomes represent interesting drug 
delivery systems (DDSs) which can be tailored in order to get the best 
performance in terms of load, vesicle size and transfection yield (Bochicchio 
et al., 2014). 
In particular, cationic liposomes represent an advanced technology to deliver 
NABDs in gene therapy (Bochicchio et al., 2016b, Chien et al., 2005, Piazza 
et al., 2016). Characterized by cationic phospholipids, they are able to carry 
molecules with negatively charges with the conseguent improvement of both 
encapsulation efficiency and cellular uptake. In this thesis, in order to 
produce carriers for NABDs delivery, the experimental activity started 
exploring cationic liposome formulations able to encapsulate 21 bases-
double stranded DNA (dsDNA), simulating siRNA molecule structure. After 
this preliminary tests siRNA sequences were effectively encapsulated in the 
produced vectors (next 5.5 section). 
The dsDNA simulating siRNA was used for an economic reason (due to the 
high cost of siRNA structures) since for this experimental section it was 
necessary to simulate only the structure and not the biological activity of 
siRNA molecule. In particular, three different kind of lipid bilayers were 
projected including N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTAP) in the formulations, a positively 
charged lipid used to improve nucleic acids encapsulation, enhancing the 
interaction with the negatively charged dsDNA. In order to achieve the 
higher dsDNA encapsulation efficiency in the smaller carrier possible, the 
charge ratio (3:1, 5:1 and 7:1 (+/-)) between the positive DOTAP and the 
negative charged dsDNA was varyied. The dsDNA-SUVs complexes were 
characterized in terms of morphology, size, surface charge (zeta potential), 
encapsulation efficiency and stability (release properties) in PBS solution 
(pH 7.4) at 37°C, simulating physiological condition. 
5.4.2 Materials 
L-α-Phosphatidylcholine (PC) from egg yolk (CAS n. 8002-43-5), 
Cholesterol (CHO) (CAS n. 57-88-5), N-[1-(2,3-Dioleoyloxy)propyl]-
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N,N,N-trimethylammonium chloride (DOTAP) (CAS n. 132172-61-3), 
Rhodamine B (CAS n. 81-88-9), potassium phosphate monobasic (CAS n. 
7778-77-0), sodium hydroxide (CAS n. 1310-73-2), 
Tris(hydroxymethyl)aminometane hydrochloride (Tris), Boric acid (CAS 
10043-35-3), Ethylenediaminetetraacetic acid (EDTA) (CAS 6381-92-6), 
Tetramethylethylenediamine (TEMED) (CAS 110-18-9) Ethidium Bromide 
(EtBr) (CAS n. 1239-45-8) and 100 bp DNA ladder (Product n. D5042) were 
purchased from Sigma Aldrich (Milan, Italy) as dried powders and used 
without further purification. Acrylamide/bis-acrylamide, 40% solution and 
Ammonium persulfate (APS) (Cat. 161-0700) were purchased from Biorad 
Laboratories. All the other chemicals and reagents such as chloroform (CAS 
n. 67-66-3), ethanol (CAS n. 64-17-5), methanol (CAS n. 67-56-1)(Sigma 
Aldrich- Milan, Italy) used were of analytical grade. 21 bases sense 
oligonucleotide (5’-CGT-ACG-CGG-AAT-ACT-TCG-ATT-3’) and 
antisense (5’-TCG-AAG-TAT-TCC-GCG-TAC-GTT-3’) were purchased 
from Eurogentec. 
5.4.3 Methodology and sperimental set-up 
5.4.3.1 Phosphate buffer solution preparation 
A phosphate buffer solution (PBS) was prepared by dissolving potassium 
phosphate monobasic 0.2 M and sodium hydroxide 0.2 M in distilled water 
thus obtaining a pH 7.4 PBS final solution. This buffer solution was used for 
carrying out liposome production and dsDNA load and stability tests. 
5.4.3.2 Tris-buffered saline solution (TBS) preparation 
Tris-buffered saline solution (TBS) was prepared dissolving 
Tris(hydroxymethyl)aminometane hydrochloride 50 mM and sodium 
chloride 100 mM in distilled water, obtaining a pH 7.5 TBS final solution 
used for the annealing of sense and antisense DNA sequences. 
5.4.3.3 Duplex-DNA generation 
A 21 base pair double-stranded DNA was prepared annealing 5’-CGT-ACG-
CGG-AAT-ACT-TCG-ATT-3’ sense strand with 5’-TCG-AAG-TAT-TCC-
GCG-TAC-GTT-3’ antisense strand. 
Sense and antisense oligonucleotides, in lyophilized powder form, were 
resuspended in MilliQ water to a final concentration of 1000 µM for both 
oligonucleotides, and stored at -20 °C. 300 µl of each oligonucleotide was 
annealed in 150 µl of TBS buffer (pH 7.5) by heating at 95 °C; after 2 
minutes, the heating block was switched off and allowed to slowly cool 
down to obtain dsDNA. 
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To evaluate DNA purity, absorbance measures at 280 nm and 260 nm were 
performed to detect the possible presence of proteic contaminants. The 
A260/A280 absorbance ratio was calculated. Good-quality DNA must have a 
A260/A280 ratio of 1.7–2.0.  
5.4.3.4 dsDNA PolyAcrylamide Gel Electrophoresis (PAGE) 
analysis 
After the duplex generation and prior to its encapsulation in liposomal 
structures, dsDNA integrity was demonstrated through native 
Polyacrylamide gel Electrophoresis. 
The acrylamide/TBE gel was prepared by mixing 2 ml of Tris/Borate/EDTA 
buffer (TBE) 5 M, 3 ml of acrylamide stock solution at 40 %, 5 ml of 
distilled water, 70 µl of APS (150 mg/ml stock solution) and 10 µl of 
TEMED. 
dsDNA (2 μg) and 100 bp DNA ladder were loaded into individual wells and 
subjected to electrophoresis on 12 % acrylamide gel (30 minutes at 80 V) in 
Tris/Borate/EDTA buffer (TBE) 1 M containing 90 mM Tris (pH 7.6), 90 
mM boric acid and 2 mM EDTA. After staining with ethidium bromide (0.5 
μg/ml), gels were viewed with UltraBright LED Transilluminator 
(Maestrogen, USA) at 470 nm. 
5.4.3.5 Preparation of cationic SUVs containing dsDNA  
dsDNA-SUVs first formulation 
Small Unilamellar liposome Vesicles were prepared by means of the Thin 
Film Hydration method followed by sonication. Briefly, PC (40 mg), CHO 
(2 mg) and DOTAP (20 mg) at 10:1:5 (mol:mol) ratio were dissolved in 1 
mL of chloroform/methanol 2:1 (vol/vol). The solvent was removed by 
evaporation in a rotary evaporator (Heidolph, Laborota 4002 Control) and 
the lipid film produced was vacuum-dried for 3 hours at 50°C in a water 
bath.  
The dried lipid film was then hydrated at room temperature with 2 mL of 
PBS (pH 7.5), pre-warmed, containing dsDNA (2.8 mg) under adequate 
stirring. The ratio of dsDNA to the total amount of lipids was 1:20 (w/w) 
with a DOTAP/DNA charge ratio of 3:1 (+/-). 
The sample was then sonicated at 45% amplitude (treated volume: 1 mL) by 
applying the duty cycle protocol previously described (4.1 section). The 
sample was stored overnight at 4°C and protected from light and was then 
sonicated at 45% amplitude (percentage of maximum deliverable power) for 
four more rounds in order to obtain SUVs.  
DOTAP, positively charged, was included in the formulation to improve 
encapsulation enhancing the interaction with negatively charged dsDNA. 
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dsDNA-SUVs second formulation 
Small unilamellar vesicles were prepared by the same Thin Film Hydration 
method followed by sonication described above but changing the 
formulation, in order to achieve an improved encapsulation efficiency. In 
this case PC (45 mg), CHO (2 mg) and DOTAP (15 mg) at 11:1:4 (mol:mol) 
ratio were used. The weight ratio of dsDNA (1.3 mg) to the total amount of 
lipids was 1:50 (w/w) and the charge ratio of DOTAP to dsDNA was 5:1 
(+/-). All the process parameters and steps used were the same describe 
above for the first formulation. 
dsDNA-SUVs third formulation 
Small unilamellar liposome vesicles were prepared again by using PC (40 
mg), CHO (2 mg) and DOTAP (20 mg) at 10:1:5 (mol:mol) ratio. The 
weight ratio of dsDNA (1.35 mg) to the total amount of lipids was 1:50 
(w/w) and the charge ratio of DOTAP to dsDNA was 7:1 (+/-). All the 
process parameter and steps used were the same describe above for the first 
and second formulations. 
5.4.3.6 Physicochemical characterization of vesicles 
Bright field imaging and fluorescence imaging  
The morphological and dimensional characterizations of MLVs were 
performed with optical microscopy (Axioplan 2- Image Zeiss) for bright 
field and fluorescence imaging. A 100 X oil immersion objective was used 
to visualize the vesicles taking advantage of the fluorochromes Rhodamine 
B, to label and visualize the vesicles, and 4',6-diamidino-2-phenylindole 
(DAPI) for label and visualize DNA sequences. 
Particle sizes  
A dimensional analysis of microscope images, performed with the software 
ImageJ was combined with a Dynamic Light Scattering analysis for MLV 
and SUV dimensional characterization. In particular, Dynamic Light 
Scattering analysis were performed by using the ZetasizerNano ZS 
(Malvern, UK) which incorporates noninvasive backscatter (NIBS) optics. 
The detection angle of 173 degrees was used. The resulting particle size 
distribution was plotted as the number of liposomes versus size. All the 
measurements were performed in triplicate. The results were expressed as 
average values. 
Zeta Potential 
In order to evaluate liposome carriers stability, their zeta potential was 
misured through Dynamic Light Scattering analysis, performed by using the 
ZetasizerNano ZS (Malvern, UK). As discussed for all the previously 
applications, the zeta potential is an important stability index of liposomes 
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which should be taken into account during liposomes bilayer formulation. 
Liposomes are stable when have  > 30 mV. 
5.4.3.7 Evaluation of dsDNA load and stability test 
Determination of SUVs encapsulated dsDNA 
For each sample, dsDNA load in SUVs was determined by UV 
spectrophotometric assay (λ=260 nm). Liposomes were centrifuged at 25000 
rpm for 2 h at 4 °C (Beckman Coulter Avanti J-25I, Ramsey, Minnesota, 
USA). The pellet containing vesicles was lysed with ethanol, and dsDNA 
was precipitated and resuspended in PBS for spectrophotometric assay 
(λ=260 nm, PBS as blank) in order to determine the initial amount of 
dsDNA prior to release. 
For all formulations, encapsulation efficiency (e.e.) was determined as the 
percentage of detected encapsulated dsDNA in liposomes to the initial 
amount of dsDNA included in the formulation; it was calculated using the 
following equation: 
 e. e. (%) = (
𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑠𝐷𝑁𝐴,   𝑚𝑔
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑠𝐷𝑁𝐴 𝑎𝑚𝑜𝑢𝑛𝑡,𝑚𝑔
) × 100 (5.9) 
dsDNA loads were determined through the ratio: 
 load (%) = (
𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑠𝐷𝑁𝐴,   𝑚𝑔
𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑒𝑠,   𝑚𝑔
) × 100 (5.10) 
In particular, the theoretical load is referred to the initial amount of dsDNA 
included in the formulation (divided by the total mass); the effective one is 
referred to the assayed dsDNA amount (divided by the total mass). 
Stability test and evaluation dsDNA release  
dsDNA release studies were performed in PBS solution (pH 7.5) at 37°C. 
Release profile has been evaluated during 10 days. Briefly, 125 μl aliquots of 
the sample were removed at given times and centrifuged to precipitate the 
liposomes. Liposomes (pellets) were lysated with ethanol and centrifuged 
again, after dsDNA precipitation ethanol was evaporated and the dsDNA 
was resuspended in PBS. dsDNA in supernatant and pellet was determined 
via UV spectrophotometric analysis (λ=260 nm, PBS as blank). 
5.4.4 Results 
5.4.4.1 dsDNA purity and integrity 
The A260/A280 ratio found for dsDNA was higher than 1.8, index of no 
proteins contamination of the sample. Moreover, the PAGE analysis showed 
an intact dsDNA as visible in Figure 29, where the DNA band is perfectly 
visible without any traces of smear or other degradation signs. 
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Figure 29. Native PAGE of dsDNA. In the first lane a 100 bp ladder 
molecular weight, in the second lane 2 µg of 21 bp dsDNA molecule 
(simulating "Homo sapiens siRNA probe Luciferase", 12833.4 g/mol). The 
relative band is well visible 
5.4.4.2 Cationic liposomes: loading and characteristics of the 
tree formulations 
Physicochemical characterization of vesicles 
Bright field and fluorescence imaging were used in the present study to 
clarify the structure of cationic liposome formulations and the related 
dsDNA-liposomes complexes. As showed in Figure 30, spherical, separated 
and defined liposomes were achieved from each formulation. 
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Figure 30 Optical microscope pictures (in bright field, Obj. 63 X and 100 X) 
of dsDNA loaded Multilamellar Vesicles (MLVs), achieved respectively from 
the first, second and third formulation 
The fluorescence visualization by using the DAPI-Rhodamine B double 
labeling technique, for the simulataneuos visualization of dsDNA and 
nanoliposomes, has shown the successful formation of nanometric 
complexes (Figure 31) even if aggregates and/or large vesicles produced 
together with SUVs are visible in the captured images. 
 
Figure 31. Fluorescence microscope picture of dsDNA liposome vesicles 
(Obj 100X). DAPI-labeled dsDNA at left; Rhodamine B-labeled liposomes at 
right 
Particles size 
For each formulation prepared, the dimensional analysis of microscope 
images prior to vesicle sonication has shown micrometric MLVs. In 
particular the diameter size was 2.9 ± 0.3 m, 2.2 ± 3.2 µm and 2.3 ± 3.5 
respectively for the fist, the second and the third formulation. A Dynamic 
Light Scattering analysis, carried out after six total sonication rounds, 
showed nanometric SUVs with diameter size of 0.056 ± 0.004 µm, 0.028 ± 
0.005 µm and 0.029 ± 0.01 µm respectively for the 3:1, 5:1 and 7:1 (+/-) 
charge ratio formulation. 
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The obtained results for both MLVs and SUVs are summarized in Table 26. 
Table 26. Loaded Multilamellar Vesicles (MLVs) and Small Unilamellar 
Vesicles (SUVs) dimensional characterization at different DOTAP/dsDNA 
charge ratio; Results are expressed as average of three determinations; SD 












3:1 5:1 7:1 
MLVs size [µm]  
± SD 
2.9 ± 0.3 2.2 ± 3.2 2.3 ± 3.5 
SUVs size [µm] 
 ± SD 
0.056 ± 0.004 0.028 ± 0.005 0.029 ± 0.01 
SUVs PDI  
± SD 
0.30 ± 0.81 0.40 ± 0.02 0.30 ± 0.04 
Zeta Potential 
Dynamic Light Scattering analysis, performed by using the ZetasizerNano 
ZS (Malvern, UK), has shown a zeta potential of 52.8 ± 1.58 mV for the 3:1 
charge ratio formulation, and a zeta potential of 68 ± 4.01 mV and 48 ± 1.7 
mV respectively for the 5:1 and the 7:1 charge ratio formulations, 
demonstrating high particles stability in all the three cases. Results are 
summarized in Table 27. 
Table 27. Zeta potential and encapsulation efficiency of dsDNA-liposomes 
complexes formulated starting from different DOTAP/dsDNA charge ratio; 













3:1 5:1 7:1 
Zeta Potential 
[mV] ± SD 




54.0 ± 1.2 
SUVs 
61.5 ± 6.7 
SUVs 
64 ± 1.4 
MLVs 
100 ± 0 
Determination of SUVs encapsulated ds-DNA 
For all formulations high effective loads were obtained. The results of SUVs 
loads determination are reported in Table 28. 
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Table 28 Theoretical and effective loads (%) in Small Unilamellar Vesicles 
(SUVs) at different DOTAP/dsDNA charge ratio; for the third formulation 
also Multilamellar Vesicles (MLVs) loads are reported. Results are 













SUVs 1st 3:1 4.27  2.30 ± 0.04 % 
SUVs 2nd 5:1 2.0  1.23 ± 0.01 % 
SUVs 3rd 7:1 2.13 1.36 ± 0.03 % 
MLVs 3rd 7:1 2.13 2.13 ± 0.00 % 
The encapsulation efficiency achieved for SUVs was 54.0 ± 1.2 % for the 
first formulation, 61.5 ± 6.7 % for the second formulation and 64 ± 1.4 % for 
the last formulation. The MLVs produced using the third formulation 
showed an encapsulation efficiency of 100 %. The results of SUVs 
encapsulation efficiency (and MLVs for the last formulation) are 
summarized in Table 27. 
Stability test and evaluation ds-DNA release  
Liposomes loaded with dsDNA underwent a stability test to evaluate their 
loading efficiency and the timing of drug release, in conditions similar to the 
intracellular environment. As shown in Figure 32, liposomes were found to 
be stable at 37°C in PBS (pH 7.4) media release for a ten days period. 
 
Figure 32. dsDNA retention in Small Unilamellar Vesicles (SUVs) and 
release in PBS: circles symbols are referred to dsDNA retained in the pellet; 
squares symbols are referred to dsDNA lost in phosphate buffer solution 
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5.4.5 Discussion 
5.4.5.1 Ultrasound assited technique in dsDNA-liposomes 
production 
The ultrasound assited technique used was indicated to encapsulate dsDNA, 
a molecule characterized by high degradability. In particular, according to 
the modelling study (see 4.1 section), through the dedicated duty cycles 
protocol, nano-liposomal vesicles were achieved in the expected diameter 
range and with a polydispersity index less than 0.4 (see Table 26). Staring 
from MLVs with 2.9 - 2.2 µm range size, after six total sonication rounds, 
SUVs with 56 - 28 nm range size were achieved. The advantages in using 
the ultrasound assisted technique were well described in the previous 
sections of chapter 5 for stable, highly loaded vitamins, ferrous sulfate and 
peptide liposomes preparation. 
Moreover, ever referring to the technique used, the effect of duty cycle 
sonication on the encapsulation efficiency and DNA loads is visible in the 
last formulation, comparing the results obtained for MLVs with those 
obtained for SUVs. 
For the 7:1 (+/-) formulation the theoretical load, expressed in percent value, 
was of 2.13 % for both micro and nanoliposomes (SUVs sample is produced 
from MLVs sample) and the effective loads achieved were 2.13 % and 1.36 
% respectively for MLVs and SUVs. 
Encapsulation efficiency was 100 % for MLVs and 64 % for SUVs. The 
different levels of DNA incorporation efficiency between MLVs and SUVs 
can be explained as an effect of the sonication process on the vesicles. The 
ultrasound assisted technique, inducing a cyclic opening and closing of 
liposomal bilayer, involves DNA losses in the sonication bulk. 
Results are in accordance with what already observed for MLVs loaded with 
vitamins and subjected to sonication, in particular the effect of sonication on 
DNA loss is similar to what seen for vitamin B12 (being highly soluble 
molecule and encapsulated in the aqueous core of liposomes such DNA). 
5.4.5.2 Including DOTAP in liposomes formulation 
Projecting the liposomes bilayer, taking into account the molecule nature to 
be encapsulated, has a great relevance in the final features of drug-carrier 
complexes. In particular, drug encapsulation efficiency (thus its effective 
load) and the zeta potential values of the carrier systems change in a manner 
that depends on the initial formulation ingredients. In particular, the 
advantages in inserting cationic lipids into liposomes bilayer, to be used as 
delivery systems for NABDs, allows both an optimization of the cellular 
uptake and a nucleic acids encapsulation efficiency. The cellular uptake of 
liposomal carriers is facilitated for cationic liposomes due to the interaction 
between their positive charge with the negative once of the cell membrane. 
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This successful interaction in the presence of DOTAP was demonstrated for 
in vivo and/or ex vivo experiments including many type of cell, such as 
monocytic leukemia cells and different cancer cell line (Pires et al., 1999, 
Campbell et al., 2001, Porteous et al., 1997, Lu et al., 2012). Moreover, 
being DNA and RNA negative charged molecules which can be neutralized 
by cationic lipids, positively charged liposomes are particularly valid nucleic 
acids carriers, ensuring their controlled drug-delivery and improving their 
internalization and expression (Ying, 2010, Li et al., 2011).  
In many works, it was demonstrated that DOTAP safety is tightly linked to 
its amount used in the formulation (Lu et al., 2012, Brgles et al., 2012). In a 
Phase I Clinical Trial of systemically administered TUSC2(FUS1) 
nanoparticles in humans, the toxicity of DOTAP was studied. Patients with 
recurrent and/or metastatic lung cancer, previously treated with platinum 
based chemotherapy, were treated with escalating doses of intravenous 
DOTAP:cholesterol nanoparticles encapsulating a TUSC2 expression 
plasmid (DOTAP:cholTUSC2) every 3 weeks. The MTD was determined to 
be 0.06 mg/kg. In particular, nanoparticles stock solution was prepared 
starting with a concentration of 20 mM DOTAP, the diluted plasmid DNA 
and the diluted nanoparticle stock were mixed in equal volumes to a final 
concentration of 4 mM DOTAP and 0.5 mg/ml of DNA. Prior to the 
treatment the assigned dose was diluted in 100 ml of 5% (w/v) dextrose 
water. 
Lu and collaborators have concluded that DOTAP:cholTUSC2 can be safely 
administered intravenously in lung cancer patients resulting in a successful 
gene uptake by human primary and metastatic tumors (Lu et al., 2012). 
In this thesis the DOTAP concentration was maintained in a safety range 
(the maximum DOTAP concentration used in the stock solution was 14 mM, 
which can be diluited to a final concentration of 4 mM containing 0.225 
mg/ml of DNA for in vivo experiment). Moreover, considering that the 
knowledge of the right DOTAP/DNA ratio is of crucial importance to 
achieve a safety and smart final lipoplex, the effect in changing the amount 
of DOTAP on liposomes final features was studied. 
5.4.5.3 Effect in changing DOTAP/DNA charge ratio on 
liposomes final features 
Effect on liposomes shape, size and zeta potential 
Liposomes shape, diameter and size dispersity are important parameters in 
drug delivery applications. 
First of all, it was demonstrated that changing the amount of DOTAP respect 
to the total mass of DNA not affects the dsDNA-nanoliposomes shape which 
ever mantain its spherical and defined conformation. Is interesting to note 
that increasing the (+/-) charge ratio, liposomes size decreases and it is 
visible in both MLVs and SUVs preparations, especially switching from the 
first to the second formulation. Increasing the charge ratio from 3:1 to 5:1 
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(+/-), MLVs diameter size changes from 2.9 µm to 2.2 µm while remains 
mostly constant (2.3 µm) in the last (7:1 charge ratio) formulation (see Table 
26). The same effect was observed for SUVs samples presenting a diameter 
size of 56 nm when 3:1 (+/-) charge ratio formulation is used and a reduced 
diameter size of 28 nm for 5:1 (+/-) charge ratio formulation. Also in this 
case the size (29 nm) doesn’t change in a relevant manner when 7:1 (+/-) 
charge ratio is used. 
Results are in accordance with a work of Marija Brgles and collaborators 
(Brgles et al., 2012) who have analized the trend in liposome size respect to 
DOTAP/DNA (+/-) charge ratio demonstrating that an increase in the charge 
ratio results in a decrease in liposome/DNA complex size. Moreover, they 
have demonstrated how liposomes size and charge of liposome/DNA 
complexes are considered key features for the transfection efficiency of 
formulation. 
In a work of Campbell and collaborators, QLS (Quasi-elastic Light 
Scattering) was used to determine the effect of DOTAP on the size 
distribution of liposomes as a function of phospholipid acyl chain length, 
degree of unsaturation, and concentration of DOTAP. They observed that 
DOTAP reduces the mean diameter of PC-containing multilamellar 
liposomes, in particular regardless of the phospholipid chain length and 
degree of unsaturation (Campbell et al., 2001). 
Again, Xiu and collaborators have demonstrated that at cationic lipid/DNA 
charge ratios between 1:1 and 2:1, the complexes have the largest diameter. 
Higher or lower charge ratios result in lipoplexes with smaller diameters (Xu 
et al., 1999). 
The chemico-physical interactions and the DOTAP-induced alterations 
occurring during the changes in liposomes bilayer fluidity and size are the 
subjects of many studies. The reduction in size can be explained by the 
DOTAP ability in facilitating head group electrostatic interactions which 
decrease the bilayer radius of curvature as a result of phospholipid-cationic 
head group contact (Campbell et al., 2001). In particular, in their work, 
Zuidam and collaborators have suggested that the quaternary amine of 
DOTAP and the phosphate group of the phospholipid DOPC may form a salt 
bridge decreasing the bilayer radius of curvature (Zuidam and Barenholz, 
1997). 
Regarding the external surface charge of nanoparticles, the zeta potential () 
is an important stability index of liposomes which should take into account 
during their bilayer formulation. As discussed for all the other applications, 
liposomes are stable when have  > 30 mV. 
Here, for all the three formulations tested, an high zeta potential was 
achieved, index of stable particles production. In particular, for the last 
formulation, due to the increased dsDNA loads (and their negative charges), 
the zeta potential was slightly reduced with respect to the other formulations, 
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ever mantaining a large excess of positive charge in the final vesicles (see 
Table 27).  
This reduction in external positive charge together with an increasing in 
DNA encapsulation efficiency is an interesting result if we consider that 
NABDs have to reach the cell nucleus dissociating from liposomes and 
overcoming the endosomes barriers. Indeed, for a successful transfection, a 
reduction in surface charge may be beneficial to allow appropriate DNA 
dissociation from the lipoplex after cellular uptake and for the endosomal 
escape thus allowing the NABDs to exert their biological function. 
Effect on liposomes encapsulation efficiency and loads 
It is important to note as increasing the DOTAP/dsDNA (+/-) charge ratio, 
the encapsulation efficiency also increases due to the presence of a greater 
amount of positive charges attracting the DNA negative once more strongly. 
Being the lipid film formulated with an increasing amount of DOTAP lipids, 
infact, more amine positive groups will interact with the negative phosphate 
groups by which the double stranded DNA (or siRNA) is composed. In the 
last formulation, increasing the DOTAP/DNA charge ratio (the 7:1 (+/-) 
sample), an encapsulation efficiency of 100% in MLVs and of 64% in SUVs 
has been obtained; this values of e.e. was higher than those obtained from 
the previous investigated formulations (Table 27). 
Considering the effective loads achieved (Table 28) and comparing this 
results with the theoretical loads obtained for each sample, it can be 
observed that the last formulation presents also the highest load. For the 7:1 
(+/-) charge ratio, the loads were 1.36 % for SUVs and 2.13 % for MLVs, 
considering a theoretical load of 2.13 %. 
Furthermore, for all the three formulations, SUVs were found to be stable at 
37 °C in PBS media release for a ten days period; load and structure are 
remained unaltered after this period. 
5.4.6 Remarks 
The performed activities have confirmed the versatility of the ultrasound 
assisted technique developed for producing lipid vectors encapsulating 
NABDs. The charge ratio (+/-) variation from 3:1 to 7:1 (+/-) by changing 
the amount of positive lipid (DOTAP) used during liposome preparation 
have allowed to an improved e.e. by passing from the first to the second up 
to the third formulation. Moreover, the stability test has shown that the 
produced vesicles can keep intact DNA molecules for more than 10 days if 
incubated in intracellular environment similar conditions (PBS solution at 37 
°C). The study demonstrated the successful preparation of a stable, highly 
loaded SUVs formulations containing dsDNA simulating siRNA, to yield 
the basis for an improved nucleic acid based drugs shelf life for gene 
therapies. Studies of dsDNA entrapment within liposomes have indeed given 
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the bases for siRNA encapsulation and transfection in cell/tissues, 
subsequently carried out and described in the next section. 
 
Part of this work has been reported in: 
Bochicchio S.; Dalmoro A.; Barba A.A.; D’Amore M.; Lamberti G.; “New 
preparative approaches of micro and nano drug delivery carriers”; Current 
Drug Delivery, 2017, 14 (2), 203-215. 
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5.5 Nanoliposomes vectors for siRNAs delivery 
Part of this research activity has been performed at Cattinara hospital, in 
Trieste, for the in vitro experimantation on cell lines and at San Giovanni di 
Dio e Ruggi D’Aragona hospital, in Salerno, for the ex-vivo testing on colon 
mucosa tissues. 
5.5.1 Generalities 
The recent discovery of RNA interference (RNAi) mechanism, and its 
effector molecule, the short interfering RNA (siRNA), has led to an 
increased interest in the development of innovative therapies, able to target 
disease components, at genetic level, that are considered ‘undruggable’ with 
the conventional medicines. 
RNA interference (RNAi) is a natural mechanism to silence gene expression 
post-transcriptionally (Figure 33). It is based on a sequence-specific RNA 
degradation, as described for the first time by Fire and co-workers in 1998 
(Fire et al., 1998), who found out that in the nematode Caenorhabditis 
elegans there were dsRNA molecules able to silence gene expression 
(Andrew Z. Fire and Craig C. Mello won the 2006 Nobel Prize in 
Physiology or Medicine, for their discovery of RNA interference, -RNAi- 
gene silencing by dsRNA).  
 
Figure 33. RNA interference mechanism. Double-stranded RNAs (dsRNAs) 
are processed by a complex consisting of Dicer and other protein activators 
and kinase into small interfering RNAs (siRNAs), which are loaded into 
Argonaute 2 (AGO2) and RNA-induced Silencing Complex (RISC). siRNAs 
are denatured and become single-strand molecules. The RISC is then active 
and, using the incorporated single-strand siRNA as template, recognizes the 
target mRNA to degrade (mRNA cleavage). RISC analyzes mRNAs and 
identifies as targets only the one with sequences perfect complementary to 
the 21-22 nucleotides of the siRNA, thus silencing their expression 
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However, while searches over new siRNA sequences, more and more 
specific for the target mRNAs, go on, the scientific community is busily 
focused on the development of suitable drug delivery systems (DDSs) able 
to vehicle this powerful molecules, otherwise not useable in their naked 
form. Due to their low stability in physiological fluids, low membrane-
permeability and their short half-life in the circulatory system, Nucleic Acid 
Based Drugs (NABDs) require to be encapsulated in suitable carriers (see 
2.2.1 paragraph). In general, the versatility and the easiness of carriers 
modification in terms of size, charge, lipid composition and linkage with 
cell-targeting molecules, are all factors affecting the successful siRNA 
delivery into the target cells/tissue (Bochicchio et al., 2014, Barba et al., 
2015). Because of their ability in meeting all of these features, liposomes 
seem to be the ideal candidates for siRNAs incorporation, solving their 
delivery issues. Liposomes on nanometric scale, known as Small 
Unilamellar Vesicles (SUVs), are particularly desired; indeed it was 
demonstrated that, due to the Enhanced Permeability and Retention (EPR) 
effect (Bregoli et al., 2016), liposomes with small dimensions can permeate 
through membrane fenestrations of diseased blood vessels penetrating into 
the tumor tissue (Kibria et al., 2016). Moreover, a positively charged 
vesicles are preferable to enhance the interaction with both the negatively 
charged siRNA, improving its encapsulation efficiency, and the cell 
plasmatic membrane, also negatively charged, improving siRNA 
incorporation in the target cells (Ibraheem et al., 2014, Kim et al., 2010). 
For all the above stated reasons, in the last few years, liposomes 
encapsulating siRNAs have been increasingly investigated for their key role 
in the development of new potential strategies for the treatment of different 
type of cancer, obesity, diabetes, neurological disorders, inflammations and 
other disabling diseases (Guo et al., 2016, Golkar et al., 2016, Wei et al., 
2016, Ryther et al., 2005, Dunckley et al., 2005, Kigasawa et al., 2010, Ran 
et al., 2014). Among these latter, Inflammatory Bowel Diseases (IBDs), 
including different pathological states such as Crohn’s Disease (CD) and 
Colitis Ulcerosa (UC), are auto-immune disorders whose origin is unknown 
and whose incidence is increasing in almost every region in the world, 
affecting 2.5-3 million Europeans, with a direct healthcare cost of 4.6-5.6 bn 
Euros/year (Burisch et al., 2013, Kaistha and Levine, 2014). The important 
cost for society are related with an high rate of sick leave, permanent work 
disability and unemployment due to the high risk of colorectal cancer, 
several times increased if compared to the healthy control population 
(Nikolaus and Schreiber, 2007, Burisch and Munkholm, 2015, Farraye et al., 
2010). The great risk in developing cancer in patients with UC and CD has 
led to search more about the genetic changes that occur as IBD progresses 
from benign mucosa to dysplasia, up to invasive colorectal cancer (Kanaan 
et al., 2012). The promoter factor that initiates cancer pathways is unknown 
and different are the molecules investigated, especially those involved in the 
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pRb-E2F1 pathway (Ying et al., 2007). In particular, E2F1 is a transcription 
factor that has a key role in the promotion of the cell cycle, its high level in 
the late G1 phase of the cell growth cycle results in the expression of 
numerous factors for DNA synthesis, and thus the progression towards the 
following S phase (Ertosun et al., 2016). Being an important regulator of the 
growth and the cells proliferation, E2F1 gene overexpression is related to 
neoplastic development in several cancerous cell lines, including gastric and 
colorectal carcinomas (Mega et al., 2005). It was demonstrated that E2F1 
promotes the aggressiveness of human colorectal cancer by activating the 
ribonucleotide reductase small subunit M2 whose high expression induces 
cancer and contributes to tumor growth and invasion (Fang et al., 2015).  
Due to the observed correlation, in this work the inhibition of E2F1 
expression was studied as a potential way to treat cancer associated to IBD 
diseases. With the aim to investigate the possibility in reducing E2F1 
expression levels, two kinds of siRNA sequences direct against E2F1 (si-
E2F1-1117 and siE2F1-1324), at different concentrations, were encapsulated 
in cationic nanoliposomes suitably designed and produced by the technique 
based on lipid Thin Film Hydration/sonication process developed in this 
thesis. The loaded nanoliposomes were then transfected in suitable human 
cell line and in intestinal human biopsy fragments (collected from healthy 
and IBD donors during lower endoscopy performed for colonic cancer 
screening) to investigate in vitro and ex vivo silencing activity. In particular, 
in order to evaluate the effective efficacy of carriers in siRNA delivery, 
nanoliposomes uptake studies and siRNA-nanoliposomes transfections were 
accomplished in both HT29 human colon adenocarcinoma cell line, where 
conditions are more reproducible, and in cultured human biopsies, in which 
the cell–cell interactions, thus the human intestinal mucosa cytoarchitecture, 
are preserved unlike isolated cell cultures. 
5.5.2 Materials and methods 
5.5.2.1 Unloaded and siRNA loaded vesicles preparation 
Nanoliposomes design  
Nanoliposomes loaded with two different siRNA sequences for E2F1 
expression inhibition were designed and produced. At first the liposomes 
bilayer was designed in order to achieve a positive charged complex able to 
cross the negative plasma membrane thus to enter in the cells. In that regard 
the cationic DOTAP phospholipid, which is also able to electrostatically 
interact with the negative siRNA molecules, was chosen as well to promote 
siRNA encapsulation inside the lipid vesicles. The charge ratio between 
DOTAP and siRNA sequences used was 8.5:1 (+/-) and was calculated 
counting 1 positive charge for each DOTAP molecule and 42 negative 
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charges for each 21 bp siRNA molecule. This ratio was chosen on the basis 
of previous work in which the effect of different DOTAP/dsDNA charge 
ratios on dsDNA encapsulation efficiency was studied (see the previous 
section) (Bochicchio et al., 2016b). The ratio was selected in order to obtain 
the highest siRNA encapsulation efficiency simultaneously getting an excess 
of positive charge on the final siRNA-SUV complex for a better cellular 
uptake. 
Nanoliposomes production 
For unloaded and siRNA-loaded vesicles production, Cholesterol (CAS 57-
88-5), L-α-phosphatidylcholine (PC) from egg yolk (CAS 8002-43-5) and 
dioleoyloxypropyl-N,N,N-trimethylammoniumpropane (DOTAP) (CAS 
132172-63-1, >99 % pure) were purchased from Sigma-Aldrich (Milan, 
Italy). The experimental siRNA sequences direct against E2F1, siE2F1-1117 
(sense sequence 5’-GAGGAGUUCAUCAGCCUUUdTdT-3’) and siE2F1-
1324 (5’-GCCACCAUAGUGUCACCACdTdT-3’ sense sequence) were 
selected according to previously reported guidelines from Poliseno and 
collaborators (Dapas et al., 2009, Poliseno et al., 2004) and were chemically 
synthesized, together with luciferase mRNA GL2 siRNA control, by 
Eurofins Genomics (Ebersberg, Germany). The GAPDH siRNA positive 
control (Cat. 4457288) and the negative control siRNA (Cat. 4457287) 
sequences were obtained from Ambion®, Thermo Fisher (Waltham, MA, 
USA). Nuclease free water (CAS 129114) was purchased from Qiagen 
(Hilden, Germany), chloroform (CAS 67-66-3), methanol (CAS 67-56-1) 
and all the other reagents were of analytical grade and were purchased from 
Sigma-Aldrich (Milan, Italy). 
siE2F1-SUVs complexes were produced using the Thin Film Hydration 
method followed by duty cycle sonication through the ultrasound based size 
reduction method developed in this thesis and previously described (4.1 
section). Briefly PC, DOTAP and CHOL at 3:0.3:1 (mol:mol) ratio were 
dissolved in 1 mL of chloroform/methanol at 2:1 (vol/vol). The solvent was 
removed by evaporation in a rotary evaporator (Heidolph, Laborota 4002 
Control) and the produced lipid film was vacuum-dried for 3 hours at 50 °C 
in a water bath, rotating at 30 rpm. The dried lipid film was then hydrated at 
room temperature with 500 µl of phosphate buffer solution (PBS; potassium 
phosphate monobasic 0.2 M, sodium hydroxide 0.2 M - pH 7.4) containing 
siE2F1-1324 at 8 μM. The sample was mixed for 30 minutes by the rotary 
evaporator (60 rpm; room temperature). The process was repeated in an 
identical manner for siE2F1-1117, siRNA positive controls (GADPH and 
GL2 inhibitors) and siRNA negative control (scramble siRNA) 
encapsulation. Finally, the above described steps were followed for unloaded 
liposomes production with the only difference in the hydration solution 
which was pure PBS not containing siRNA sequences. 
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At the end of the process a total of six samples containing Multilamellar 
Vesicles (MLVs) were achieved, maintained at room temperature for 2 
hours, and then diluted to a final volume of 1 mL by adding 500 µl of PBS 
pH 7.4 thus obtaining a siRNA concentration of 4 µM for the loaded samples 
with a 1:260 (w/w) siRNA/total lipids ratio. 
In order to get liposomes of nanometric size, samples were sonicated at 45% 
amplitude (treated volume: 1 mL) applying a duty cycle consisting of 2 
irradiation rounds of 10 seconds, each followed by 20 seconds of pause to 
prevent thermal vesicle disruption, obtaining Large Unilamellar Vesicles 
(LUVs). The samples were stored at 4 °C for one night, protected from light, 
and were then sonicated at 45% amplitude for four more rounds in order to 
achieve SUVs. The VCX 130 PB Ultrasonic Processors of Sonics & 
Materials Inc. USA instrument was used (maximum power 130 W, 
frequency 20 kHz; sonotrode tip length 137 mm; sonotrode tip diameter 3 
mm) as for all the other applications (5.1; 5.2; 5.3; 5.4 sections). 
5.5.2.2 Unloaded and siRNA loaded vesicles characterization 
Morphology 
The morphological characterizations of unloaded and siRNA loaded 
liposomes were performed with optical microscope in fluorescence field 
(Axioplan 2- Image Zeiss, Jena, Germany) equipped with a software to 
capture the images. The Rhodamine B dye (CAS 83-68-9-Sigma-Aldrich, 
Milan, Italy) was used to visualize lipid vesicles. DAPI dye (4’6-diamidino-
2-phenylindole-Thermo Fisher Scientific, Waltham, MA, USA) was used to 
visualize siRNA molecules in the liposomes aqueous core. A 100 X oil 
immersion objective was used. 
Size and zeta potential  
A dimensional analysis of MLVs microscope images, performed with the 
software ImageJ, was combined with a Dynamic Light Scattering analysis 
for unloaded LUV, SUV and siRNA-SUV characterization. Size and zeta 
potential determinations were performed by using the ZetasizerNano ZS 
(Malvern, UK) with noninvasive backscatter (NIBS) optics. The detection 
angle of 173 degrees was used. The resulting particle size distribution was 
plotted as the number of liposomes versus size. All the measurements were 
performed in triplicate. The results were expressed as average values. 
Encapsulation efficiency (EE) by spectrophotometric and 
electrophoretic assay 
After removing an aliquot for the Electrophoretic assay in order to measure 
the unencapsulated siRNA, siE2F1-1117-SUVs and siE2F1-1324-SUVs 
samples were centrifuged overnight at 30000 rpm (Beckman Optima L-90K 
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Ultacentrifuge, SW 55 Ti rotor). The released siRNA was examined by 
submitting the recovered supernatants of the two samples to an UV 
spectrophotometric assay performed using Lambda 25 UV/VIS 
Spectrophotometer. An absorption spectrum from 200 nm to 300 nm was 
investigated for both the samples and the maximal wavelength for RNA 
molecules, 260 nm, was considered. The encapsulation efficiency (EE) was 
determined as the percentage of siRNA encapsulated in liposomes to the 
initial amount of siRNA included in the formulation and was calculated 
using the equation: 
 EE (%) = (
𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑖𝑅𝑁𝐴,   µ𝑔
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑠𝑖𝑅𝑁𝐴 𝑎𝑚𝑜𝑢𝑛𝑡,   µ𝑔
) × 100  (5.11) 
where the amount of siRNA encapsulated in liposome was calculated 
subtracting the amount of siRNA presents in the supernatant of the 
centrifuged sample from the total amount of siRNA included in the 
formulation. 
An electrophoretic assay on 1.5 % agarose (Cat. A7002, ≥99 % pure, Sigma-
Aldrich) gel was performed to evaluate the eventual not encapsulated 
amount of siRNA invisible at the spectrophotometric assay. For the agar gel 
a Tris/Borate/EDTA buffer (TBE - 0.5 X) was used and 25 µl of ethidium 
bromide (0.5 mg/ml) were added to the solution to visualize siRNA in the 
UV-spectrum. The gel was loaded with a 123 bp molecular marker (M.M., 
Cat. D5042, Sigma-Aldrich), and with both siE2F1-1117-SUV and siE2F1-
1324-SUV complexes. The naked forms of siE2F1-1117 and siRNA-1324 
were also loaded and used as control samples. Sample volumes equivalent to 
1 µg of siRNA were disposed in each well. The electrophoresis run was 
performed for 30 minutes at 80 V, using the same 0.5 X TBE solution as 
previously done for the gel preparation. The result of the electrophoresis was 
detected with UltraBright LED Transilluminator (Maestrogen). 
5.5.2.3 Cell culture condition 
The human colorectal adenocarcinoma cell lines HT29 and LoVo-109 were 
cultured in low glucose Dulbecco’s modified Eagle’s medium (DMEM) and 
RPMI medium respectively. Both medium were supplemented with 10% 
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin (Euroclone, Milan, Italy). 
5.5.2.4 Colon tissue culture condition 
Biopsies of human colon, isolated from six different donors, were collected 
during a lower endoscopy. For tissue culture, fragments, with the epithelium 
facing upward, were placed on a stainless-steel mesh positioned over the 
central well of an organ-culture dish containing Dulbecco’s modified eagle’s 
medium (F-12 HAM), HEPES, NaHCO3, pyridoxine and L-glutamine 
(Sigma-Aldrich). The dish was placed in a modular incubator chamber, 
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gassed with 5% CO2 and 95% O2, and then incubated at 37°C for 24 h 
(Piazza et al., 2016). By using this setting, one tissue biopsy was incubated 
with unloaded Rhodamine B-SUVs, to test their cellular uptake, and the 
other five were transfected with siRNA-SUVs complexes, to test their ability 
in E2F1 silencing. All clinical investigations have been conducted according 
to the declaration of Helsinki principles. Patient's consent for participation in 
this study was registered. Local Ethical committee approved the study 
protocol. 
5.5.2.5 Uptake study in tissue biopsies 
To test liposomes uptake in colon tissues, biopsy fragments of a female 
patient were incubated with unloaded liposomes labelled with Rhodamine B. 
For this purpose, unloaded Rhodamine B-labelled SUVs were prepared. 
Briefly, a 500 µl aliquot of unloaded SUVs sample was taken and marked 
with 1.5 µL of 5 mg/mL Rhodamine B-solution. After 2 h of incubation at 
room temperature, the excess of Rhodamine B was removed by 
centrifugation for 1.5 h at 9000 rpm (Beckman Coulter Avanti J-25I 
Centrifuge, JA2550 rotor). The sample was washed two times with PBS and 
re-centrifuged, then the supernatant, carefully removed, was put away and 
the pellet resuspended in 500 μl of PBS and 60 μl aliquots were used to 
overly cultured biopsies in the presence of culture medium. After 24 hours of 
incubation at 37 °C the culture medium was removed and the tissue 
fragments were frozen. The frozen tissue fragments were put in Cryostat 
Embedding Medium (05-9801 Killik Bio-Optica- Milan, Italy), in order to 
achieve tissue sections through the use of a cryostat (Leica CM1950, 
Wetzlar, Germany). DAPI (1:1000 diluited) was added to the sections, to 
visualize the cell nuclei composing the colon tissues. The sections were 
studied under a fluorescence microscope with a 20 X objective. 
5.5.2.6 siRNA-SUVs transfection in cells 
The sequences of the siRNAs directed against the transcription factor E2F1 
mRNA (siE2F1 1324, siE2F1 1117) and the luciferase mRNA (siGL2, 
control) have been previously described (Dapas et al., 2009) and reported in 
5.5.2.1 paragraph together with siRNAs-SUVs complexes preparation. 
To study the effects of siRNA-SUVs on cell number and on E2F1 mRNA, 
8x10
4
 HT29 cells were seeded in 12 well-plates in the presence of 1 ml of 
10% fetal calf serum-containing medium. The day after seeding, cell 
transfection was conducted in 400 μl of serum-free medium by using 1.3 μg 
of the siRNA-SUVs complexes or 1.3 μg of siRNA mixed with 
Lipofectamine®2000 (1 mg/ml) (Invitrogen, Carlsbad, CA, USA) at a 
weight ratio siRNA-transfectant of 1:1 (w/w). siRNA concentration 
corresponded to 220 nmol/L. After 3 hours at 37°C, transfection medium 
was removed, cells were washed with PBS and then 1 ml of complete 
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medium was added to the cells. The effect of the siRNA-SUVs were 
evaluated three days after transfection. To evaluate the effects of siRNA-
SUVs on E2F1 mRNA levels, total RNA was extracted from cells, 
quantified and then quality evaluated as described (Baiz et al., 2009). 
Reverse transcription was performed using 500 ng of total RNA in the 
presence of random hexamers and MuLv reverse transcriptase (Applied 
Biosystem, Foster City, CA, USA). Real time PCR was performed with the 
7900/HT Detection System (Applied Biosystems) and all amplification 
reactions were conducted in triplicate, utilizing SYBER Green Master mix 
solution (Applied Biosystems). The primers and the real-time amplification 
conditions were previously described (Farra et al., 2011). The relative 
amounts of each target mRNA were normalized by 28S rRNA content 
according to Pfaffl (Pfaffl, 2004). 
To study the effects of siRNA-SUVs on cell viability, 5x10
3
 HT29 cells or 
LoVo-109 were seeded in 96 microplate in 200 µl of complete medium/well. 
Three days after transfection of 220 nM siRNA-SUVs and siRNA-
Lipofectamine®2000 complexes, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT, Sigma-Aldrich, St Louis, MO, USA) test was 
conducted according to standard procedure (Farra et al., 2011).  
5.5.2.7 siRNA-SUVs transfection in colon tissue 
Tissue cultures from 5 donor were transfected with three different siRNA 
concentrations: 50 nM, 100 nM and 200 nM. At first the intermediate 100 
nM concentration was used. Afterwards, the concentration was doubled and 
halved. 
Transfection of 100 nM siRNA-SUV complexes in donor 1 
The biopsy was obtained during the colonoscopy of a 27 years old male 
donor, suffering from Irritable Bowel Syndrome. The tissue fragments were 
prepared as described for colon tissue culture (5.5.2.4 paragraph) and were 
transfected with the siE2F1-SUVs complexes. Furthermore, in order to study 
the eventual E2F1 expression changes in presence of inflammation, siRNA-
liposome complexes were transfected with and without the presence of 
lipopolysaccharides from Escherichia Coli (EC-LPS), used as inflammatory 
agent. In total, 8 fragments were incubated and the experiment was set as 
follow: one fragment was treated only with a culture medium (basal sample) 
and another one with the culture medium containing 2 µl of EC-LPS. The 
other 6 fragments were transfected respectively with siE2F1-1117-SUVs 
cultured in a pure medium; siE2F1-1117-SUV cultured in a medium 
containing EC-LPS; siE2F1-1324-SUV cultured in a pure medium; siE2F1-
1324-SUV cultured in medium containing EC-LPS; siRNA positive control-
SUV; siRNA negative control-SUV. The latter two were both cultured in a 
medium without EC-LPS. In order to obtain a concentration of 100 nM 
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siRNA in the culture medium, a volume of 30 µl was transfected for all the 
samples. The plates were incubated at 37°C. After 24 hours, the transfection 
was stopped, the culture medium was removed, the tissues were recovered 
and the E2F1 expression was examined by Western blot technique. 
Transfection of 200 nM siRNA-SUV complex in donors 2 and 3 
Donor 2, a 54 years old female, had a colorectal cancer screening that it was 
found to be in the standards and donor 3 was a 36 years old male, suffering 
from Morbus Crohn. In total 4 fragments of colon tissue for each donors 
were treated and, for both, the transfection was set as follows: one fragment 
was treated only with a culture medium (basal sample) and the other three 
fragments were transfected respectively with siE2F1-1324-SUVs, siRNA 
positive control-SUVs and siRNA negative control-SUVs complexes. The 
volume of siRNA-SUVs samples transfected was 60 µL for all the plates, 
thus obtaining a final siRNA concentration of 200 nM. Transfections were 
executed in the same conditions above described. 
In the sight of the results obtained from donor 1, siE2F1-1117-SUVs 
complexes together with the EC-LPS treatments were excluded from this 
and from the subsequent experiments. siE2F1-1117-SUVs and EC-LPS 
treatments seemed to have no influence on the expression of E2F1 (see 
5.5.3.4 results section) and thus were not further studied. 
Transfection of 200 nM and 50 nM siRNA-SUV complex in donors 4 
and 5 
Patient 4, a 24 years old male, was a donor suffering from Ulcerative Colitis 
and patient 5, a 27 years old male, was a donor suffering from ileal Morbus 
Crohn. In this case, in order to find a correlation between siRNA 
concentration transfected in tissue and E2F1 expression inhibition, fragments 
of the same patient were treated with two different concentrations: 200 nM 
and 50 nM. In total, for both donors, 7 fragments of colon tissue were 
cultured. One fragment was the basal sample (treated only with culture 
medium) and the other 6 fragments were treated as described for patients 2 
and 3 but using the two siRNA concentrations. 
5.5.2.8 Evaluation of E2F1 protein expression after transfection 
in tissue: Western blot 
Total proteins were isolated by colon specimen lysis in a buffer composed of 
50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 0.1% SDS, 1% NP40 
(Sigma-Aldrich) supplemented with protease and phosphatase inhibitors 
(CalbioChem). After samples centrifugation, the proteins present in 
supernatants were quantified with the Bradford method (Bradford, 1976). 40 
µg of total proteins extract from colon tissue were separated by 10% sodium 
dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) and then 
transferred to nitrocellulose membrane (Biorad). Blotting membranes were 
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incubated with blocking solution with 5% non-fat dried milk powder 
dissolved in Tris-Buffered Saline Tween-20 (TBST) buffer (pH 7.5) 
composed of 10 mmol⁄L Tris–HCl, 150 mmol⁄L NaCl, and 0.1% Tween20, 
for 1 h at room temperature, washed three times, and then incubated with 
rabbit polyclonal anti E2F1 (1:300 dilution) (Proteintech –Cat. Numb. 
12171-1-AP) overnight at 4 °C. After three washes with TBST buffer, the 
membranes were incubated for 1 hr with horseradish peroxidase–linked goat 
anti rabbit secondary antibody (1:2000 dilution) (Immunoreagents). Internal 
controls were carried out using β-Actin rabbit antibody (1:1000 dilution) 
(ABM) and Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) antibody 
(1:5000 dilution) (Biorbyt). 
The membranes were then processed by using ImageQuant
TM
 LAS 4000 
Biomolecular Imager (GE Healthcare Bio-sciences, Little Chalfont, United 
Kingdom) by treating with enhanced chemiluminescence western blotting 
detection reagents (Clarity Western ECL Substrate, Biorad, cat. 170-5060). 
Following films scanning, bands intensities were measured by densitometry 
analysis using the ImageJ software. 
5.5.3 Results and discussion 
5.5.3.1 Unloaded and siRNA loaded vesicles 
Nanoparticles formulation and production 
The production process (formulation and manufacturing) is of crucial 
importance in preparing siRNA-liposomes complexes with the desired size 
without affecting siRNAs integrity. The ultrasound assisted method adopted, 
described, modelled and applied in previous section (Chapter 4) (Barba et 
al., 2014) has been successfully used to produce stable siRNA-SUVs 
complexes on nanometric scale, useful for the EPR effect which involves 
carriers extravasation through tumor vascular fenestrations of 50 – 100 nm 
range size. 
Considering the high degradability of siRNA molecules, thus the difficulty 
in preserving them during all production steps, one of the main goal was to 
produce liposomes on nanometric size ensuring the integrity of siRNAs 
molecular structure at the end of the process as well as preserving their 
biological activity. 
In particular, in the developed process, the ultrasonic energy provided in 
duty cycle, was used to break the lipid bilayer of large vesicles (MLVs) into 
smaller pieces, then these pieces close themselves in spherical structures 
producing SUVs still containing the starting totally RNA molecules. The 
high encapsulation efficiency obtained together with the vesicles nanometric 
size achieved showed efficacy and safety of the developed technique. 
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Morphology 
Liposomes shape is the first factor affecting carriers uptake in the cellular 
compartment. Spherical nanoparticles uptake in mammalian cells was 
demonstrated to be 3.75-5 times more than rod-shape nanoparticles, 
indicating that carriers curvature can affect the entry in the plasma 
membrane (Chithrani and Chan, 2007). In that regard, the morphological 
properties of the unloaded liposomes achieved during our production process 
were studied. As shown in Figure 34 spherical MLVs, LUVs and SUVs were 
obtained respectively after the hydration step, after 2 rounds of duty cycle 
sonication and after 6 total rounds of the size reduction process. For all the 
samples spherical vesicles were obtained with the loss of multiple layers 
moving from MLVs to LUVs and SUVs. 
 
Figure 34. Fluorescence microscopy images of merged lipid vesicles 
labelled with Rhodamine B dye and visualized with a 100 X objective. A) 
Multilamellar Vesicles (MLVs) not subjected to the size reduction process; 
B) Large Vesicles (LVs) after two rounds of duty cycle sonication; C) Small 
Vesicles (SUVs) after six rounds of duty cycle sonication 
Formation of siRNA loaded liposomes was also investigated in fluorescence 
microscopy. As visible in Figure 35 siRNA-SUVs complexes were obtained. 
Vesicles labelled with the two different dyes, the red one for liposomes and 
the green one for siRNA visualization, are in the same location and have the 
same spherical shape, implying that the siRNA molecules were successful 
complexed with the liposomes. The small complexes obtained are called 
SUVs for the presumable presence of just one lipid bilayer surrounding the 
aqueous core. 
 
A B C 
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Figure 35. Fluorescence images of siRNA loaded nanometric vesicles 
labelled with Rhodamine B (on the left) and siRNA DAPI labelled (on the 
right) visualized with a 100 X objective 
Size and zeta potential 
The carriers size is a key factor affecting liposomes performance as drug 
delivery systems during the diffusion-mediated transport into the diseased 
tissue. For this reason, one of the main liposomes relevant features resides in 
the easy way by which their dimensions can be modified. The diameter size 
of unloaded liposomes produced was analyzed and the obtained values are 
summarized in Table 29, presented as average of three determinations. After 
two rounds of duty cycle sonication, MLVs (2.66 ± 1.24 µm) are turned into 
LUVs, vesicles which are still of micrometric size (1.76 ± 0.66 µm) but 
containing only one lipid bilayer. After four more rounds of sonication, 
SUVs were achieved of nanometric size (24.86 nm ± 5.8). 
Table 29. Size of produced unloaded Multilamellar Vesicles (MLVs), Large 
Unilamellar Vesicles (LUVs) and Small Unilamellar Vesicles (SUVs). 
Results are expressed as average of three determinations with SD as 
standard deviation 
Unloaded liposomes sample Size (µm) ± SD 
MLVs 2.66  1.24 
LUVs 1.76  0.66 
SUVs 0.025  0.006 
In general, the lipid composition affects the dimensions of MLVs. As 
already discussed in the 5.4 section, in the case of cationic liposomes it has 
been demonstrated that the diameter is influenced by the amount of DOTAP 
in the lipid membranes: the quaternary amine groups of the cationic lipid 
DOTAP and the phosphate group of PC, interact with each other. This strong 
interaction makes the membrane more stable and compact, and causes a 
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smaller particle size than could be expected without the interaction. The salt 
bridge between the functional groups of the two constitutive lipids results in 
a smaller bilayer radius of curvature which increases the stability and the 
encapsulation efficiency of the liposomes that contain drugs (Campbell et 
al., 2001). The size obtained moving from MLVs to the nanometric 
liposomes instead depends from the reduction process applied. It is 
important to point out that the transition from multilamellar to unilamellar 
vesicles takes only few seconds using the ultrasound based sizing technique 
described. The technique was modelled by Barba and collaborators in order 
to predict the size of spherical liposomes as an effect of the ultrasound 
application (Barba et al., 2014). 
In Table 30 it is possible to note that the loaded liposomes diameter value 
(33-38 nm range size) is higher than that found for the unloaded ones (25 
nm). This can be due to the fact that the liposomes have encapsulated large 
siRNA molecules, while the unloaded liposomes only contain PBS hydration 
solution. The sizes of the loaded liposomes, even when larger than those of 
the unloaded one, is still considered optimal being smaller than the 
dimensions of the expected fenestrations in the EPR effect. These 
fenestrations are typically 50 – 100 nm in size and the passive mechanism of 
permeation through the vessel gaps is an important pathway for nanoparticle 
accumulation into to the diseased tissue (Steichen et al., 2013).  
Table 30. Size, PDI and zeta potential of siE2F1-1117 and siE2F1-1324 
produced loaded Small Unilamellar Vesicles (SUVs). Results are expressed 
as average of three determinations with SD as standard deviation 
siRNA-SUVs 
sample 
Size (nm) ± SD PDI ± SD 
Zeta Potential 
(mV) ± SD 
siE2F1-1117 SUVs 32.91  4.82 0.32  0.04 8.70  1.60 
siE2F1-1324 SUVs 38.11  5.57 0.43  0.017 18.02  1.07 
unloaded SUVs 24.86  5.8 0.26  0.005 27.90  1.60 
Also the PDI is higher in both loaded samples than in the unloaded one, 
suggesting a broader distribution of the sizes of the loaded particles; even if 
the sample is not really monodisperse, PDI value remains low. 
Another important feature is the surface charge of liposomes. Zeta potential 
() was analyzed for both unloaded and SUVs encapsulating siRNAs 
samples, the results are presented in Table 30. The zeta-potential was 
positive for all the samples making the produced liposomes applicable for 
the encapsulation of negative siRNA molecules. The positive zeta-potential 
also promotes the fusion with the negatively charged cell membrane. In 
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particular, the  of siRNA loaded liposomes (about 9-18 mV range) is lower 
than that of the unloaded one (28 mV). This can be ascribed to the partially 
neutralization of DOTAP charges by the negative siRNA molecules after the 
complexation, making liposomes less positively charged. It can be observed 
that the  value of the siE2F1-1324-SUVs liposomes (18.02  1.07 mV) 
appears to be significantly higher than the zeta-potential of the siE2F1-1117-
SUVs sample (8.70  1.60 mV). This can be explained considering that 
when liposomes are formed, the largest part of the negatively charged 
hydrophilic siRNA is encapsulated in the aqueous core, however, a small 
part of the siRNA molecule can have an electrostatics interaction with the 
DOTAP molecules at the outer of the liposomes surface. For siE2F1-1117-
SUVs sample it is possible that a strong complexation and a less core 
encapsulation occurred. 
Encapsulation efficiency (EE) by spectrophotometric and 
electrophoretic assay 
The result of the UV-analysis shows no siRNA presence in the supernatants 
for siRNA-SUVs thus suggesting that under our condition the encapsulation 
rate is close to 100 %. This result indicates the optimal DOTAP/siRNA (+/-) 
charge ratio used and, more generally, the efficacy of liposomal bilayer 
design as well that of the production technique used. The result of the 
electrophoretic assay is given in Figure 36. 
 
Figure 36. UV-image of the agar gel after the electrophoretic assay. 
Following the order: M.M., DNA 123 bp; Lane 1, Naked siE2F1-1117; Lane 
2, Nanoliposomes-siE2F1-1117; Lane 3, Naked siE2F1-1324; Lane 4, 
Nanoliposomes-siE2F1-1324 
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The absence of bands in the lanes 2 and 4 shows no detectable amounts of 
unloaded siRNA confirming the 100 % siRNA encapsulation efficiency in 
the liposomes and also showing the high stability of the formed complexes 
since no decomplexation under the electric field was observed. Complex 
stability is a very important parameter to take into account due to the high 
degradability and toxicity of free siRNA. Moreover, this result indicates the 
success of the ultrasound assisted technique used which allows to preserve 
siRNA integrity since no evidence of nucleic acids degradation were visible 
on the gel.  
5.5.3.2 Effects of siRNA-nanoliposomes on the vitality of human 
colon carcinoma cell lines  
Based on the promising physical characterization of SUVs above reported, 
their delivery properties were investigated in a commonly used model of 
colon cells, i.e. the cell line HT29. As siRNA, a siRNA directed against the 
transcription factor E2F1 (siE2F1) was used, which was previously 
demonstrated to be able to reduce the vitality and growth of different 
cultured human cells (Dapas et al., 2009). 
Three days post transfection, siE2F1- SUVs were able to significantly reduce 
the vitality of the colon carcinoma cell line HT29, compared to SUVs loaded 
by a control siRNA (siGL2- SUVs) (Figure 37 A, white columns). This 
result was comparable to that obtained delivering siE2F1 by a commonly 
used commercial transfection reagent (siE2F1- Lipofectamine®2000) 
(Figure 37 A, grey columns), thus proving the effectiveness of our SUVs. 
The un-specific toxicity of SUVs in relation to Lipofectamine®2000 was 
then investigated. To this purpose, the un-specific effects on cell viability of 
each of the carriers either alone or loaded by the control siGL2 were 
compared. Data (Figure 37 B) clearly indicate that SUVs are far less toxic 
(Figure 37 B) than Lipofectamine®2000. This is a desirable property for a 
delivery agent, which should leave to the carried molecule all the biological 
effects without introducing its own un-specific toxicity. Indeed, an un-
specific toxicity of the carrier can confound the determination of the 
biological effect(s) of a given drug making the evaluation of its therapeutic 
potential very problematic. 
The decrease in cell vitality observed for siE2F1- SUVs in HT29 was 
confirmed by a reduction in cell counting (Figure 37 C). This proves the 
ability of the prepared SUVs to properly delivering siE2F1, which is 
expected to down regulate cell growth. To further confirm the functional 
delivery, we also show that siE2F1- SUVs were able to significantly reduce 
the mRNA level of E2F1 (Figure 37 D) compared to the control siGL2- 
SUVs. 
Finally, to exclude that the delivery efficacy of our SUVs might be cell type 
dependent, the effects in a different human colon-carcinoma cell line, i.e. 
LoVo109 were explored. Results (Figure 37 E) indicate that also in the 
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LoVo109 cell line siE2F1-SUVs can reduce cell vitality, proving the general 
delivery effectiveness of siE2F1-SUVs in colon cells. 
Together the presented data indicate the efficacy of the delevoped SUVs in 
the delivery of siE2F1 with negligible un-specific toxic effects, at least in the 
human cell line considered. This is a relevant feature for any novel anti-
cancer approach, which should overcome the well-known un-specific 
toxicity of available anticancer approaches. Based on these encouraging 
results, it was moved to the evaluation of SUVs delivery effectiveness in a 
more complex model, i.e. colon tissue cultures, as below detailed. 
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Figure 37. A) siE2F1-nanoliposome complexes and siE2F1-Lipofectamine® 
2000 effects on HT29 cell vitality (*P=0.0001 siE2F1 vs siGL2 nanolipo, 
Unpaired t test; **P=0.01 siE2F1 vs siGL2 lipo2000, Unpaired t test with 
Welch correction); B) Un-specific effects on cell of nanoliposomes and 
Lipofectamine®2000 alone or loaded by the control siGL2; C) Cell counting 
after siE2F1-nanoliposomes transfection in HT29 cell line; D) E2F1 mRNA 
levels after siE2F1 –nanoliposomes transfection in HT29 cells (*P=0.0068 
siE2F1 vs siGL2 nanolipo, Unpaired t test); E) siE2F1-nanoliposome 
complexes effects on LoVo109 cell vitality. All data are reported as mean ± 
SEM 
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5.5.3.3 Uptake study in colon tissue cultures  
The above reported data strongly support the effectiveness of the prepared 
SUVs. However, the delivery efficacy can significantly vary in more 
complex scenario such as that represented by an organized tissue. Here, cell-
cell interaction as well as the presence of the extracellular matrix can affect 
particle uptake. Thus, the ability of the produced SUVs to penetrate the 
colon mucosa tissue was tested. To this end, SUVs were marked by a red die 
and the distribution within the colon mucosa was analysed (Figure 38); 
tissue cell architecture was visualized by DAPI staining of the nuclei. Data 
indicate the presence of SUVs spread all over the colon tissue suggesting an 
effective tissue penetration including non-easy-to reach regions such as the 
villi and the intestinal crypts. Notably, no evident signs of cell damage were 
observed thus confirming the absence of any significant toxicity as observed 
in vitro.  
 
Figure 38. Fluorescence microscope images of colon tissue section after 24 
h of incubation with liposomes; 20 X objective. A) cell nuclei were visualized 
with DAPI, B) unloaded liposomes were Rhodamine B-labelled, C) cell 
nuclei and labelled liposomes images merge 
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5.5.3.4 Evaluation of E2F1 protein expression after transfection 
in tissue: Western blot 
After siE2F1-1324 nanoliposomes transfection, an inhibition of E2F1 
expression level was observed in four of five donor’s biopsy analysed, 
delineating a successful result obtained also in a dynamic human model. In 
particular, the E2F1 inhibition was observed at 100 nM siRNA concentration 
and also at 200 nM siRNA achieving a silencing effect till 80.5 %. No 
reduction effects were observed using 50 nM siRNA concentration. 
Differences in E2F1 expression levels between different donor’s tissues after 
siRNA transfections have highlighted a patient-dependent effect (Piazza et 
al., 2016). Moreover, differences in proteins expression levels between the 
same biopsy fragments after siRNA transfections were also found as 
expected for a dynamic human model which, if on one side represents a 
great way to overcome the limits of cell cultures, being these just a small 
part of the entire tissue architecture, on the other side can be less controllable 
due to the different basal characteristics of the fragments. In fact, the 
constituent types of cells can differ from one tissue fragment to another, a 
tissue portion can, for example, be more superficial and thus mostly 
composed of epithelial cells, another portion, being less superficial, can be 
constituted from epithelial, blood and lamina cells. This has to be taken into 
account for this kind of transfection experiments whose results are below, 
patient to patient, detailed. 
siRNA-SUV complexes (100 nM) transfected in donor mucosa 1 
The first transfection was done in colon tissue biopsy of donor mucosa 1 as 
described in materials and methods, using a concentration of siE2F1-1117 
and siE2F1-1324 of 100 nM. All the silencing values of E2F1 and GAPDH 
were normalized for both the basal sample and the negative control sample. 
As shown in Figure 39, the addition of the pro-inflammatory factor EC-LPS 
had no effect on E2F1 expression without increasing its levels as can be 
expected, therefore was left out of the subsequent experiments. Also the 
inhibition of E2F1 expression after siE2F1-1117-nanoliposomes transfection 
was considered not significant thus liposomes loaded with siE2F1-1117 were 
left out of the subsequent transfections. The inhibition of E2F1 expression 
with siE2F1-1324 loaded liposomes, normalized for both the control 
untreated sample (Figure 39 A) and the positive control sample (Figure 39 
B), was of 20 %. The silencing of E2F1 expression with siE2F1-1324 loaded 
liposomes in tissue treated also with EC-LPS was of 65 % compared to the 
tissue treated with only EC-LPS. This result was considered interesting and 
siE2F1-1324-SUV sample was taken for further transfections to verify the 
expression values obtained after liposomes treatments without EC-LPS. The 
expression of GAPDH was also evaluated as positive control. As seen in 
Figure 39, the expression of GAPDH was inhibited significantly only in the 
sample transfected with the siRNA-SUVs positive control, with a 43.6 % of 
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inhibition normalizing for the basal sample, confirming the successful 
transfection. Moreover, the negative control did not show inhibition of E2F1 
or GAPDH expressions, demonstrating the absence of random silencing 
effects. 
 
Figure 39. E2F1 and GAPDH expressions in donor 1 after siRNA-
nanoliposome transfection at 100 nM. The proteins band quantification is 
normalized to Actin. The order of the analyzed samples is: Tissue incubated 
in 1. Only medium; 2. Medium with EC-LPS; Tissue transfected with: 3. 
siE2F1-1117 nanoliposomes; 4. siE2F1-1117 nanoliposomes in medium 
with EC-LPS; 5. siE2F1-1324 nanoliposomes; 6. siE2F1-1324 in medium 
with EC-LPS; 7. Positive control nanoliposomes and 8. Negative control 
nanoliposomes. Figures A are referred to E2F1 expression levels normalized 
respect to the not treated (NT) or basal sample. Figures B are referred to 
E2F1 expression levels normalized respect to the siRNA negative control 
(CTRL – siRNA) treated sample 
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siRNA-SUV complex (200 nM) transfected in donors mucosa 2 and 3 
The results of the Western Blot analysis for patients 2 and 3 are shown in 
Figure 40. As can be seen in the first graph of Figure 40 A, relatively to the 
patient 2, the expression of E2F1, normalized to the basal (not treated) 
sample, is inhibited of 43.2 % and of about the 37 % normalizing for the 
scramble siRNA negative control treated tissue (second graph of Figure 40 
A). The expression of GAPDH does not appear to be silenced after the 
transfection of the siRNA-positive control-nanoliposomes. This result can be 
explained by the fact that, being colon tissue biopsies not completely 
comparable with one another (they can differ for the nature and amount of 
cells they are made from, for their weight which is not exactly equal, for a 
different enzymatic activity), the transfection process can go in a different 
manner also between fragments of the same patient. For example if the tissue 
fragment in which the positive control-nanoliposomes is transfected contains 
more cells than the fragment transfected with siE2F1-1324 complexes, 
liposomes will reach a smaller fraction of the total cell nuclei and the siRNA 
concentration will be insufficient to lower the proteins expression levels. 
This might have caused a lower inhibition of GAPDH expression in patient 2 
and no inhibition of E2F1 expression in patient 3 in which anyway the 
expression of GAPDH was inhibited of 38 % after positive control 
nanoliposomes transfection normalizing for both the not treated and the 
negative control samples (Figure 40 B), confirming the liposomes ability in 
enter the cells and release siRNAs molecule as well as the successful 
transfection. The negative control was valid for all the transfections done 
and, for both the patients, no significant inhibition of E2F1 and GAPDH 
expression was found in the presence of a scramble sequences, 
demonstrating, once more, the absence of random silencing effects. 
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Figure 40. E2F1 and GAPDH expressions in donors 2 (A) and 3 (B) after 
siRNA-nanoliposome transfection at 200 nM. The proteins band 
quantification is normalized to Actin. The order of the analyzed samples is: 
1. Tissue fragment incubated in medium; Tissue fragments transfected with: 
2. siE2F1-1324 nanoliposomes; 3. Positive control nanoliposomes; and 4. 
Negative control nanoliposomes. E2F1 expression levels are normalized 
respect to the basal (not treated) sample and respect to the siRNA negative 
control (CTRL – siRNA) treated sample 
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siRNA-SUV complex (200 nM and 50 nM) transfected in donors 
mucosa 4 and 5 
E2F1 and GADPH expression levels after 50 nM and 200 nM siRNA-
nanoliposomes transfections were determined for patients 4 and 5. 
Normalizing for the basal sample no significative inhibitions of E2F1 and 
GAPDH expressions were found for both the patients when siRNAs were 
used at 50 nM (Figure 41 A-B). Instead, at 200 nM siE2F1-1324 
nanoliposomes a significant inhibition was observed in both patients 4 and 5. 
In particular, in patient 4, the E2F1 expression level was decreased by 80.5 
% respect to the basal tissue (Figure 41 A) and by the 40.3 % in patient 5 
(Figure 41 B) ever normalizing to the not treated tissue. Normalizing for 
siRNA negative control treated sample, E2F1 inhibition percentages don’t 
change in a significant manner confirming the absence of random effects. 
Regarding the GAPDH expression this was not reduced in patient 4 (Figure 
41 A) but significantly reduced in patient 5 decreasing of the 64.3 % respect 
to the basal tissue (Figure 41 B), thus confirming that differences in biopsy 
fragments structures, weight and cells composition can affect transfection 
process which, anyway, has proved to be efficient in silencing E2F1 in both 
the last two patients with the explored liposomal delivery systems.  
Data  indicate the ability of the produced nanoliposomes in encapsulating the 
siRNA molecules in an effective manner, in delivering them excellently into 
the colon cell line and human colon tissue studied and in their ability in 
release their content once inside the endosome compartment. Moreover, 
E2F1 protein level reduction indicates the successful siRNA entrance in the 
cell nuclei and the selectivity of the used siRNA-1324 sequence against 
E2F1 mRNA. All this finding suggests a promising potential of the 
developed nanoliposomes-siRNA complexes for the treatment of diseases in 
which the pathophysiology is characterized by an excessive expression of 
E2F1 transcription factor as cancer forms associated to IBDs. 
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Figure 41. E2F1 and GAPDH expressions in donors 4 (A) and 5 (B) after 
siRNA-nanoliposome transfection at 200 nM and 50 nM. The proteins band 
quantification is normalized to Actin. The order of the analyzed samples is: 
1. Tissue fragment incubated in medium; Tissue fragments transfected with: 
2. siE2F1-1324 nanoliposomes; 3. Positive control nanoliposomes; and 4. 
Negative control nanoliposomes. E2F1 expression levels are normalized 
respect to the basal (not treated) sample and respect to the siRNA negative 
control (CTRL – siRNA) treated sample 
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5.5.4 Remarks 
In this thesis, taylored designed SUVs loaded with an anti E2F1 siRNA have 
been produced and tested in vitro and ex vivo models of colon tissue.  
To produce SUVs the lipidic thin film hydration combined with a size 
reduction process via sonication in duty cycle was used. This developed 
preparative protocol is far less complex and more rapid than the one usually 
adopted for liposomes size reduction. The produced liposomes are in the 
nanometric size range and thus can take advantage of the EPR effect. 
Moreover, nanoliposomes have shown high degree of size homogeneity, 
relevant feature that can guarantee a uniform behavior in terms of delivery 
properties, and the siRNA encapsulation rate reaches almost 100% 
indicating a remarkable capability of siRNA loading. 
Together, the characteristics of the designed SUVs resulted in a low 
unspecific toxicity in cultured colon cells compared to commonly used 
transfection reagents. This is a desirable property for a delivery agent, which 
should leave to the carried molecule all the biological effects without 
introducing its own un-specific toxicity. Moreover, SUVs loaded by siE2F1 
were effective in the down regulation of the target in cultured cells and in the 
consequent reduction of cell growth. Finally, a remarkable uptake and target 
silencing efficiencies were observed in cultured human biopsy of colon 
mucosa. 
In conclusion, whereas further studies in more complex models are required, 
the developed SUVs have the potential to contribute to the development of 
novel effective anti-colorectal cancer therapies for a future personalized 
medicine. 
 
Part of this work has been reported in: 
Bochicchio S.; Dalmoro A.; Barba A.A.; Grassi G.; Lamberti G.; 
“Liposomes as siRNA delivery vectors”; Current Drug Metabolism, 2015, 
15, 882-892 
Bochicchio S.; Dapas B.; Russo I.; Ciacci C.; Piazza O.; De Smedt S.; Pottie 
E.; Barba A.A.; Grassi G.; “In vitro and ex vivo delivery of tailored siRNA-
nanoliposomes for E2F1 silencing as a potential therapy for colorectal 
cancer”, IJP - International Journal of Pharmaceutics, 2017, in press 
  










6. Concluding Remarks 
In this chapter the work done is resumed 















Liposomes engineering has revolutionized active molecules delivery by 
providing new tools to customize therapeutics for specific clinical 
application and to enhance micronutrients controlled release in nutraceutical 
field thus solving the major drawbacks of bioactive compounds linked to 
their low stability, limited membrane-permeability, short half-life and low 
bioavailability. 
In this PhD thesis lipid nanostructured vectors with tailored features to be 
used for both nutraceutical and pharmaceutical applications were realized 
through the design of novel production processes, expressly developed in 
order to overcome the limits of conventional methods. To date, one of the 
major drawback of the processes used for liposomes production resides in 
the impossibility to manufacture large volumes of product in output despite 
the high energy consumption, long times of production together with the use 
of toxic solvents and other process drastic conditions.  
Therefore, in order to respond to the needs of a better process performance, 
improving the efficiency and cutting down energy consumption, two novel 
techniques, sharing the ultrasound technology as process intensification tool 
used in particles size reduction and homogenization operations, were 
designed and developed. 
Starting with the use of the ultrasounds as alternative energy, a particles size 
reduction process was developed and coupled with the bench scale 
conventional Thin Film Hydration (TFH) technique. In this method, after 
solvents evaporation through the use of a rotary evaporator, a lipid film is 
formed and then hydrated, spontaneously producing micrometric vesicles 
characterized by the presence of several bilayers. In order to produce, in a 
versatile manner structures with modulable dimension (micro or nano), the 
method was revisited by adding the duty cycle sonication treatment. 
A dynamic model able to describe the curvature of a lipid bilayer under the 
effect of ultrasonic energy was then proposed and tested and the 
phenomenological aspects involved in vectors constitution were 
investigated. In particular, starting from micrometric vesicles, the energy is 
used to break the lipid bilayer into smaller pieces, then these pieces close 
themselves in spherical structures producing small liposomes. 
Due to its easiness, reliability, versatility and its great potential in reducing 
time spent, the ultrasound intensification tool was also used for liposomes 
homogenization operation during vesicles production through the simil-
microfluidic approach. In particular, a new simil-microfluidic bench scale 
apparatus able to produce lipid vectors directly on nanometric scale was 
designed and fabricated. 
Through the use of constructive expedients (millimetric diameter tubes, 
peristaltic pumps, injection needle) it was possible to reproduce the 
phenomenology connected to the vesicles formation through a microfluidic 
approach. In particular, liposomes formation is governed by the molecular 
                                                                Nano-liposomes vectors for peptide delivery   
  157 
diffusion between two phases: the lipids/organic solvent and the water; this 
latter simultaneously diffuses into the organic solvent in order to reduce its 
concentration below the critical value required for the lipids solubilization. 
Liposomes formation happens at the interfaces between the alcoholic and 
water phases, when they start to interdiffuse in a direction normal to the 
liquid flow stream, changes in flow conditions result in a size variations of 
the insertion section of the organic phase reflecting on the vesicles 
dimensional features. For instance, it was shown that the liposomes 
dimensional distibution increases as increasing the ratio between the water 
volumetric flow rate to the lipids-ethanol volumetric flow rate; on contrary, 
ultrasonic energy enhances the homogenization of the hydroalcoholic bulk 
and its duty cycle application efficaciously promoted a better vesicles 
dimensional distribution. This result was also confirmed by working at equal 
flow rates but at different lipid concentrations. 
In general, it is important to underline that while making the large scale 
nanoliposomes production a safe and low cost process (working at room 
conditions and in absence of toxic solvents) the developed simil-microfluidic 
apparatus is also highly productive due to the use of ultrasound, a scalable 
tool for process intensification. 
Several active molecules were successfully encapsulated in different classes 
of lipid nanostructured vectors (neuter, cationic and anionic) by using the 
ultrasound assisted tool at first coupled with the conventional THF method 
and subsequently used as integrant part of the homogenization section of the 
simil-microfluidic bench scale apparatus. For nutraceutical applications, 
nanoliposomes containing vitamins with different hydrophobicity (α-
tocopherol, ergocalciferol, vitamin B12) and ferrous sulfate, with highly 
interesting features for supplements market, were produced trought the use 
of ultrasound assisted TFH method and the simil-microfluidic apparatus, 
respectively. 
Micro liposomal vesicles containing vitamins with tailored dimensions (2.9 
μm - 5.7 μm range size) were produced, obtaining, after sonication in duty 
cycle, small vesicles (40 nm - 51 nm range size). High encapsulation 
efficiency was obtained in both large vesicles (72.0 ± 00 % e.e., vitamin 
B12; 95.0 ± 7.07 % e.e., α-tocopherol; 81.5 ± 2.12 %, ergocalciferol) and 
small liposomes (56.2 ± 8.51 %, vitamin B12; 76.3 ± 14.02 %, α-tocopherol; 
57.5 ± 13.9 %, ergocalciferol). An increase of encapsulation efficiency in 
small vesicles from 40% to 56.2 % between vitamin B12 encapsulated with 
the developed technique or by breaking unloaded preformed liposomes 
(conventional approach), has been achieved. 
Through the simil-microfluidic method it was possible to produce ferrous 
sulfate-nanoliposomes with high encapsulation efficiencies (a 97% e.e. was 
achieved using the last formulation tested) and good dimensional features 
(127-135 nm, not sonicated vesicles; 48-76 nm, sonicated vesicles) to be 
used for the cure of iron deficiencies related diseases, such anemia. 
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Elevated process yield if compared to the THF and Ethanol Injection 
classical bench scale techniques was achieved without the use of drastic 
conditions. 
The efficiency and sustainability of the developed process could will have a 
great impacts on the nutraceutical-processing industries thus drastically 
reducing process time and costs finally making iron-nanoliposomal based 
nutraceutical products cheaper. 
Nanoliposomes containing KRX29, a new synthetized peptide for a not 
conventional heart failures therapy and nucleic acids based drugs (NABDs), 
therapeutic agents used in gene therapy, were successfully produced for 
pharmaceutical purposes. 
Through the use of the developed ultrasound assisted process KRX29-
nanoliposomes were successfully produced. Starting from micrometric 
vesicles (7.2 - 11.7 μm range size) nanoliposomes (22 - 35 nm range size) 
were obtained and the effect of their surface charge on both peptide 
encapsulation and recovery efficiency was studied. By using the higher 
charge ratio formulation (13:1 (-/+)) the highest encapsulation efficiency 
(about 100%) was achieved in both large and small vesicles while at the 
lower charge ratio formulation (1:1 (-/+)) the best ability to recover the 
entrapped peptide was obtained. 
Preliminary experiments in which dsDNA was used to simulate the structure 
of siRNA molecule have confirmed the versatility of the ultrasound assisted 
technique for producing micro (2.2 - 2.9 μm) and nano lipid vectors (28 - 56 
nm) encapsulating NABDs. By varying the charge ratio from 3:1 to 7:1 (+/- 
DOTAP/dsDNA) it was shown that an high encapsulation efficiency (64 % 
e.e. in nanoliposomes and 100 % e.e. in large vesicles) was possible by using 
the 7:1 (+/-) charge ratio. 
In the light of these results, siRNAs-nanoliposomes complexes for E2F1 
protein expression inhibition were successfully produced to potentially treat 
cancer associated to Inflammatory Bowel Diseases. Nanoliposomes (33-38 
nm range size) characterized by an high siRNA encapsulation efficiency 
(100 %) and a very low cytotoxicity in cells when compared with the 
commercial transfection agent Lipofectamine 2000, were obtained through 
the TFH/sonication technique. Moreover, the produced complexes have 
shown an excellent uptake in the cultured human colon mucosa tissues 
and a remarkable anti-E2F1 expression effect after siE2F1-1324-
nanoliposomes transfection with a clear tendency to respond in a patient-
dependent way. 
In this thesis the formulative and chemical engineering approaches have 
allowed to achieve nanostructured vectors, able to deliver, in a controlled 
manner, different active molecules, with the desired features (tailored on the 
application of interest), produced through safe and inexpensive processes 
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Tailored developed nanoliposomes loaded with a siRNA against the 
transcription factor E2F1 (siE2F1), were produced and delivered to human 
colorectal adenocarcinoma cell lines and to intestinal human biopsies. 
siE2F1 loaded nanoliposomes were produced through a dedicated ultrasound 
assisted technique producing particles with about 40 nm size (Small 
Unilamellar Vesicles, SUVs) and 100% siRNA encapsulation efficiency. 
Compared to other production methods, the one proposed here can easily 
produce particles in the nanometric scale by suitable ultrasonic duty cycle 
treatments. Furthermore, SUVs have a high degree of size homogeneity, a 
relevant feature for uniform delivery behaviour. 
siE2F1-loaded SUVs demonstrated a very low cytotoxicity in cells when 
compared to a commercial transfection agent. Moreover, SUVs loaded with 
siE2F1 were effective in the down regulation of the target in cultured colon 
carcinoma cells and in the consequent reduction of cell growth. Finally, a 
remarkable uptake and target silencing efficiencies were observed in 
cultured human biopsy of colonic mucosa. In conclusion, whereas further 
studies in more complex models are required, the siE2F1-SUVs generated 
have the potential to contribute to the development of novel effective 
inflammatory bowel diseases-associated colorectal cancer therapies for a 
future personalized medicine. 
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2. Bochicchio S.; Dalmoro A.; Barba A.A.; D’Amore M., Lamberti G.; 
“New preparative approaches of micro and nano drug delivery carriers” 
Current Drug Delivery, 2017 - online 2016 
Abstract 
The full success of pharmacological therapies is strongly depending from the 
use of suitable, efficient and smart drug delivery systems (DDSs). Thus 
DDSs development is one of the main challenges in pharmaceutical industry 
both to achieve tailored carrier systems based on drug features and to 
promote manufacturing innovations to reduce energetic resources, emissions, 
wastes and risks. Main functions of an ideal DDS are: to protect loaded 
active molecules from degradation in physiological environments; to deliver 
them in a controlled manner and towards a specific organ or tissue, to allow 
the maintenance of the drug level in the body within therapeutic window. 
Smart features, such as those able to induce active molecule release upon the 
occurrence of specific physiological stimuli, are also desirable. Under the 
manufacturing point of view, the current industrial scenery is obliged to 
respond to the increasing market requirements and to the mandatory rules in 
sustainable productions such as raw material and energy savings. In this 
work a general framework on drug delivery systems preparation techniques 
is presented. In particular two sections on innovation in preparative 
approaches carried out are detailed. These latter involve the use of 
microwave and ultrasonic energy applied in the production of polymeric and 
lipidic delivery systems on micro- and nanometric scale. The novelties of 
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these preparative approaches are emphasized and examples of developed 
drug delivery carriers, loaded with vitamins and drug mimicking siRNA, are 
shown. 
 
3. Dalmoro A.; Abrami M.; Galzerano B.; Bochicchio S.; Barba A.A.; 
Grassi M.;Larobina D.; “Injectable chitosan/b-glycerophosphate system 
for sustained release: gelation study, structural investigation, and erosion 
tests”- Current Drug Delivery, 2017- online 2016 
Abstract 
Hydrogels can constitute reliable delivery systems of drugs, including those 
based on nucleic acids (NABDs) such as small interfering ribonucleic acid 
(siRNA). Their nature, structure, and response to physiological or external 
stimuli strongly influence the delivery mechanisms of entrapped active 
molecules, and, in turns, their possible uses in pharmacological and 
biomedical applications. In this study a thermo-gelling chitosan/β-glycero-
phosphate system has been optimized in order to assess its use as injectable 
system able to: i) gelling at physiological pH and temperature, and ii) 
modulate the release of included active ingredients. To this aim we first 
analyzed the effect of acetic acid concentration on the gelation temperature. 
We then found the "optimized composition", namely, the one in which the 
Tgel is equal to the physiological temperature. The resulting gel was tested, 
by low field nuclear magnetic resonance (LF-NMR), to evaluate its average 
mesh-size, which can affect release kinetics of loaded drug. Finally, films of 
gelled chitosan, loaded with a model drug, have been tested in vitro to 
monitor their characteristic times, i.e. diffusion and erosion time, when they 
are exposed to a medium mimicking a physiological environment (buffer 
solution at pH 7.4). Results display that the optimized system is deemed to 
be an ideal candidate as injectable gelling material for a sustained release. 
 
4. Piazza O.; Russo I.; Bochicchio S.; Barba A. A.; Lamberti G.; Zeppa P.; 
Di Crescenzo V.; Carrizzo A.; Vecchione C.; Ciacci C.; “Cyclin D1 Gene 
Silencing by siRNA in ex vivo human tissues cultures” Current Drug 
Delivery, 2017- online 2016 
Abstract 
Short interfering RNAs (siRNAs) are double-stranded RNA molecules able 
to specifically targeting genes products responsible for human diseases. 
Cyclin D1 (CyD1) is a cell cycle-regulatory molecule, up-regulated at sites 
of inflammation in several tissues. CyD1 is a very interesting potential target 
in lung and colon inflammatory diseases.  
Objective. The aim of this paper was testing CyD1 expression in human lung 
and colon tissues after the application of an inflammatory stimulus, and 
verifying its gene silencing by using siRNA for CyD1 (siCyD1).  
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Method. Colon and pulmonary biopsies were treated with siCyD1 by using 
two different transfection carriers: a) invivofectamine and b) ad hoc 
produced nanoliposomes. After 24 hours of incubation with nanoliposomes 
encapsulating siRNA or invivofectamine-CyD1siRNA, in presence or 
absence of EC-LPS, we analysed the protein expression of CyD1 through 
Western-Blotting.  
Results. After EC-LPS treatment, in both colon and pulmonary biopsies, an 
overexpression of CyD1was found (about 64% and 40% respectively). 
Invivofectamine-CyD1 siRNA reduced the expression of CyD1 
approximately by 46% compared to the basal condition, and by around 65% 
compared to EC-LPS treated colon samples. In lung, following 
invivofectamine siRNA silencing in the presence of EC-LPS, no reduction 
was observed. Ad hoc nanoliposomes were able to enter colon and lung 
tissues, but CyD1 silencing was reported in 2 colon samples out of 4 and no 
efficacy was demonstrated in the only lung sample we studied.  
Conclusion. It is possible to silencing Cyclin D1 expression in vitro “organ 
culture” model. Our preliminary results encourage further investigations, 
using different siRNA concentrations delivered by nanoliposomes. 
 
5. D’Apolito R.; Bochicchio S.; Dalmoro A.; Barba A. A.; Guido S.; 
Tomaiuolo G.; “Microfluidic investigation of the effect of liposome 
surface charge on drug delivery in microcirculation  ”Current Drug 
Delivery, 2017 – online 2016 
Abstract 
Nano-carrier drug transport in blood microcirculation is one of the hotspots 
of current research in drug development due to many advantages over 
traditional therapies, such as reduced side-effects, target delivery, controlled 
release, improved pharmacokinetics and therapeutic index. Despite the 
substantial efforts made in the design of nanotherapeutics, the big majority 
of the used strategies failed to overcome the biological barriers to drug 
transport encountered in human microvasculature, such as transport by blood 
flow via the microcirculatory network and margination, the mechanism 
according to which particles migrate along vessel radius to the wall. In fact, 
drug transport efficiency in microvasculature is affected by both the 
particulate nature of blood and drug carrier properties, such as size, shape 
and surface charge. In this work, the effect of the surface charge of 
liposomes on their margination in blood flow in microcapillaries was 
experimentally evaluated. By high-speed video microscopy and image 
analysis it was found that the two custom-made liposomes (one neuter and 
the other positively charged) tend to drift laterally, moving towards the wall 
and accumulating in the cell-free layer. In particular, neuter and cationic 
liposomes showed a comparable margination propensity, suggesting that the 
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presence of blood cells governs the flow behavior independently on 





In recent years much attention has been focused on using lipid carriers as 
potential delivery systems for bioactive molecules due to their favorable 
properties such as high biocompatibility, size and composition versatility. In 
this paper formulation, preparation and characterization of liposomes, a class 
of powerfully versatile lipidic carriers, produced by means of an innovative 
ultrasound-assisted approach based on the thin-film hydration method, are 
presented and discussed. The main aim of this study is to obtain 
nanostructures (Small Unilamellar Vesicles, SUVs), less than 100 nm in 
size, loaded with different vitamins (B12, tocopherol and ergocalciferol), 
starting from lipidic microstructures (Multilamellar Large Vesicles, MLVs). 
Suitable formulations, sonication protocols and nanoliposomes were pointed 
out. SUVs with diameter size ranging from 40 nm to 51 nm were achieved 
starting from MLVs with a diameter range of 2.9–5.7 μm. Starting from 
MLVs with higher encapsulation efficiency for all kind of vitamins, SUVs 
with an encapsulation efficiency of 56% for vitamin B12, 76% for α-
tocopherol and 57% for ergocalciferol were obtained. Stability tests have 
shown that the used lipid composition allows to keep intact the nanovesicles 
and their content for more than 10 days if incubated at simulated 
extracellular environment conditions. 
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Nucleic Acid Based Drugs (NABDs) constitute a class of promising and 
powerful therapeutic new agents with limited side effects, potentially 
useable against a wide range of diseases, including cancer. Among them, the 
short interfering RNAs (siRNAs), represent very effective molecules. 
Despite their in vitro efficacy, the major drawback that limits siRNAs usage 
consists in a difficult delivery due to their very low stability in physiological 
fluids, and to their limited membrane-permeability through physiological 
barriers. On the other hand, the liposomes (lipid bilayers closed in vesicles 
of various sizes) represent interesting drug delivery systems (DDSs) which 
can be tailored in order to get the best performance in terms of load, vesicle 
size and transfection yield. In this work, the current state of study in these 





The use of liposomes in several fields of biotechnology, as well as in 
pharmaceutical and food sciences is continuously increasing. Liposomes can 
be used as carriers for drugs and other active molecules. Among other 
characteristics, one of the main features relevant to their target applications 
is the liposome size. The size of liposomes, which is determined during the 
production process, decreases due to the addition of energy. The energy is 
used to break the lipid bilayer into smaller pieces, then these pieces close 
themselves in spherical structures. In this work, the mechanisms of rupture 
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of the lipid bilayer and the formation of spheres were modelled, accounting 
for how the energy, supplied by ultrasonic radiation, is stored within the 
layers, as the elastic energy due to the curvature and as the tension energy 
due to the edge, and to account for the kinetics of the bending phenomenon. 
An algorithm to solve the model equations was designed and the relative 
calculation code was written. A dedicated preparation protocol, which 
involves active periods during which the energy is supplied and passive 
periods during which the energy supply is set to zero, was defined and 
applied. The model predictions compare well with the experimental results, 
by using the energy supply rate and the time constant as fitting parameters. 
Working with liposomes of different sizes as the starting point of the 
experiments, the key parameter is the ratio between the energy supply rate 
and the initial surface area. 
 




The development of gene therapy along with advances in nanotechnology 
have opened one of the most promising frontiers for the treatment of cancer 
allowing effective and customizable treatments. In the controlled release of 
new therapeutic agents based on nucleic acids, a key role is played by 
delivery systems, able to carry not only a protective function but also a smart 
release activity. From here, the new challenges of scientific research. 
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In the pharmaceutical/nutraceutical field the methods concerning the 
encapsulation of active molecules in polymeric and lipid materials are 
constantly evolving. Of particular interest are those based on the so-called 
"Process Intensification". Examples of innovative approaches relate to the 
exploitation of some effective tools of process intensification are microwave 
and ultrasound, used for the energy supply in an unconventional way. 
 Book chapter 
11.   
 
Bochicchio S.; Lamberti; Barba A.A.; “Phenomenological and formulation 
aspects in tailored nanoliposomes production” chapter in book Liposomes, 
InTech Ed., 2016, in press 
Abstract 
Liposomes as cell-mimetic system have attracted wide attention of 
researchers in various branches of the drug delivery topic as they can be 
highly functionalized and personalized thus solving the major drawbacks of 
bioactive molecules linked to their low stability, limited membrane 
permeability, short half-life and low bioavailability. The development of 
sustainable processes able to produce ad hoc liposomes in a rapid manner 
through the use of not labored techniques, avoiding drastic conditions, is of 
great relevance for the industrial sector. In this chapter two novel liposomes 
production processes, the Ultrasound assisted Thin Film Hydration and the 
simil-microfluidic techniques sharing the same size 
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reduction/homogenization preparative step are presented. The 
phenomenological aspects involved in vectors constitution through the duty 
cycle sonication process (bilayer rupture/vesicles formation mechanisms) 
and through the simil-microfluidic approach (intubated flows interdiffusion 
mechanisms) are described. Finally, two applications as case histories 
involving the use of the developed techniques for relevant classes of active 
molecule delivery are described. In particular a pharmaceutical application 
concerns the encapsulation of siRNA molecule, used for gene therapy, inside 
cationic nanoliposomes, and a nutraceutical application consists in the 
production of ferrous sulphate anionic liposomal formulations with 
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